



## CURRICULUM VITAE

**JAROSLAW P. MACIEJEWSKI, M.D., PH.D., F.A.C.P.**

### Current Position

Chair of Translational Hematology and Oncology Research Department Taussig Cancer Center  
Associate Director, Translational Research Case Comprehensive Cancer Center  
Board certification Internal Medicine 1999  
Board certification Hematology 2001, recertification 2012  
ECFMG Certification: U.S. Medical Licensing Examination (Steps I/II/III) 1994

### Office Address

Cleveland Clinic  
Taussig Cancer Institute  
Department of Translational Hematology and Oncology  
9500 Euclid Ave, NE6, Cleveland, Ohio 44195  
216-445-5962: Fax: 216-636-2498  
maciejj@ccf.org

### Date of Birth

January 1, 1965 Warsaw, Poland

### Citizenship

Naturalized U.S. Citizen (2001)

### Langages

English, Polish, German, Russian

### Education

|             |                                                                                                                                                                                    |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1995-1998   | Internal Medicine Residency PGY1-3                                                                                                                                                 |
| 1993 - 1995 | ECFMG Certification: U.S. Medical Licensing Examination (Steps I/II). Postdoctoral Fellowship, Hematology Branch, National, Heart, Lung and Blood Institute, NIH, Bethesda, MD USA |
| 1990        | M.D.: Humboldt-University Medical School, Berlin, Germany                                                                                                                          |
| 1990        | Ph.D.: Institute of Medical Immunology, Humboldt-University Medical School, Berlin, Germany                                                                                        |
| 1989 - 1990 | Internship, Department of Internal Medicine (6 months); Department of Surgery (6 months), Humboldt- Medical School (Charite), Berlin, Germany                                      |
| 1983 - 1989 | Medical School of the Humboldt-University, Berlin, Germany                                                                                                                         |
| 1983        | Graduated from the Max Planck High School, Berlin, Germany                                                                                                                         |

### Employment:

|             |                                                                                                                                        |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------|
| 2016-       | Associate Director for Translational Research, Taussig Cancer Institute, Case Comprehensive Cancer Center                              |
| 2013-2016   | Associate Director for Lerner Research Institute Case Comprehensive Cancer Center                                                      |
| 2011 -2022  | Program Co-Leader, Pathogenesis of Hematologic Disorders, Case CCC                                                                     |
| 2009 -      | Chairman, Department of Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH                    |
| 2001 - 2008 | Director, Flow Cytometry Laboratory, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH                                         |
| 2001 - 2009 | Head, Experimental Hematology and Hematopoiesis Section, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH                     |
| 2000 - 2001 | Staff Scientist, Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD USA                                    |
| 1998 - 2000 | Hematology Fellowship, Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD USA                              |
| 1995 - 1998 | Resident PGY II/ III (Internal Medicine), Department of Medicine; University of Nevada Medical School, Reno, NV USA                    |
| 1995 - 1996 | Resident PGY I (Internal Medicine), Department of Medicine;                                                                            |
| 1995 - 1996 | Assistant Research Professor in Microbiology, Department of Microbiology University of Nevada Medical School, Reno, NV, USA            |
| 1993 - 1995 | Postdoctoral Fellow, Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD USA                                |
| 1990 - 1993 | Postdoctoral Fellow, Cell Biology Section, Clinical Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD USA |
| 1988 - 1989 | Graduate Student, Institute for Medical Immunology, Humboldt-University Medical School (Charite), Berlin, Germany                      |
| 1987 - 1988 | Graduate Student, Laboratory of Cellular Immunology Dermatologic Clinic, Humboldt-University Medical School (Charite), Berlin, Germany |

**Awards and Honors:**

|           |                                                                                                                                     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------|
| 1987      | Robert Koch Award of the Humboldt-University, Berlin, Germany (Doctoral Research Award)                                             |
| 2001      | Vice-chairman of Scientific Review Board, Medical Advisory Board of the International Aplastic Anemia and Myelodysplasia Foundation |
| 2002      | Chairman of the Medical Advisory Board of the International Aplastic Anemia and Myelodysplasia Foundation                           |
| 2004-2006 | Editorial Board, Experimental Hematology                                                                                            |
| 2006-     | <b>Fellow of the American Society of Clinical Investigation</b>                                                                     |
| 2007      | <b>Celgene ASH Hematology Young Investigator Research Award</b>                                                                     |
| 2008-2012 | Member of Editorial Board, Blood Journal                                                                                            |
| 2008      | ASH/NIH MDS Advisory Panel Member                                                                                                   |
| 2009      | Elected Member, ASH Committee for Myeloid Malignancies                                                                              |
| 2009      | <b>Fellow of American College of Physicians</b>                                                                                     |
| 2010      | <b>Sam and Maria Miller Excellence in Research Award</b>                                                                            |
| 2010      | <b>ASH 2010 Plenary Session, Abstract No. 1</b>                                                                                     |
| 2011      | <b>Leadership in Science Award, AA, &amp;MDS Int. Foundation</b>                                                                    |
| 2012      | Member, Scientific Committee on Myeloid Neoplasia, American Society of Hematology                                                   |
| 2012      | <b>ASH 2012 Plenary Session, Abstract No. 2</b>                                                                                     |
| 2014      | <b>Chairman, Scientific Committee on Myeloid Neoplasia, American Society of Hematology</b>                                          |
| 2015-     | <b>Member, Editorial Board, Leukemia Journal</b>                                                                                    |
| 2016      | Honorary Member, Polish/American Medical Association                                                                                |
| 2016      | <b>Fellow, Association of American Physicians (AAP)</b>                                                                             |
| 2019      | Elected Eminent Polish-American Scientist, Kosciuszkeo Foundation, NewYork, NY                                                      |
| 2020      | <b>Cleveland Clinic Sohnes Award for Outstanding Research Achievement</b>                                                           |

**National Institutes of Health**

2004 NIH Study Section Reviewer, Special Emphasis Section, Hereditary Bone Marrow Failure  
 2004 -2006 Reviewer, NIH Special Emphasis Panel; Hematology II; P01 Review Section  
 2007 Member, Division of Clinical Research Clinical Sciences Peer Review Council  
 2008 University of Texas MD Anderson Cancer Center, P01 Review Section, Site Visit  
 2009 Reviewer, NIH NCI Review Study Section  
 2009 Reviewer, Hematology II Review Study Section  
 2009 Reviewer, RC1 Review Study Section  
 2010 Reviewer, NHLBI P01 Review Panel  
 2011 Reviewer, NIH Hematology II Study Section  
 2011 Ad hoc reviewer, NIDDK P01 Reviewer  
 2014 Ad hoc reviewer, K23 Special Emphasis section  
 2015-2020 **Standing member, Molecular and Cellular Hematology Study Section, NIH**  
 2014 NIH NCI P01 study section ad hoc reviewer  
 2017 Ad hoc member P01 NCI Study Section  
 2018 Ad hoc member P01 Special Emphasis Study Section  
 2022 Ad hoc member F30 NRSA Individual Fellowship Study Section

**Department of Defense**

2010-2011 Standing member CMRP DOD BMF study section,  
 2022 Ad hoc reviewer CMRP DOD BMF study section,

**US Food and Drug Administration**

2022 Cellular Tissue and Gene Therapies Advisory Committee Member

**Academic Appointments:**

2001 Associate Staff Cleveland Clinic Foundation  
 2004 Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine Case Western Reserve University  
 2006 Staff, Cleveland Clinic Foundation  
 2007 Full Professor of Medicine, Cleveland Clinic Lerner College of Medicine Case Western Reserve University

**Institutional Responsibilities:**

Member Fellowship Educational Committee, Cleveland Clinic  
 Member, Institutional Strategic Research Council, Taussig Cancer Center  
 Member, Lerner Research Institute Executive Committee, Cleveland Clinic  
 Member, Tissue Sample Repository Advisory Committee, Cleveland Clinic  
 Director, Hematologic Malignancies and Stem cell Program, CCCC  
 Associate Director for Translational Research, CCCC  
 Director, Experimental and Clinical Hematology Fellowship Program

**Memberships and Societies:**

American Society of Hematology  
 American Society of Clinical Investigation (ASCI)  
 American College of Physicians  
 American Association of Physicians (AAP)  
 American Association of Cancer Research  
 American Society of Advancement of Science

### **Editorial Experience**

Member Editorial Blood, Exp. Hematology 2004-2006  
Member Editorial Board, Blood 2008-2014  
Reviewer for Blood, Leukemia, Haematologica, Nature Genetics, Nature, Exp. Hem., JCI, JCO, J Immunology, Nature Medicine  
Guest Editor, Seminar in Oncology  
Member Editorial Board, Leukemia 2016-current

### **Research Funding History**

#### **Past**

American Society of Hematology Scholar Award (PI: Maciejewski) "Intracellular Immunization with rh HIV Reverse Transcriptase Antibodies  
1997 – 1998 \$150,000

NIH/NHLBI - R01 HL634770 (PI: Maciejewski) Research Project Grant (R01) "Human Cytomegalovirus Latency in Hematopoietic Cells"  
1996-1998 \$ 1,250,000

American Cancer Society (PI: Maciejewski) "Pathophysiologic Role and Pharmacologic Effects of TRAIL/Apo-2L in MDS  
1/01/03-12/31/04 \$18,000

Aplastic Anemia & MDS International Foundation (PI: Maciejewski) "Immune Pathophysiology of Myelodysplastic Syndrome"  
7/01/03 - 06/30/05 \$60,000

NIH/NHLBI - R13 HL078319 (PI: Maciejewski) NIH Support for Conferences and Scientific Meetings (R13) "Bone Marrow Failure Scientific Symposium"  
3/01/04 - 12/31/05 \$ 42,400

State of Ohio BRTT (PI: Muschler; Co-I: Maciejewski) "Connective Tissue Stem Cells"  
7/01/03 - 06/30/06 \$150,000

Protein Design Labs, Inc. (PI: Maciejewski) "Flow Cytometric VB typing in UC Treated with Nuvion"  
10/31/04 - 01/31/07 \$150,000

NIH/NHLBI - R01 HL73429 (PI: Maciejewski) Research Project Grant (R01) "Molecular T-Cell Repertoire in Aplastic Anemia"  
12/01/03 - 11/30/07 \$1,117, 500

Aplastic Anemia & MDS International Foundation (PI: Maciejewski) "Differential Inhibition of Normal Stem Cells in PNH"  
7/15/04 - 03/15/08 \$105,000

NIH/NCRR – U54 Supplemental Pilot Proposal (PI: Maciejewski) "SNP-Array Karyotyping in Aplastic Anemia"  
7/07/06 - 06/30/08 \$100,000

NIH/NCI - P20 CA103736 (PI: Berger; Co-I: Maciejewski) Aging - Cancer Research Program Development (CWRU) "Chromosomal Abnormalities and Instability in Aging Process"  
9/30/03 - 08/30/08 \$50,000

NIH/NCI - R21 CA123006 (PI: Hsi; Co-I: Maciejewski) Exploratory/Developmental Research Grant Award (R21)

“Characterization of Methods for Preservation of Phosphoproteins in Fixed Tissues”

9/01/06 - 08/31/08 \$628,575

NIH/NIA - R01 AG024980 (PI: Muschler, Co-I: Maciejewski) Research Project Grant (R01) “Optimizing Assays of Human Stem Cells in Bone Marrow”

9/30/04 - 01/31/09 \$1,530,00

CELGENE Corporation (PI: Maciejewski) Investigator Initiated Clinical Study “Correlation between FISH and SNP-A Based Karyotyping and Response to Lenalidomide”

3/01/08 - 03/01/09 \$174, 00

NIH/NCI - R01 CA112112 (PI: Epling-Burnette; Co-I: Maciejewski) Research Project Grant (R01) “Targeted Drug Therapy for LGL Leukemia”

07/01/05 - 06/30/09 \$1,211,058

Scott Hamilton Research Award (PI: Maciejewski) “Methylation Profiling in MDS to Predict Response to Hypomethylating Agents

08/10/08 - 07/10/09 \$100,000

NIH/NCRR - U54 RR019391 (PI: Maciejewski) Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (U54) “Bone Marrow Failure Clinical Research Center”

09/01/03 - 08/31/09 \$5,507,401

NIH/NHLBI - R01 HL082983 (PI: Maciejewski) Research Project Grant (R01) “Predisposition to Chromosomal Alterations in MDS”

09/30/05 - 09/29/09 \$1,518,825

NIH/NCI - R01 CA113972 (PI: Maciejewski) Research Project Grant (R01) “TCR Diagnostics in LGL Leukemia and Immune Cytopenias”

04/01/05 - 03/31/10 \$1, 250, 00

NIH/NHLBI - K24 HL077522 (PI: Maciejewski) Mid-Career Investigator Award in Patient-Oriented Research (K24) “Training/Research Center - Bone Marrow Failure Syndromes”

05/01/05 - 04/30/10 \$492,075

Aplastic Anemia & MDS International Foundation (PI: Maciejewski) “Identification of Mutations in C-Cbl as Pathogenetic Factors in Patients with MDS”

07/01/08 - 06/30/10 \$60,000

NIH/NCI - R01 CA117928-05 (PI: Ganapathi; Co-I: Maciejewski) Research Project Grant (R01) “Topoisomerase II Beta in Myeloid Differentiation by Retinoids”

12/01/05 - 11/30/10 \$1,200,000

CELGENE Corporation - VZ-MDS-PI-0263 (PI: Maciejewski) Investigator Initiated Clinical Study “Identification of TET2 Mutations and 5hmC Levels and their Impact on Response to Therapy with Hypomethylating Agents in Patients with MDS”

08/01/10 - 07/31/11 \$83,479

EISAI Corporation - EISAI1008JM (PI: Maciejewski) Investigator Initiated Clinical Study “Cytogenetic Response to Decitabine in MDS with C7 Abnormalities”

08/03/10 - 08/02/11 \$65,000

NIH/NCRR - C06 RR028655-01 (PI: Maciejewski) Extramural Research Facilities Improvement Program (C06)

“Translational Hematology and Oncology Research Expansion Project”

03/25/10 - 02/05/12 \$2,039,261

USARMY- BM090088 (PI: Lindner; Co-I: Maciejewski)

‘Insertional Mutagenesis for detection of Leukemogenic

pathways ‘ 07/01/10-12/31/12 \$154,500

BMFRP - Exploration Hypothesis Development Award “Complementation of MDS Clones with Lentivirus Expression Libraries” NIH/NCI - R01 CA131076-03 (PI: List; Co-I: Maciejewski) R01 Subaward - H. Lee Moffitt Cancer Center, FL “Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome”

07/01/08-06/30/13 \$ 375,000

Case Comprehensive Cancer Center (PI: Jacobberger; Co-I: Maciejewski) Pilot Funding P30CA043703 – Subaward “Cell-Based Assays for Measuring Epigenetic Modifications in Myeloid Malignancies by Flow Cytometry”

04/01/11 - 03/31/13 \$100,000

CWRU/NCI - R21subaward (PI: Jacobberger; Co-I: Maciejewski) “Cell Signaling as a Leukemia Biomarker”

05/15/12 - 04/30/13 \$12,000

USARMY- W81XWH-0910671 (PI: Sauntharajah; Co-I: Maciejewski) DOD Peer Reviewed Medical Research Program (PRMRP) “Next Generation DNMT1 Depletion Therapy for Leukemia”

09/01/09 - 08/31/13 \$2,622,980

NIH/NCI - R01 CA127264-02 (PI: Alamsan; Co-I: Maciejewski) Research Project Grant (R01) “Cdk-2 Independent Role of Cyclin E in Cell Survival”

12/23/08 - 11/30/13 \$1,567,720

NIH/NHLBI - R01 HL098511-01 (PI: Maciejewski) Research Project Grant (R01) “Molecular Pathogenesis of MDS and CMML”

01/29/10 - 11/30/13 \$1,570,000

NIH/NCI - R01 CA138858-02 (PI: Sauntharajah; Co-I: Maciejewski) Research Project Grant (R01) “Optimizing Decitabine Regimen + Formulation for Non-DNA Damaging DNMT1 Depletion Therapy”

07/01/09 - 05/31/14 \$1,646,010

NIH/NIAID - R01 AI08557801-01 (PI: Maciejewski) Roadmap Transformative R01 Program (R01) “Viral Pathogenesis of Idiopathic Bone Marrow Failure and Immune Cytopenias”

09/25/09 - 08/31/14 \$1,962,500

NIH/NHLBI - K24 HL077522-06 (PI: Maciejewski) Mid-Career Investigator Award in Patient-Oriented Research (K24) “Training/Research Center - Bone Marrow Failure Syndromes”

07/01/10 - 02/14/15 \$671,500

Case Comprehensive Cancer Center Pilot Grant (PI: Maciejewski) “Somatic mutations as prognostic biomarkers in lenalidomide therapy”

04/01/14 - 03/31/15 \$65,000

Alexion Pharmaceuticals, Inc. (PI: Makishima, Co-I Maciejewski) “Frequency of PNH Clones in Myeloproliferative Neoplasia and Myelodysplastic-Myeloproliferative (PNH-MDS) Overlap Syndromes”

03/12/14 - 03/11/16 \$117,000

Leukemia and Lymphoma Society (PI: Maciejewski) LLS Translational Research Program “Implications of STAT3 Mutations in Large Granular Lymphocyte Leukemia”

10/01/12 - 09/30/15 \$600,000

RA Pharmaceuticals (PI: Maciejewski) "Testing of a novel C5 inhibitors in Paroxysmal Nocturnal Hemoglobinuria"  
10/01/14 - 09/30/15 \$26,000

USARMY BMRFP Idea Award – DOD University of Missouri, Kansas City (PI: Mukherji; Co-I: Maciejewski) "Rescue of TET2 Haploinsufficiency in MDS Patients Using Cosubstrate"  
06/20/13-05/31/16 \$140,000/yr

ACS Research Scholar Award (PI: LaFramboise; Co-I: Maciejewski) "Tumor Suppressor Gene Identification in Myeloid Malignancies"  
09/01/12 - 08/31/16 \$177,661

CCCC/NCI - P30 CA043703 Genomics Pilot Award "Somatic mutations as prognostic biomarkers in lenalidomide therapy"  
04/01/14 – 03/31/16 \$65,000

AAMDS1409JM Evans MDS (PI: Maciejewski) "Identification of determinants of response and relapse in patients treated with hypomethylating agents"  
07/07/14 - 07/06/16 \$100,000

NIH/NHLBI - R01HL123904 (PI: Maciejewski/Padgett) Research Project Grant (R01) Resubmission "RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic Target"  
04/01/15 - 03/31/19 \$2,058,580

NIH/NHLBI – R01 HL128425 (PI: Maciejewski) Research Project Grant (R01) "The Role of Somatic Mutations in Aplastic Anemia"  
08/01/15 - 06/30/19 \$1,585,500

NIH/NHLBI - R01HL118281 (PI: Maciejewski/Padgett) Research Project Grant (R01) "Investigations of consequences of U2AF1 mutations in MDS"  
04/01/13 - 03/31/17 \$1,507,000

Texas A&M/NCI - R03 CA198630 (PI: Cheriya; Co-I: Maciejewski) R03 – Subaward "Myelodysplastic Syndrome Target Identification and Validation"  
09/01/16 - 08/31/17 \$31,700

NHLBI - R01 HL114582 (PI: Straczynowski) Co-I: Maciejewski R01 - Subaward "Role of TRAF6 in Myelodysplastic Syndrome"  
08/01/14 - 04/30/18 \$34,475

AAMDS1409JM (PI: Sekeres, Co-PI Maciejewski) "Translational auxiliary studies for MDS Consortium"  
07/01/14 - 12/31/16 \$300,000

Evans Foundation - EPE1509JM (PI: Maciejewski) Basic Research Science Grant "Role of the Defects of Spliceosomal Gene LUC7L2 in Pathogenesis of MDS"  
09/31/15 - 08/31/17 \$400,000

Celgene Corporation (PI: Maciejewski) "New Factors Predictive of Response to Lenalidomide; Implications for Targeting and Mechanism of Action"  
10/31/14 - 12/31/2016 \$130,000

Velosano Research Grant CCF (PI: Maciejewski) "Treatment of TET2 mutant MDS with metformin"  
03/01/16 - 02/28/17 \$75,000

LRI Center of Excellence (PI: Maciejewski) "CMML Center of Excellence"

03/01/16 - 02/28/19 \$1,500,000

NIH/NHLBI – R01 HL128425 (PI: Maciejewski/Padgett) Research Project Grant (R01) “Novel Spliceosomal Defects in Myelodysplastic Syndromes”

09/01/16 - 06/30/20 \$1,520,250

### **Current**

NCI P30 CA043703 (PI: Gerson; Co-I: Maciejewski) Case Comprehensive Cancer Center Support Grant (P30) Associate Director, CCCC for LRI and Co-Leader, Pathogenesis Treatment of Hematopoietic Disorders Program, CCCC

04/01/18 - 03/31/23 \$60,350/yr

NIH/NHLBI - R35HL135795 (PI: Maciejewski) Outstanding Investigator Award (R35) “Therapeutic Implications of Molecular Defects in BMF”

01/01/17 - 12/31/23 \$5,500,000

Taub Foundation (PI: Maciejewski) “DNA dioxygenase inhibitor therapy in leukemia”

05/01/19-05/01/22 \$600,000

LLS Translational Research Proposal (PI: Jha) “Develoment of tattoo inhibitors for tattoo mutant MDS”

07/01/19-07/01/22 \$600,000

Dresdner MDS Foundation (PI: Padgett) “Pathogenise of DDX41 MDS”

09/13/19-09/13/21 \$500,000

NIH/NCI R21 CA349138 (PI: LaFramboise; Maciejewski CO PI) “Exploratory /Developmental Bioengineering Research Grants (EBRG)

10/20/21-11/1/23 \$ 442,750,000

DOD Bone Marrow Failure Idea Development Award (PI Maciejewski) “Immune Evasion as a Mechanism of Clonal Escape in Aplastic Anemia”

04/01/2021-3/31/23 \$508,095

NIH/NCI R01CA257544-01- PI:(Maciejewski/Jha) “Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms”

05/01/2021 – 04/30/2026 \$2,300,000

The Leukemia & Lymphoma Society, Translational Research Program, (PI: Maciejewski) “HLA Mutations and Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (aHSCT)”

11/01/2021 – 10/31/2024 \$600,000

NIH/NISSK R01 DK131923-01 (PI: Maciejewski/Jha) Eltrombopag as a TET2 dioxygenase inhibitor for expansion of hematopoietic stem cells \$2,300,000

07/01/2022 – 06/31/2027

### **PI of investigator-initiated clinical protocols (selection)**

- Phase II pilot study of Enbrel in myelodysplastic syndrome. (PI)
- Phase II pilot study of anti-ILreceptor mAb in moderate aplastic anemia. (PI)
- Phase I/II trial of rabbit ATG in severe aplastic anemia.(PI)
- Phase II trial of Campath mAb in myelodysplastic syndrome. (co-PI)



- Phase II trial of Rapamycin in moderate and refractory or relapsed severe aplastic anemia. (co-PI)
- Pilot trial (Phase I) of CD34+ selection and T cell add-backs in unrelated allogeneic partially- matched stem cell transplantation. Screening and Longitudinal Study protocol for patients with bone marrow failure syndromes. (PI)
- TRIUMPH Pivotal Phase II, Double-Blind, Placebo-Controlled Trial, (Site-PI)
- SHEPHERD Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria (site-PI)
- PHAROATrial of APL-2 in patients with paroxysmal nocturnal hemoglobinuria (site-PI)
- Phase II Achillion (ACH-0144471 in refractory patients with paroxysmal nocturnal hemoglobinuria

### **Current and former trainees**

| Trainee                       | Training Period | Training Position                    | Current Position                                                           |
|-------------------------------|-----------------|--------------------------------------|----------------------------------------------------------------------------|
| Eric Bruenning                | 1997            | Graduate Student (Ph.D.)             | Private Biotech Company                                                    |
| Audhuri Chudhuri              | 1996-1999       | Graduate Student (Ph.D.)             | Private Biotech Company                                                    |
| Christine Crapnell            | 1996-1999       | Graduate Student (Ph.D.)             | Post Doc, Duke Univ.                                                       |
| Robert Massey                 | 1995-1998       | Graduate Student (Ph.D.)             | NIH, Staff Scientist                                                       |
| Antonio Risitano              | 2001-2003       | Hematology Research Fellow           | Assistant Professor, University of Naples, Italy                           |
| Marcin Wlodarski              | 2004-2007       | Graduate Student (M.D., Ph.D.)       | Associate Prof. in Hematology, St. Jude Childrens Hospital                 |
| Lukasz Gondek                 | 2004-2008       | Post Doc Fellow                      | Assistant Professor in Hematology, Johns Hopkins Hospital                  |
| Isabel Bretschneider, M.S.    | 2008            | Visiting Student                     | Graduate Student, Humboldt University                                      |
| Evan Howe, M.S.               | 2003-2005       | Research Assistant                   | Graduate, CWRU                                                             |
| Christine Hung, M.S.          | 2005-2006       | Medical Student, CCLCM               | Resident, Neurology, Mt. Sinai Med School                                  |
| Magdalena Tarnowska           | 1999--2000      | Medical Student                      | Internist, St Mary's Hospital, Baltimore                                   |
| Andrew Dunbar                 | 2004-2007       | Medical Student                      | Instructor in Medicine, Memorial Sloan Kettering, NY                       |
| Sharam Kordasti, M.S.         | 2005-08         | Visiting Grad. Student               | Assistant Professor in Hematology, King's College, London                  |
| Hadrian Szpurka, Ph.D.        | 2005-2008       | Graduate Student                     | Director for Onc. Diagnostics, Eli Lilly                                   |
| Megan Quimper, M.S.           | 2005-2007       | Summer Student                       | Medical Student, Univ. of Pittsburgh                                       |
| Rebecca Ganetzky, M.S.        | 2007-2011       | Medical Student, CCLCM               | Assistant Professor in Genetics. University Penn                           |
| Theresa Guo, M.S.             | 2008-2011       | Medical Student, CCLCM               | NIH, Howard Hughes Student, Bethesda                                       |
| Sandra Smieszek, M.S.         | 2008-Pres       | Vis. Student, King's College, London | Graduate Student, King's College, UK                                       |
| Aaron Viny, M.D.              | 2005-2009       | Med. Student, CCLCM (M.S)            | Assistant Professor in Hematology Sloan Kettering, Columbia University, NY |
| Bianca Serio, M.D.            | 2005-2007       | Post Doc Fellow                      | Hematologist, Univ. of Salerno, Italy                                      |
| Ramon Tiu, M.D.               | 2006-2008       | Hem/Onc Fellow                       | Vice Pres. For Hem Research Takeda                                         |
| Marcin Wlodarski, M.D., Ph.D. | 2008            | Post Doc Fellow                      | Associate Prof., U. of Freiburg, Germany                                   |

|                            |                    |                                 |                                                                         |
|----------------------------|--------------------|---------------------------------|-------------------------------------------------------------------------|
| Nelli Bejanyan, M.D.       | 2008-2012          | Hem/Onc Fellow                  | Associate Professor; Lee H Moffet Cancer Center                         |
| Monika Jasek, Ph.D.        | 2007-2010          | Post Doc Res. Fellow            | Associate Professor; Hirshfelt Institute of Hematology, Wroclaw, Poland |
| Sanjay Mohan, M.D.         | 2007-2011          | Hem/Onc Fellow, CCF             | Assistant Professor of Medicine, Vanderbilt University                  |
| Mohammed Shaik, M.D.       | 2009-2010          | Hematology Res. Fellow          | Medical director, NWU Regional Hospitals                                |
| Guibin Chen., M.D.         | 1999-2001          | Postdoctoral fellow             | Staff Scientist, NIH                                                    |
| Magdalena Plasilova., M.D. | 2002-2005          | Postdoctoral fellow             | Resident, Sloan Kettering Cancer Center                                 |
| Weihua Zeng., M.D.,        | 1998-2001          | Postdoctoral fellow             | Instructor in Medicine, Univ. of Albuquerque                            |
| Soumit Basu, M.D., Ph.D.   | 2005-2006          | Resident, Internal Med          | Assistant Professor in Hematology, FHCC, WA                             |
| Rose Beck, M.D., Ph.D.     | 2005-2004          | Resident, Pathology             | Assistant Professor of Pathology, CWRU                                  |
| Rhami Koriati, M.D.        | 2007-2008          | Resident, Internal Med          | Assistant Prof., Univ. Mich. Ann Arbor, MI                              |
| Zachariah McIver, M.D.     | 2006-2007          | Resident, Internal Med          | Assistant Prof. Univ. of Louisiana, New Orleans, LU                     |
| Giri Ramsingh, M.D.        | 2005-2007          | Resident, Internal Med          | Assistant Prof. in Hematology, USC Los Angeles                          |
| Vivek Subbiah, M.D.        | 2006-2007          | Resident, Pediatrics            | Assistant Professor in Oncology, MD Anderson                            |
| Nina Babel, M.D.           | 2006-2007          | Visiting Scholar                | Associate Prof., Humboldt Univ., Germany                                |
| Jungwon Huh, M.D.          | 2008               | Visiting Scholar                | Asst. Prof., Ewha Univ., Seoul, S. Korea                                |
| Hoon Kook, M.D.            | 1998-2000          | Visiting Scholar                | Professor, Choman Univ., S. Korea                                       |
| Hideki Makishima, M.D.     | 2008-2015          | Visiting Scientist              | Project Scientist, THOR, CC; Japan                                      |
| Hideki Muramatsu, M.D.     | 2009               | Visiting Scholar                | Associate Prof. University of Nagoya, Japan                             |
| Yogen Saunthararajah, M.D. | 2007-2008          | Junior Faculty                  | Staff, Cleveland Clinic, THOR                                           |
| Fred Reu, M.D.             | 2007-Pres          | Jr. Faculty, Asst. Prof, CCLCM  | Associate Staff, Cleveland Clinic, THOR                                 |
| Andrew Schade, M.D., Ph.D. | 2005-2008          | Jr. Faculty, Asst. Prof, CCLCM  | Vice Pres. of Oncology Diagnostics, Elli Lilly                          |
| Mikhael Sekeres, M.D.      | 2005-2007          | Junior Faculty                  | Prof. in Hematology, University of Miami, FL                            |
| Andrez Jerez, M.D., Ph.D.  | 2010-2012          | Visiting Scholar                | Associate Prof. in Hematology, Murthia, Spain                           |
| Hirotooshi Sakagushi, MD   | 2011               | Visiting Scholar                | Asst. Prof., University of Nagoya , Japan                               |
| Sarah Abu Kar, M.D.        | 2011               | Postdoctoral fellow             | Resident Cleveland Clinic                                               |
| Peter Chomczynski, B.S.    | 2011; 2014-present | Undergraduate; Graduate Student | CWRU, Cleveland Ohio                                                    |
| Yuka Sugimoto, M.D.        | 2009-2011          | Visiting scholar                | Associate Prof., U. of Sendai, Japan                                    |
| Ania Jankowska, Ph.D.      | 2005-2011          | Grad Student & Research Fellow  | Staff Scientist, University of Indiana                                  |

|                                   |              |                               |                                                                    |
|-----------------------------------|--------------|-------------------------------|--------------------------------------------------------------------|
| Manuel Afable, M.D.               | 2010-2013    | Clinical Research fellow      | CWRU, University Hosp., Cleveland, OH                              |
| Bartłomiej Przychodzen, M.S.      | 2008-2019    | Bioinformatics Fellow         | Cleveland Clinic, THOR                                             |
| Fabiola Traina                    | 2010-2011    | Post Doc. Fellow              | Associate Professor, U. of São Paulo School of Medicine; Brazil    |
| Inez Gomez, M.D., Ph.D.           | 2011-2012    | Visiting Scholar              | Associate Professor, Valencia, Spain                               |
| Holleh Husseinadeh, M.D.          | 2012-2013    | Evans Scholar                 | Assistant Prof. in Hematology, University of Pennsylvania          |
| Amina Kozaric, Ph.D.              | 2012-2013    | Fullbright Scholar            | Associate Professor, University of Sarajevo                        |
| Naoko Hosono, M.D., Ph.D.         | 2012-2014    | Research Fellow               | Prof. Of Hematology, University of Fukui, Japan                    |
| Chantana Rakpan, M.D.             | 2012-2014    | Research Fellow               | Associate Prof. in Hematology University of Bangkok, Thailand      |
| Wenyi Shen, M.D.                  | 2012-2013    | Research Fellow               | Associate Professor; China                                         |
| Dayong Huang, M.D.                | 2013-2014    | Research Fellow               | Associate Professor; University of Beijing, China                  |
| Swapna Thota, M.D.                | 2013-present | Evans Scholar                 | Associate Staff, Hem/Onc, Roswell Cancer Institute                 |
| Rawaa Hadibnissan                 | 2013-2014    | Summer Student                | Student, Ohio Northern College of Pharmacy                         |
| Bhumika Patel, M.D.               | 2014-present | Evans Scholar                 | Associate Staff, Hem/Onc, Cleveland Clinic                         |
| Eiju Negoro, M.D, PhD             | 2014-present | Post Doc. Research Fellow     | Assistant Prof. of Hematology, University of Fukui, China          |
| Srinivasa Sanikommu, M.D.         | 2015-2016    | Evans Scholar                 | Assistant Prof. in Hematology, Levine Cancer Center                |
| Dewen You, Ph.D.                  | 2015-present | Post Doc. Research Fellow     | Cleveland Clinic                                                   |
| Mai Mostafa Mohammed Kamal, Ph.D. | 2015-present | Post Doc. Research Fellow     | Cleveland Clinic                                                   |
| Yasunobu Nagata, Ph.D.            | 2016-present | Post Doc. Research Fellow     | Assistant Prof. in Hematology, University of Tokyo, Japan          |
| Sayer Rashed Al Harbi, PhD        | 2015-present | Post Doc. Research Fellow     | Cleveland Clinic                                                   |
| Suresh Balasubramanian, M.D.      | 2016-present | Evans Scholar                 | Hem/Onc Fellow, Karmanos Cancer Institute Detroit                  |
| Taha Bat, M.D.                    | 2016-present | Evans Scholar                 | Hem/Onc Fellow, Roswell Cancer Institute                           |
| Asad Mohammed Fahad, M.D.         | 2017-2018    | Evans Scholar                 | Hem/Onc Fellow, Karmanos Cancer Institute                          |
| Abinav, Goyal M.D.                | 2017-2018    | Post Doc. Research Fellow     | Experimental Therapeutics Fellow, THOR                             |
| Sagar, Patel M.D.                 | 2018-present | Bone Marrow Transplant Fellow | Assistant Prof. in Hematology, University of Utah                  |
| Louis, Williams                   | 2018-2018    | Research Fellow               | Assistant Staff, Cleveland Clinic                                  |
| Durrani, Jibran                   | 2018-2019    | Clinical Research Fellow      | NIH, Hematology Fellow                                             |
| Kongkiatkamon, Sunisa             | 2018-2019    | Visiting Scholar              | Assistant Professor in Hematology, University of Bangkok, Thailand |

|                   |              |                           |                                                           |
|-------------------|--------------|---------------------------|-----------------------------------------------------------|
| Visconte, Valeria | 2006-present | Post Doc Fellow           | Assistant Prof. Cleveland Clinic                          |
| Adema, Vera       | 2015-2020    | Post Doc Fellow           | MDACC,                                                    |
| Vatolin, Sergi    | 2015-2019    | Project Scientist         | Assistant Research Professor CWRU                         |
| Kistagari, Ashwin | 2019-2020    | Research Fellow           | Assistant Research Professor Vanderbilt University        |
| Awada, Hassan     | 2019-present | Medical Resident          | Hematology Oncology Fellow Rosswell Park Cancer Institute |
| Rainey, Magdalena | 2019-2020    | Medical Student           | Cleveland Clinic                                          |
| Gurnari, Carmelo  | 2019-present | Post Doc Fellow           | Cleveland Clinic, THOR                                    |
| Hong, Sanghee     | 2019-2020    | Clinical Research Fellow  | Hematology Oncology Fellow CWRU                           |
| Misam, Zawit      | 2020-2021    | Post Doc                  | Hem/Onc Fellow, University of Cincinnati, OH              |
| Bahaj, Waled      | 2021-present | Research Fellow           | Cleveland Clinic Fellow, THOR                             |
| Kewan, Tariq      | 2021-present | Research Fellow           | Cleveland Clinic Fellow, THOR                             |
| Pagliuca, Simona  | 2019-2021    | Post Doc Research Scholar | Attending Physician Nancy Hospital, France                |

**Patents**

- 2016-036 A drug candidate for pharmacological regression of aging US2018/019454
- 2017-079 Dioxygenase antagonists: Principle to offset the consequences of mutations in cancer and leukemia US2018 62/591,884
- 2018-132 Small Molecules that modulate NAD<sup>+</sup> in Cells as Stem cell anti-senescence drugs to prevent aging CCF2018 Invention disclosure
- 2018-155 Small molecule modulators (PDI inhibitors) of ER stress response that and eliminate cancer cells US2018 62/723,519

**Original articles and reviews****Total: 503 ► First and Senior Author: 226****Journal Covers:**

2006                      **Blood Journal Cover, Volume 108, No. 7**  
 2012                      **Blood Journal, Cover, Volume 120 No. 16**  
 2012                      **Blood Journal, Cover, Volume 120 No. 15**  
 2021                      **Blood Journal Cover, Volume 137 No. 26**

**1989**

1. Eckert R, Volk HD, Diezel W, **Maciejewski JP**, Hiepe F, Forner K, von Baehr R. (1989). Prevention of graft-vs-host reaction induced immunodeficiency by treatment with splenopentin 8(Dac-SP5). *Allerg. Immunol. (Leipz)* **35**: ►

**1990**

2. Eckert R, **Maciejewski JP**, Weber H, Volk HD, Diezel W, Forner K, von Baehr R. (1990) Splenopentin (Dac-SP5)--influence on engraftment and graft-vs-host reaction after non-H-2 bone marrow transplantation in mice. *Exp. Clin. Endocrinol.* **96**:307-313 ►

3. **Maciejewski JP**, Wachter M, Elstner E, Weber H, Diezel W, Seiler FR, Volk HD. (1990). Cytofluorometric and cytomorphologic analysis of human bone marrow cells derived from stromal cultures stimulated by GM-CSF, IFN- $\gamma$  and splenopentin pentapeptide. *Eur. J. Immunol.* 20:1209-1213. ►
4. Weber HA, **Maciejewski JP**, Eckert R, Schutt M, Diezel W, Volk HD. (1990) Splenopentin (Dac-SP-5) accelerates the restoration of myelopoietic and immune systems after sublethal radiation in mice. *Int. J. Immunopharmacol.* 12:761-768.  
1991
5. **Maciejewski JP**, Weber H, Neuhaus K, Wachter M, Elstner E, Seiler FR, Volk HD. (1991). Comparative analysis of the influences of IL-1, IL-3 and GM-CSF on the commitment of granulocyte-macrophage progenitors in vitro. *Ann. Hematol.* 63:242-248. ►
6. **Maciejewski JP**, Weber H, Eckert R, Neuhaus K, Diezel W, Volk HD. (1991). Haematopoetische effekte von diacetyl-splenopentin in vitro and in vivo. *Z. Klin. Med.* 46:631-634. ►
7. Young NS, Rosenfeld S, Antunez-de-Mayolo J, Hibbs J, Liu J, **Maciejewski JP**, St. Jeor S, Shimomura S., Kajigaya S. (1991) Viruses and bone marrow failure. *Schweiz. Med. Wochenschr Suppl.* 43:28-32.  
1992
8. **Maciejewski JP**, Bruening EE, Donahue RE, Mocarski ES, Young NS, St. Jeor S. (1992). Infection of hematopoietic progenitor cells by human cytomegalovirus. *Blood* 80:170-178.
9. **Maciejewski JP**, Liu JM, Green SW, Walsh CE, Plumb M, Pragnell IB, Young NS. (1992). Expression of stem cell inhibitor (SCI) gene in patients with bone marrow failure. *Exp. Hematol.* 20:1112-1117. ►
10. Diezel W, Weber H, **Maciejewski JP**, Volk HD, (1992) The effects of splwnopentin (Dac-SP-5) on in vitro myelopoiesis and on AZT-induced bone marrow toxicity. *Int. J. Immunopharmacol.* 15, 269-273 ►  
1993
11. **Maciejewski JP**, Bruening EE, Donahue RE, Sellers SE, Carter C, Young NS, St. Jeor S. (1993). Infection of mononucleated phagocytes with human cytomegalovirus. *Virology* 195:327-336. ►  
1994
12. **Maciejewski JP**, Anderson S, Katevas P, Young NS (1994). Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. *Br. J. Haematol.* 87:227-234. ►
13. **Maciejewski JP**, Hibbs JR, Anderson S, Katevas P, Young NS (1994). Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. *Exp. Hematol.* 22:1102-1110. ►
14. **Maciejewski JP**, Weichold FF, Young NS (1994). HIV-1 suppression of hematopoiesis in vitro mediated by envelope glycoprotein and TNF- $\alpha$ . *J. Immunol.* 153:4303-4310. ►  
1995
15. **Maciejewski JP**, Selleri C, Anderson S, Young NS (1995). Fas antigen expression on CD34+ human marrow cells is induced by interferon- $\gamma$  and tumor necrosis factor- $\alpha$  and potentiates cytokine-mediated hematopoietic suppression in vitro. *Blood* 85:3183-3190. ►
16. **Maciejewski JP**, Weichold FF, Young NS, Cara A, Zella D, Reitz MS. Jr, (1995). Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. *Nature Med.* 1:667-673. ►
17. **Maciejewski JP**, Selleri C. (equal contribution), Sato T., Cho HJ., Keefer IK., Nathan CF., Young NS (1995). Nitric

oxide suppression of human hematopoiesis in vitro. Contribution to interferon- $\gamma$  and tumor necrosis factor- $\alpha$ . *J. Clin. Invest.* 96:1085-1092. ►

18. **Maciejewski JP**, Selleri C, Sato T, Anderson S, Young NS (1995). Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. *Br. J. Haematol.* 91:245-252. ►
19. Sato T, Selleri C, Young N.S, **Maciejewski JP** (1995). Hematopoietic inhibition by interferon-gamma is partially mediated through interferon regulatory factor-1. *Blood* 86:3373-3380. ►
20. Selleri C, Sato T, Anderson S, Young NS, **Maciejewski JP** (1995). Interferon- $\gamma$  and tumor necrosis factor- $\alpha$  suppress both early and late stages of hematopoiesis and induce programmed cell death. *J. Cell. Physiol.* 165:538-546. ►

### 1996

21. Selleri C, **Maciejewski JP** (equal contribution), Sato T, Young NS (1996). Interferon- $\gamma$  constitutively expressed in the stromal microenvironment of marrow cultures mediates potent hematopoietic inhibition. *Blood.* 87:4149-4157. ►
22. **Maciejewski JP**, Selleri C, Anderson S, Young NS (1996). A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. *Blood* .88:1983-1991. ►
23. **Maciejewski JP**, Young NS, Yu M., Anderson SM, Sloand EM (1996). Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria. *Thromb. Res.* 83:433-447. ►

### 1997

24. **Maciejewski JP**, Sloand EM, Sato T, Anderson S, Young NS (1997). Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. *Blood* 89:1173-1181. ►
25. Sloand EM, Young NS, Kumar P, Weichold FF, Sato T, **Maciejewski JP** (1997). Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. *Blood* 89:1357-1363. ►
26. Sato T, Selleri C, Anderson S, Young NS, **Maciejewski JP** (1997). Expression and modulation of cellular receptors for interferon- $\gamma$ , tumor necrosis factor- $\alpha$ , and Fas on human bone marrow CD34+ cells. *Br. J. Haematol.* 97:356-365. ►
27. Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, Young NS, **Maciejewski JP** (1997). Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon- $\alpha$  in chronic myelogenous leukemia. *Blood* 89:957-964. ►
28. Sloand EM, Young NS, Sato T, Kumar P, Kim S, Young NS, **Maciejewski JP** (1997). Secondary colony formation after long-term bone marrow culture using peripheral blood and bone marrow of HIV-infected patients. *AIDS* 11: ►
29. Selleri C, Sato T, Raiola AM, Rotoli B, Young NS, **Maciejewski JP** (1997). Induction of nitric oxide synthase is involved in the mechanism of Fas-mediated apoptosis in haemopoietic cells. *Br. J. Haematol.* 99:481-489. ►
30. Sato T, Selleri C, Young NS, **Maciejewski JP** (1997). Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon- $\gamma$  due to phosphorylation of Stat1 and Stat3. *Blood* 90:4749-4758. ►
31. Sloand E.M, Young NS, Sato T, Kim S, **Maciejewski JP** (1997). Inhibition of interleukin-1 $\beta$ -converting enzyme in

human hematopoietic progenitor cells results in blockade of cytokine-mediated apoptosis and expansion of their proliferative potential. *Exp. Hematol.* 26:1093-1099. ►

32. Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett J, Rotoli B, Young NS, **Maciejewski JP** (1997). Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon- $\alpha$  chronic myelogenous leukemia. *Focus Biotherapy Cancer* 1: 108-109. ►
33. Zhuravskaya t. **Maciejewski JP**, Netski DM, Bruening E, Mackintosh RF, St. Jeor S. (1997) Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency. *Blood* 90:2482-2491.
34. Young NS., **Maciejewski JP**. (1997) The pathophysiology of acquired aplastic anemia. *N. Engl. J. Med.* 336:1365-1372.

### 1998

35. Sato T, Kim S, Selleri C, Young NS, **Maciejewski JP** (1998). Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome. *Leukemia* 12:1187-1194. ►
36. Sloan EM, **Maciejewski JP**, Sato T, Bruny J, Kumar P, Kim S, Weichold FF, Young NS. (1998) The role of interleukin-converting enzyme in Fas-mediated apoptosis in HIV-1 infection. *J. Clin. Invest.* 101:195-201. ►
37. Weichold FF, Zella D, Barabitskaja O, **Maciejewski JP**, Dunn DE, Sloan EM, Young NS. (1998) neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. *Blood* 91:907-915. ►
38. Selleri C, **Maciejewski JP**, Pane F, Raiola AM, Mostarda I, Salvatore F, Rotoli B. (1998) Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. *Blood* 92:981- 989. ►
39. Sloan EM, **Maciejewski JP**, Dunn D, Moss J, Brewer B, Kirby M, Young NS. (1998) Correction of the PNH defect by GPI-anchored protein transfer. *Blood* 92:4439-4445. ►

### 1999

40. Selleri C, **Maciejewski JP**, De Rosa G, Raiola A, Risitano AM, Picardi M, Pezzullo L, Luciano L, Ricci P, Varriale G, Della Cioppa P, Del Vecchio L, Rotoli B. (1999) Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant. *Bone Marrow Transplant.* 23:1029-1037. ►
41. **Maciejewski JP**, St. Jeor SC (1999). Human cytomegalovirus infection of human hematopoietic progenitor cells. *Leuk. Lymphoma* 33:1-13. ►
42. Chaudhuri AC, St. Jeor S, **Maciejewski JP** (1999). Apoptosis induced by human cytomegalovirus infection can be enhanced by cytokines to limit the spread of virus. *Exp. Hematol.* 27:1194-1203. ►

### 2000

43. **Maciejewski JP**, Kim S, Sloan E, Selleri C, Young NS (2000). Sustained long-term hematologic recovery despite a marked quantitative defect in the stem cell compartment of patients with aplastic anemia after immunosuppressive therapy. *Am J Hematol.* 65, 123-128. ►
44. Crapnell K, Chaudhuri AC., Netski D, Zanjani E, St. Jeor S, **Maciejewski JP** (2000). Human cytomegalovirus can infect bone marrow megakaryocytes. *Blood.* 95, 487-93. ►
45. Selleri C, **Maciejewski JP** (2000). The role of FAS-mediated apoptosis in chronic myelogenous leukemia. *Leuk Lymphoma* 372, 83-97.
46. Tisdale JF, Dunn DE., **Maciejewski JP** (2000). Cyclophosphamide and other new agents for the treatment of severe aplastic anemia. *Semin Hematol.* 37, 102-9. ►



47. Sloand E.M., Kim S, **Maciejewski J.P.**, Van Rhee F, Chaudhuri A., Barrett J., Young N.S. (2000) Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. *Blood* 95, 74
  48. Sloand EM, **Maciejewski J**, Kumar P, Kim S, Chaudhuri A, Young NS. (2000) Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells. *Blood* 96, 2735-9.
  49. Young NS, **Maciejewski JP**. (2000) Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes "Why? Why? Why?". *J Clin Invest.* 106, 637-41. ►
- 2001
50. Brümmendorf TH, Rufer N, Holyoake TL, **Maciejewski JP**, Young NS, Barnett, MJ, Eaves CJ, Eaves AC, Lansdorp P (2001) Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. *Ann N Y Acad Sci.* 938:293-303.
  51. Selleri C, **Maciejewski JP**, (2001). Nitric oxide and cell survival: Megakaryocytes say "NO" *J Lab Clin Med* 137,225-230.
  52. Bruemendorf TH, **Maciejewski JP** (equal contribution), Mak J, Young NS, Lansdorp PM (2001). Telomere length in peripheral blood cells of bone marrow failure patients. *Blood* 97, 895-900. ►
  53. Zeng W, **Maciejewski JP**, Young NS (2001). Characterization of autoreactive T-cells in aplastic anemia. *J.Clin. Invest.* 108, 765-773.
  54. **Maciejewski JP**, Follman D, Rivera C, Simonis T, Young NS (2001). Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and PNH/aplastic anemia syndrome. *Blood.* 98, 3513-3519. ►
  55. Kook H, Young NS, **Maciejewski JP** (2001). Increased cytotoxic T cells with effector phenotype in aplastic anemia *Exp. Hematol.* 29, 1270-1279. ►
- 2002
56. **Maciejewski JP**, Rivera C, Dunn D, Young NS (2002). Clinical features of the relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria. *Brit J Hematol.* 115, 1015-1022. ►
  57. **Maciejewski JP**, Risitano A, Kook H, Zeng Z, Chen G, Young NS (2002). Immune pathophysiology of aplastic anemia. *Int. J. Hematol.* 76, 207-214. ►
  58. **Maciejewski JP**, Risitano AM, Wisch L, Geller N, Barrett JS, Young, NS (2002). A pilot study of the recombinant soluble recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. *Br. J. Hematol.* 117, 119-126. ►
  59. **Maciejewski JP**, Risitano A, Nunez O, Young NS (2002). Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. *Blood.* 99, 3129-35. ►
  60. Chen G, Kirby M, Young NS and **Maciejewski JP** (2002). Superior growth of glycosphosphatidylinositol-anchored protein-deficient progenitor cells in vitro is due to the higher apoptotic rate of progenitors with normal phenotype in vivo. *Exp Hematol* 30, 774-782. ►
  61. Kook H, Zeng W, Wlodarski M, Risitano A., Lotteman C, Young NS, **Maciejewski JP** (2002). Changes in VB-repertoire in aplastic anemia. Effects of multiple immunosuppressive regimens. *Blood* 99, 3668-75. ►
  62. Risitano A, Kook H, Zeng Z, Chen G, Young NS, **Maciejewski JP** (2002). Significance of oligoclonal and polyclonal expansion within CD8 and CD4 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by VB CDR3 Spectratyping and Flow Cytometry. *Blood* 100, 178-183. ►
  63. Sloand E, Kim S, **Maciejewski JP**, Tisdale J, Follmann D, Young NS. (2002) Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. *Blood* 100:1185-91. ►
  64. Young NS, **Maciejewski JP**, Sloand E, Zeng W, Chen G, Risitano AM, Myiazato A (2002) The relationship of aplastic anemia and PNH. *Int. J. Hematol.* 76, 168-172. ►



65. Sloand E, Kim S, Fuhrer M, Risitano AM, Nakamura R, **Maciejewski JP**, Young NS (2002) Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. *Blood*. 100, 4427-4432.
66. Zeng W, **Maciejewski JP**, Chen G, Risitano AM, Kirby M, Young NS. (2002) Selective Reduction of NKT Cells in the Bone marrow of aplastic Anemia and myelodysplastic syndrome. *Brit. J Hematol*. 119, 803-809.
67. Holada K, Simek J, Young NS, **Maciejewski JP**, Vostal JG. (2002) distinct pattern of of prion protein expression i platelets derived from normal individuals and patients with paroxysmal nocturnal hemoglobinuria. *Blood*. 100, 341-
68. Selleri C, **Maciejewski JP**, Catalano LC, Ricci P, Andretta C, Luciano L, Rotoli B (2002). Effects of cyclosporine on he hematopoietic and immune function in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. *Cancer* 95, 1911-1923
69. Sauntharajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, **Maciejewski JP**, Simonis T, Molldrem J, Young, NS, Barrett JA. (2002) HLA DR15 (DR2) is over-represented in myelodysplastic syndrome and aplastic anemia, and predicts a response to immunosuppression in myelodysplastic syndrome. *Blood* 100, 1570-1574.
70. Tisdale JF, **Maciejewski, JP**, Nunez O, Rosenfeld SJ, Young, NS (2002). Late Complications Following High-Dose Cyclophosphamide (Cy) as Initial Treatment for Severe Aplastic Anemia (SAA) Follow up of a Randomized Trial. *Blood* 100, 4668-4670.
71. **Maciejewski JP**, Sloand E, Nunez O, Young N. (2003). Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. *Blood* 102:3584-3586. ►  
2003
72. Risitano A.M., Holada K., Chen G., Simek J., Vostal J.G., Young N.S., **Maciejewski J.M.** (2003) CD34+ cells from paroxysmal nocturnal hemoglobinuria (PNH) patients are deficient in surface expression of normal prion protein (Prp<sup>c</sup>). *Exp. Hematol*. 31, 65-72 ►
73. Plasilova M, Risitano A, **Maciejewski JP**. (2003) Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic diseases. *Hematology* 8:173-181. ►
74. **Maciejewski JP** and Selleri C. (2003). Evolution of clonal cytogenetic abnormalities in aplastic anemia. *Leukemia Lymphoma* 45:433-440. ►
75. **Maciejewski JP** and Risitano AM. (2003). Hematopoietic stem cells in Aplastic Anemia. *Arch. Med. Res*. 34: ►
76. **Maciejewski JP**. Paroxysmal nocturnal hemoglobinuria. (2003). Aplastic Anemia and MDS International Foundation Newsletter. ►
77. Lee JJ, Nam CE, Kook H, **Maciejewski JP**, Kim YK, Chung IJ, Park KS, Lee IK, Hwang TJ, Kim HJ (2003). Constitution and telomere dynamics of bone marrow stromal cells in patients undergoing allogeneic bone marrow transplantation. *Bone Marrow Transplant* 32:947-52
78. Sloand EM, Fuhrer M, Keyvanfar K, Mainwaring L, **Maciejewski JP**, Wang Y, Johnson S, Barrett AJ, Young NS. (2003) Cytogenetic abnormalities in paroxysmal nocturnal haemoglobinuria usually occur in haematopoietic cells that are glycosylphosphatidylinositol-anchored protein (GPI-AP) positive. *Br J Haematol*:23:173-6.
79. Selleri, C, **Maciejewski JP**, Mountouri N, Patricia Ricci, Visconte V, Serio B, Luciana L, Rotoli B (2003). Involvement of nitric oxide in farnesil transferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells. *Blood* 102:1490-1498.
80. Beck RC, Stahl S, O'Keefe CL, **Maciejewski JP**, Theil KS and His ED. (2003). Detection of mature T cell leukemias by flow cytometry using anti-t cell receptor Vβ antibodies. *Am. J Clin Path* 120:785-794.
81. Chen G, Kook H, Zeng W, Young NS and **Maciejewski JP**. (2003). Is there a direct effect of antithymocyte globulin on hematopoiesis? *J. Hematol*. 5:255-261. ►

2004

82. Risitano AM, **Maciejewski JP**, Green S, Plasilova M, Zeng W, and Young NS. (2004). In vivo dominant immune responses in aplastic anemia patients: molecular tracking of putatively pathogenic T cell clones by TCR $\beta$ -CDR3 sequencing. *Lancet* 364:355-364.
83. O'Keefe C, **Maciejewski JP**, Risitano AM (2004). Clinical implications of T cell receptor repertoire analysis after allogeneic stem cell transplantation. *Hematol.* 9:189-198.
84. O'Keefe CL, Sobecks, RM, Rodriguez A, Bell, K, Kuczkowski E, Bolwell BJ and **Maciejewski, JP**. (2004). Molecular TCR diagnostics can be used to identify shared clonotypes after allogeneic hematopoietic stem cell transplantation. *Exp. Hematol.* 32,1010-1022. ►
85. O'Keefe CL, Plasilova M, Risitano AM, Rodriguez AR, Wlodarski M, Young NS and **Maciejewski JP** (2004). Molecular analysis of T cell receptor clonotypes in LGL – a clonal model for polyclonal responses. *J Immunol* 172, 1960-1969. ►
86. Plasilova M, Risitano AM, O'Keefe CL, Rodriguez A, Wlodarski, M and **Maciejewski, JP**. (2004). Shared and individual specificities of immunodominant cytotoxic T cell clones in paroxysmal nocturnal hemoglobinuria as determined by molecular analysis. *Exp. Hematol* 32:261-269. ►
87. Kim JA, Rao P, Graor H, Rothchild K, O'Keefe C and **Maciejewski JP**. (2004). CDR3 spectratyping identifies clonal expansion within T-cell subpopulations that demonstrate therapeutic antitumor activity. *Surgery* 136:295-302. ►
88. Khaiboullina SF, **Maciejewski JP**, Crapnell K, Pari GS, Zanjani ED, St.Jeor S (2004) Human cytomegalovirus persistence in bone marrow progenitor cells from healthy donors and after in vitro infection. *Br J Haematol.* 126:410-417.
89. Kearns WG, Sutton JF, **Maciejewski JP**, Young NS, Liu JM. (2004). Genomic instability in bone marrow failure syndromes. *Am J Hematol.* 76:220-224.
90. Sloand EM, Mainwaring L, Keyvanfar K, Chen J, **Maciejewski J**, Klein HG, Young NS. (2004). Evidence for transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria. *Blood* 104:3782-8.
91. Khaiboullina SF, Rizvanov AA, Otteson E, Miyazato A, **Maciejewski J**, St Jeor S. (2004). Regulation of cellular gene expression in endothelial cells by sin nombre and prospect hill viruses. *Viral Immunol.* 17:234-251.
92. Chen G, Zeng W, Miyazato A, Billings E, **Maciejewski JP**, Kajigaya S, Sloand EM, Young NS. (2004). Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. *Blood* 104:4210-8.

2005

93. Howe EC, Wlodarski M, Ball E, **Maciejewski JP** (2005). Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndrome. *Exp. Hematol.* 33:1357-1362.
94. Beck R, Wlodarski M, Gondek L, Theil KS, Tuthill R, Bolwell B, and **Maciejewski JP** (2005) Efficient identification of T-cell clones associated with graft-versus-host disease in target tissue allows for subsequent detection in peripheral blood. *Brit J. Hematol.* 129, 411-4119 ►
95. Wlodarski M, O'Keefe Ch, Howe E, Rodriguez A, Warshawsky I, Loughran T, **Maciejewski JP** (2005). Pathologic clonal cytotoxic T cell responses - non random nature of the T cell receptor restriction in large granular lymphocyte leukemia. *Blood* 106:2769-1780 ►
96. **Maciejewski JP** and Risitano AM. (2005). Aplastic anemia: management of adult patients. *Hematology* (Am Soc Hematol Educ Program) 110-117. ►
97. Risitano RM, **Maciejewski JP**, Muranski P, Wlodarski M, O'Keefe C, Sloand EM and Young NS (2005). Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients. *Leukemia* 19:217-222.

98. Chen G, Zeng W, **Maciejewski JP**, Keyvanfar K, Billings EM, Young NS (2005) Differential gene expression in hematopoietic progenitors from paroxysmal nocturnal hemoglobinuria patients reveals an apoptosis/immune response in normal phenotype cells. *Leukemia* 19, 862-868.
  99. Bego M, **Maciejewski JP**, Khaiboullina S, Pari G and St Jeor S. (2005). Characterization of an anti-sense transcript spanning the UL81-82 locus of HCMV. *J. Vir.* 79:11022-34.
  100. Dean R, Masci P, Pohlman B, Andresen S, Serafino S, Sobecks R, Kuczkowski E, Curtis J, **Maciejewski JP**, Rybicki L, Kalaycio M, Hsi E, Theil K and Bolwell BJ. (2005) Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival. *Bone Marrow Transplant* 36, 1049-1052.
  101. Omine M, Kinoshita T, Nakakuma H, **Maciejewski JP**, Parker CJ and Socie G. (2005). Paroxysmal nocturnal hemoglobinuria. *Int J Hematol.* 82:417-421.
- 2006
102. Zeng W, Miyazato A, Chen G, Kajigaya S, Young NS and **Maciejewski JP** (2006). Interferon- $\gamma$ -induced gene expression in CD34 cells. Identification of pathologic cytokine-specific signature profiles. *Blood* 107:167-175 ►
  103. Schade AE, Powers J, Wlodarski MW and **Maciejewski JP** (2006). Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. *Blood* 107:4834-40. ►
  104. Wlodarski M, Gondek G, Nearman N, Rodriguez A, Plasilova M, Sekeres M, and **Maciejewski JP**. (2006) Molecular strategies for detection and quantitation of clonal cytotoxic T cell responses in myelodysplastic syndrome and aplastic anemia. *Blood* 108:2632-2641. ►
  105. Szpurka H, Tiu R, Murugesan G, Dola S, Hsi ED, Theil KS, Sekeres MA and **Maciejewski JP** (2006). Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. *Blood* 108:2173-81. ►
  106. Tiu R and **Maciejewski JP** (2006). Immunologic pathogenesis of paroxysmal nocturnal hemoglobinuria. *Int J. Hematol.* 84:113-117. ►
  107. Schade AE, Wlodarski MW, **Maciejewski JP** (2006) Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes. *Cell Cycle* 5:2571-2574. ►
  108. Wlodarski M, Schade A, **Maciejewski JP** (2006). T- large granular lymphocyte leukemia: current molecular concepts. *Hematology*, 11:245-256. ►
  109. Nearman ZP, Wlodarski M, Jankowska AM, Howe E, Narvaez Y, Ball E and **Maciejewski JP**. (2006). Immunogenetic factors determining the evolution T-cell large granular lymphocyte leukemia and associated cytopenias. *Brit. J. Hem.* 136, 237-248. ►
  110. Murugesan G, Aboudola S, Szpurka H, Verbic MA, **Maciejewski JP**, Tubbs RR and Hsi E. (2006). Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. *Am J Clin Pathol.* 125:625-633. ►
  111. Sloand EM, Scheinberg P, **Maciejewski JP** and Young N. (2006). Successful treatment of pure red cell aplasia with anti-IL-2 receptor antibody (Daclizumab). *Annals of Int. Med.* 144:181-185. ►
  112. Sobecks R, Ball EJ, **Maciejewski JP**, Rybicki LA, Brown S, Kalaycio M, Pohlman B, Andresen S, Theil K, Dean R, Bolwell BJ. (2006). Survival difference of AML patients receiving HLA matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors (KIRs). *BJH.* 355:1233-1238 ►
  113. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu C, **Maciejewski JP**, Rollins SA, Mojcik CF, Rother RP and Luzzatto L. (2006). Safety and efficacy of the C5 complement inhibitor eculizumab in patients with paroxysmal nocturnal

hemoglobinuria. *NEJM*. 355:1233-1243.

## 2007

114. **Maciejewski JP**, O'Keefe C, Gondek L and Tiu R. (2007). Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones. *Folia Histochemica at Cytobiologica* 45: ►
115. O'Keefe CL, Tiu R, Gondek L, Powers J, Theil KS, Kalaycio M, Sekeres MA, and **Maciejewski JP**. (2007). High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. *Exp Hematology* 35:240-251. ►
116. Nearman ZP, Szpurka H, Serio B, Warshawsky I, Theil K, Lichtin A, Sekeres MA and **Maciejewski JP** (2007). Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. *Am. J Hematology* 10:1076-1079. ►
117. Tiu R, Gondek L, O'Keefe C and **Maciejewski JP** (2007). Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. *Leukemia* 21:1648-1657. ►
118. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS and **Maciejewski JP**. (2007). Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. *Leukemia* 21: ►
119. O'Keefe CL, Gondek L, Kuczkowski E, Sobecks RM, Rodriguez A, Narvaez Y, McIver Z, Tuthill R, Laughlin M, Bolwell B and **Maciejewski JP** (2007). Molecular analysis of alloreactive CTL Post-HSC transplantation. *J. Immunol* 179: 2013-2022. ►
120. Gondek LP, Dunbar AJ, Szpurka H and **Maciejewski JP** (2007). SNP array-based detection of uniparental disomy and cryptic chromosomal abnormalities in variants of MPD. *PlosOne* 11:e1225. ►
121. Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, **Maciejewski JP** and Hsi ED. (2007). Bone marrow phospho-STAT5 expression in chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. *Am J Surg Pathol*. 31:233-239.
122. Golshayan A, Jin T, **Maciejewski J**, Fu AZ, Bershadsky B, Kattan MW, Kalaycio ME, Sekeres MA. (2007). Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. *Br J Haematol*. 137:125-132.
123. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, Lombardi G, Wlodarski MW, **Maciejewski JP**, Farzaneh, Mufti (2007). CD4<sup>+</sup>CD25<sup>high</sup> Foxp3<sup>+</sup> regulatory T-cells in myelodysplastic syndrome (MDS). *Blood* 110:847-850. ►
124. Gondek LP, Haddad AS, O'Keefe CL, Tiu R, Wlodarski M, Sekeres MA, Theil KS and **Maciejewski JP** (2007). Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low risk myelodysplastic syndromes. *Exp. Hematol* 35, 1728-38. ►
125. Sekeres MA, Fu AZ, **Maciejewski JP**, Golshayan AR, Kalaycio ME and Kattan MW. (2007). A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndrome. *Cancer* 109:1125-32.
126. Brodsky RA, Young NS, Antonioli E, Rotoli B, Schrezenmeier H, Schubert J, Urbano-Ispizua A, Coyle L, de Castro C, Fu C, **Maciejewski JP**, Bessler M, Kroon H, Rother RP and Hillmen P. (2007). Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. *Blood* 111:1840-7.
127. Sobecks RM, Ball EJ, Askar M, Theil KS, Rybicki LA, Thomas D, Brown S, Kalaycio M, Andresen S, Pohlman B, Dean R, Sweetenham J, Bernhard L, Cherni K, Copelan E, **Maciejewski JP** and Bolwell BJ. (2007). Influence of killer immunoglobulin-like receptor (KIR)/HLA ligand matching on achievement of T-cell (CD3<sup>+</sup>) complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem transplantation. *Bone Marrow Transplant*. 3

## 2008

128. Jankowska AM, Gondek LP, Szpurka H, Nearman ZP, Tiu R and **Maciejewski JP** (2008). Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome. *Leukemia* 22(3):551-8. ►

129. Schade AS, Jankowska A, Szpurka H, and **Maciejewski JP** (2008). Dasatinib, a small molecule protein tyrosine kinase inhibitor, potently inhibits T cell activation and proliferation. *Blood* 111:1366-77. ►
130. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS and **Maciejewski JP**. (2008) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD and MDS-derived AML. *Blood* 111:534-42. ►
131. Wlodarski MW, Nearman Z, Powers J, Leahy P and **Maciejewski JP**. (2008). Expression profiling reveals discrete differences between normal cytotoxic effector lymphocytes and immunodominant large granular lymphocytes. *J. Leuk. Biol.* 83(3):589-601. ►
132. Haddad AS, Subbiah V, Lichtin AE, Theil KS and **Maciejewski JP**. (2008). Hypocupremia and bone marrow failure. *Hematologica* 93, e1-5. ►
133. McIver Z, Serio B, Dunbar A, O'Keefe CL, Powers J, Wlodarski M, Jin T, Sobecks R, Bolwell B and **Maciejewski JP**. (2008). Double negative Tregs induce allotolerance when expanded after allogeneic bone marrow transplant. *Brit J. Immunol.* 141:170-8. ►
134. Viny AD, Lichtin A, Pohlman B, Loughran TP and **Maciejewski JP**. (2008). Chronic B-cell dyscrasias are an important clinical feature of LGL leukemia. *Leukemia and lymphoma* 2008 49(5):932-8. ►
135. Wlodarski MW, Narvaez Y, Jiang Y, Rodriguez A, Lichtin A and **Maciejewski JP**. (2008). Polarized cytotoxic T lymphocyte responses in patients with unexplained neutropenia. *Exp. Hematol.* 36: 293-300. ►
136. Subbiah V, Viny AD, Rosenblatt S, Pohlman B and **Maciejewski JP**. (2008). Clinical features of patients with T-cell large granular lymphocyte leukemia distinguish patients with splenomegaly and those who benefit from splenectomy. *Exp. Hematol.* 36:1078-83. ►
137. Szpurka H, Schade AE, Jankowska AM and **Maciejewski JP**. (2008). Altered lipid raft composition and defective apoptotic signal transduction in paroxysmal nocturnal hemoglobinuria. *Brit J Hem.* 142(3):413-22. ►
138. **Maciejewski JP** and Mufti GJ (2008) Whole genome scanning as a cytogenetic tool in hematologic malignancies. *Blood* 112:965-74. ►
139. Dunbar AJ, Gondek L, O'Keefe Ch, Rataul M, Szpurka H, Sekeres MA, Wang XF, McDevitt MA **Maciejewski JP** (2008) Detection of Acquired Uniparental Disomy Using 250K SNP-Array Technology Reveals Novel Missense Mutations in *c-CBL* in Patients with Malignant Myeloid Disorders. *Cancer Research* 68:10349-57. ►
140. Szpurka H, Gondek LP, Mohan S, His ED, Theil KS, **Maciejewski JP**. (2008) Biallelic cMPL W515L mutation in RARS-T due to acquired 1p uniparental disomy. *Leukemia* 23(3):610-4. ►
141. Babel N, Brestrich G, Gondek LP, Hammer MH, Wlodarski MW, Poliak N, Karaivanov S, Volk H, Reinke P and **Maciejewski JP**. (2008). Restricted clonotypic spectrum of CMV-specific cytotoxic T-cells obtained after pp 65 peptide pool stimulation. *J Am Soc Nephrol.* 20(2):344-52. ►
142. Jiang Y, Sauntharajah Y, Dunbar D, Rataul M, Gondek LP, Mohan S, O'Keefe Ch, **Maciejewski JP** (2008) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. *Blood* 13:1315-25. ►
143. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, **Maciejewski JP**. (2008). Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. *J Natl Cancer Inst.* ►
144. Lai, D., Loughran T., **Maciejewski JP.**, Sasu S., Song S, Eppling-Burnette PK., Paquette R RL (2008) Amegakaryocytic thrombocytopenia and pure red cells aplasia due to occult large granular lymphocyte leukemia. *Leu Res.* 32(5):823-7.
145. Risitano AM, **Maciejewski JP**, Salleri C, Rotoli B. (2008). Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes. *Curr Stem Cell Res Ther.* 2:39-52.
146. Fanning Lr, Lesniewski ML, Lazarus H., Kozik MM, Hegerfedt Y, Ratajczak M, Greco N, Haviemik P, Paul P, **Maciejewski JP**, Laughlin MJ. (2008) Allogeneic transplantation of multiple umbilical cord blood units in adults: role of pre-transplant mixed lymphocyte reaction to predict host vs. graft rejection. *Leukemia* 22 (9):1786-90.

147. Lesniewski ML, Haviernik P, Weitzel RP, Kadereit S, Kozik MM, Fanning LR, Yang YC, Hegerfeldt Y, Finne MR, Ratajczak MZ, Greco N, Paul P, **Maciejewski JP**, Laughlin MJ. (2008). Regulation of IL-2 expression by transcription factor BACH2 in umbilical cord blood CD4(+) T cells. *Leukemia* 22:2293-4.
  148. Haferlach C, Bacher U, Tiu R, **Maciejewski JP**, List A. (2008). Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. *Cancer Genet Cytogenet* 187:101-11. ►
  149. Sekeres MA, **Maciejewski JP**, Giagounidis AA, Wride K, Knight R, Raza A, List AF. (2008) Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndrom J *Clin Oncol*. 26:5943-9.
- 2009
150. Mohan SR, **Maciejewski JP** (2009). Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. *Curr Opin Hematol*. 16 :27-34 ►
  151. **Maciejewski JP**, Tiu RV, O'Keefe C (2009). Application of array-based whole genome scanning technologies as a cytogenetic tool in hematologic malignancies. *Br. J. Haematol* 146(5):479-88. ►
  152. Jankowska A, Afable E, McDevitt M, **Maciejewski JP** (2009). TET2 Gene Harbors Mutations Associated with Myeloid Malignancies *Blood* 113:6403-10. ►
  153. Tiu RV, Gondek LP, O'Keefe CL, Huh J, Sekeres MA, Elson P, McDevitt MA, Wang XF, Levis MJ, Karp JE, Advani AS, **Maciejewski JP** (2009). New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. *J Clin Oncol* 27(31):5219-26. ►
  154. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, **Maciejewski JP** (2009). Mutations of E3 ubiquitin ligase *cbl* family members constitute a novel common pathogenic lesion in myeloid malignancies. *J Clin Oncol* 27(36):6109-16. ►
  155. Muramatsu H, Makishima H, Jankowska AM, Cazzolli H, O'Keefe C, Yoshida N, Xu Y, Nishio N, Hama A, Yagasaki H, Takahashi Y, Kato K, Manabe A, Kojima S, **Maciejewski JP** (2009). Mutations of E3 ubiquitin ligase *Cbl* family members a novel type of pathogenic lesion in juvenile myelomonocytic leukemia. *Blood* 115(10):1969-75. ►
  156. Mohan S, Clemente M, Afable M, Cazziolli H, Bejanyan N, Wlodarski M, Lichtin A, **Maciejewski JP** (2009). Therapeutic Implications of Variable Expression of CD52 on Clonal Cytotoxic T Cells in CD8+ Large Granular Lymphocyte Leukemia. *Haematologica* 94:1407-14 ►
  157. Wei S, Chen X, Rocha K, Williams A, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu L, Dewald G, **Maciejewski JP**, List A (2009). Gene Dosage of the Cell Cycle Regulatory Phosphatases Cdc25C and PP2A Determines Sensitivity to Lenalidomide in Del(5q) MDS. *PNAS*. 106:12974-9. ►
  158. Ye Y, McDevitt MA, Guo M, Zhang W, Galm O, Gore SD, Karp JE, **Maciejewski JP**, Kowalski J, Tsai HL, Gondek JP, Tsai HC, Wang X, Hooker C, Smith BD Carraway HE, Herman JG (2009). Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. *Cancer Res*. 69(21):8482-90.
  159. Tiu R, Yacoub H, **Maciejewski JP**, Sila CA (2009). Recurrent ischemic stroke in paroxysmal nocturnal hemoglobinuria: paroxysmal nocturnal hemoglobinuria or missed patent foramen ovale? *J Stroke Cerebrovasc Dis*. Sep-Oct; 18(5):409-10.
  160. Makashima H, Rataul M, Gondek LP, Huh J, Cook JR, Theil KS, Sekeres MA, Kuczkowski E, O'Keefe C, **Maciejewski JP** (2009). FISH and SNP-A Karyotyping in Myelodysplastic Syndromes: Improving Cytogenetic Detection of Del (5q), Monosomy 7, Del (7q), Trisomy 8 and Del(20q) *Leuk Res* 2010 Apr;34(4):447-53. ►
  161. Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, **Maciejewski JP** (2009). Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. *Leuk Res* 34(6):708-13. ►
  162. Jasek M, Gondek LP, Bejanyan N, Tiu R, Huh J, Theil KS, O'Keefe C, McDevitt MA, **Maciejewski JP** (2009). TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of

heterozygosity or deletion of 17p. *Leukemia* 2010 Jan; 24(1):216-9. ►

## 2010

163. O'Keefe CL, McDevitt MA, Maciejewski JP (2010). Uniparental disomy in myeloid malignancies cancer. *Blood* 115(27):2731-39. ►
164. Szpurka H, Jankowska A, Makishima H, Bejanyan N, Hsi E, Sekeres M, Maciejewski JP (2010). TET2 Mutations, Chromosomal Lesions Found in RARS-T Patients. *Leuk Res.* 34(8):969-73. ►
165. Viny A, Jasek M, Clemente M, Askar M, Ishwaran H, Nowacki A, Maciejewski JP (2010). MICA Polymorphism Identified by Whole Genome Array Associated with NKG2D-Mediated Cytotoxicity in T-Cell Large Granular Lymphocyte Leukemia. *Haematologica* Oct; 95(10):1713-21. ►
166. Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP (2010). Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. *Genes Chromosomes Cancer* 49(4):390-9. ►
167. Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Latham D, Paulic K, Afable M, Saba HI, Loughran TP Jr, Maciejewski JP (2010). Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. *J Clin Oncol.* 28(13):2253-8. ►
168. Sugimoto Y, Muramatsu H, Makishima H, Prince C, Jankowska AM, Yoshida N, Xu Y, Nishio N, Hama A, Yagasaki H, Takahashi Y, Kato K, Manabe A, Kojima S, Maciejewski JP (2010). Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. *Br J Haematol.* 150(1):83-7. ►
169. Howard M, Hsi E, Maciejewski JP (2010). T/NK Large Granular Lymphocyte Leukemia and Coexisting Monoclonal B-cell Lymphocytosis-like Proliferations: An Unrecognized and Frequent Association. *Am J Pathol.* 133(6):936-41. ►
170. Makishima H, Jankowska AM, Tiu RV, Hadrian Szpurka H, Yuka Sugimoto Y, Hu Z, Guin K, Keddache MA, Patrick Putnam P, Mikkael A, Sekeres MA, Moliterno A, List AF., McDevitt MA, Maciejewski JP (2010). Novel homo- and hemizygous mutations in ezh2 in myeloid malignancies. *Leukemia* 24:1799-804. ►
171. Smieszek S, Richter R, Przychodzen B, Maciejewski J (2010). Silicosection and elucidation of the plant circadian clock using bayesian classifiers and new genemining algorithm. *Adv Exp Med Biol.* 680:43-56. ►
172. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A (2010). Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. *Nature* 468(7325):839-43.
173. Bejanyan N, Fu AZ, Lazaryan A, Fu R, Kalaycio M, Advani A, Sobecks R, Copelan E, Maciejewski JP, Sekeres MA (2010). Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia. *Cancer* 116(15):3614-20.
174. Hu Z, Negrotto S, Gu X, Mahfouz R, Ng KP, Ebrahim Q, Copelan E, Singh H, Maciejewski JP, Sauntharajah Y (2010) Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. *Mol Cancer Ther.* 9(6):1536-43.
175. Sloan EM, Olnes MJ, Weinstein B, Wu C, Maciejewski JP, Scheinberg P, Young NS (2010). Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. *Haematologica* 95:382-7.
176. Advani AS, Tiu R, Sauntharajah Y, Maciejewski JP, Copelan EA, Sobecks R, Sekeres MA, Bates J, Rush ML, Tripp B, Salvado A, Noon E, Howard M, Jin T, Hsi E, Egorin MJ, Lim K, Cotta CV, Price C, Kalaycio M (2010). Phase I study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. *Leuk Res.* Dec;34(12):1622-6.
177. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gaken J, Lea NC, Przychodzen B, Mian SA, Nasser EE, Shoot C, Westwood NB, Strupp C, Gattermann N, Maciejewski JP, Germing U, Mufti GJ (2010). Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low abundance mutant clones with early origins, but indicates no definite prognostic value. *Blood* 116(19):3923-32.

178. Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, **Maciejewski JP**, Tiu RV, Diffronzo N, Horowitz MM, Antin JH (2010). Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biological and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. *Biol Blood Marrow Transplant.* (3):291-9.
  179. Sloand E, Pfannes L, Ling C, Jasek M, Calado R, Tucker ZC, Feng X, Hematti P, **Maciejewski JP**, Dunbar C, Barrett J, Young N (2010). Graft-vs.-Host Disease: Role of Inflammation in the development of chromosomal abnormalities of keratinocytes. *Biol Blood Marrow Transplant.* 12:1665-73.
  180. Sekeres MA, **Maciejewski JP**, Erba HP, Afable M, Englehaupt R, Sobecks R, Advani A, Seel S, Chan J, Kalaycio ME (2010). A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. *Cancer* 117(6):1253-61.
  181. Byrne MT, Bergman AK, Ruiz AI, Silver BJ, **Maciejewski JP**, Tiu RV (2010). Postsplenectomy thromboembolic disease in congenital sideroblastic anaemia. *BMJ Case Rep.* 2010. [PM:22778251]
  182. Sloand EM, Pfannes L, Ling C, Feng X, Jasek M, Calado R, Tucker ZC, Hematti P, **Maciejewski J**, Dunbar C, Barrett J, Young N (2010). Graft-versus-host disease: role of inflammation in the development of chromosomal abnormalities of keratinocytes. *Biol Blood Marrow Transplant* 16:1665-73.
  183. Sekeres MA, O'Keefe C, List AF, Paulic K, Afable M, Englehaupt R, **Maciejewski JP** (2011). Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. *Am J Hematol.* 1:102-3. ►
- 2011
184. O'Keefe CL, Sugimori C, Afable M, Clemente M, Shain K, Araten DJ, List A, Epling-Burnette PK, **Maciejewski JP** (2011). Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria. *Leukemia* Feb; 25(2):379-82. ►
  185. Afable M, Wlodarski WW, Gondek L, O'Keefe Ch, Tiu T, Haddad A, Risitano R, **Maciejewski JP** (2011). SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. *Blood* June; 117(25): 6876- 6884. ►
  186. Afable MG, Shaik M, Sugimoto Y, Elson P, Clemente MJ, Makishima H, Sekeres MA, Lichtin A, Advani A, Kalaycio M, Tiu RV, O'Keefe C, **Maciejewski J** (2011). Efficacy of rabbit antithymocyte globulin in severe aplastic anemia. *Haematologica.* Sep; 96(9):1269-75. ►
  187. Tiu RV, O'Keefe CL, Gondek LP, Huh J, Mohamedali A, Advani A, List AF, Sekeres MA, McDevitt MA, Mufti G, **Maciejewski JP** (2011). Prognostic Impact of SNP Array Karyotyping in Myelodysplastic Syndromes. *Blood* 117, ►
  188. Tiu RV, Visconte V, Traina F, Schwandt A, **Maciejewski JP** (2011). Updates in Cytogenetics and Molecular Markers in MDS. *Curr Hematol Malig Rep.* 2011 Jun; 6(2):126-35. ►
  189. Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, Siddaiah H, Shaik M, Szpurka H, Hsi E, Advani A, Paquette R, **Maciejewski JP** (2011). CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. *Blood* May 26; 117(21):e198-206. ►
  190. Askar M, Sobecks R, Morishima Y, Kawase T, Nowacki A, Makishima H, **Maciejewski JP** (2011). Predictions in the Face of Clinical Reality: HistoCheck versus High- Risk HLA Allele Mismatch Combinations Responsible for Severe Acute Graft-versus-Host Disease. *Biol Blood Marrow Transplant.* Sep; 17(9):1409-15. ►
  191. Jankowska AM, Szpurka H, Calabro M, Mohan S, Schade AE, Clemente M, Silverstein RL, **Maciejewski JP** (2011). Loss of expression of neutrophil proteinase-3: a contributory factor in thrombotic risk in paroxysmal nocturnal hemoglobinuria. *Haematologica.* Jul; 96(7):954-62. ►
  192. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, **Maciejewski JP** (2011). Mutational spectrum analysis of CMML includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A. *Blood* Oct; 118:3932- 41. ►



193. Clemente M, Wlodarski MW, Makishima H, Viny HD; Bretschneider B; Shaik M; Bejarian N, Lichtin A, Hsi E; Paquette RL, Loughran TP, **Maciejewski JP** (2011). Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. *Blood* Oct 20; 118(16):4384-93. ►
  194. Afable MG 2nd, Tiu RV, **Maciejewski JP** (2011). Clonal evolution in aplastic anemia. *Hematology Am Soc Hematol Educ Program*. 2011:90-5. ►
  195. Feng X, Scheinberg P, Wu CO, Samsel L, Nunez O, Prince C, Ganetzky RD, McCoy JP, **Maciejewski JP**, Young NS (2011). Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. *Haematologica*. Apr; 96(4):602-6. ►
  196. Bego MG, Keyes LR, **Maciejewski JP**, St Jeor SC (2011). Human cytomegalovirus latency-associated protein LUNA is expressed during HCMV infections in vivo. *Arch Virol*. 156(10):1847-51. ►
  197. Kojima S, Nakao S, Young N, Bacigalupo A, Gerard G, Hirano N, **Maciejewski J**, Deeg J, Marsh J, Zhang FK, Lee JW, Ozawa K (2011). The Third Consensus Conference on the treatment of aplastic anemia. *Int J Hematol*. 93:832-7
  198. Sekeres MA, **Maciejewski JP**, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R (2011). Perceptions of Disease State, Treatment Outcomes, and Prognosis Among Patients with Myelodysplastic Syndromes: Results From an Internet-Based Survey. *Oncologist* 2011;16(6):904-11.
  199. Bodo J, Sedlak J, **Maciejewski JP**, Almasan A, Hsi ED (2011). HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. *Apoptosis* Sep;16(9):914-23.
  200. Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, **Maciejewski JP**, McDevitt MA, Moliterno AR (2011). Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocythosis and post-polycythemia vera myelofibrosis, but not essential thrombocythosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. *Haematologica* Oct;96(10):1462-9.
  201. Ng KP, Ebrahim Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, Gu X, Advani A, Kalaycio M, Sobecks R, Sekeres M, Copelan E, Radvovoyevitch T, **Maciejewski J**, Mulloy JC, Sauntharajah Y (2011). p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. *Leukemia* Nov;25(11):1739-50
  202. Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G, Rybicki LA, Kalaycio M, **Maciejewski JP**, Houghton JA, Almasan A (2011). An anti-apoptotic Bcl-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. *Blood* Sep 29;118(13):3579-90. ►
- 2012**
203. Makishima H, Sugimoto Y, Szpurka H, Clemente MJ, Ng KP, Muramatsu H, O'Keefe C, Sauntharajah Y, **Maciejewski JP** (2012). CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors. *Leukemia* Jul; 26(7):1547-54. ►
  204. Hama A, Muramatsu H, Makishima H, Sugimoto Y, Szpurka H, Jasek M, O'Keefe C, Takahashi Y, Sakaguchi H, Doisaki S, Shimada A, Watanabe N, Kato K, Kiyoi H, Naoe T, Kojima S, **Maciejewski JP** (2012). Molecular lesions in childhood and adult acute megakaryoblastic leukaemia. *Br J Haematol*. Feb; 156(3):316-25. ►
  205. Sauntharajah Y, **Maciejewski J** (2012). Polycomb segment myeloid malignancies. *Blood* Feb 2; 119(5):1097-8. ►
  206. Makishima H, Visconte V, Sakguchi H, Jankowska AM, Abu Kar S, Jerez A, Przychodzen B, Bupathi M, Guinta K, Afable MG, Sekeres MA, Padgett RA, Tiu RV, **Maciejewski JP** (2012). Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. *Blood* Apr 5; 119(14):3203-10. ►
  207. Jerez A, Gondek LP, Jankowska AM, Makishima H, Przychodzen B, Tiu RV, O'Keefe CL, Mohamedali AM, Batista D, Sekeres MA, McDevitt MA, Mufti GJ, **Maciejewski JP** (2012). Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited. *J Clin Oncol*. Apr 20; 30(12):1343-9. ►
  208. Sugimoto, Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A, Jerez A, Szpurka H, O'Keefe CL, Guinta K, Afable M, Tiu R, McGraw KL, List AF, **Maciejewski JP** (2012). Cytogenetic and molecular predictors of response in patients with myeloid malignancies with del (5q) treated with lenalidomide. *J Hematol Oncol.*; 5(1):4. ►

209. Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultonwood J, Mufti GJ, **Maciejewski JP** (2012). Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. *Blood* Jun 21; 119(25):6109-17. ►
210. **Maciejewski JP**, Padgett RA (2012). Defects in spliceosomal machinery: a new pathway of leukaemogenesis. *Br J Haematol.* Jul; 158(2):165-73. ►
211. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Ng KP, Olson T, Przychodzen BP, Afable M, Gomez-Segui I, Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, Wlodarski MW, Porkka K, Sekeres MA, List A, Mustjoki S, Loughran TP, **Maciejewski JP** (2012). STAT3 mutations unify the pathogenesis of chronic disorders of NK cells and T cell large granular lymphocyte leukemia. *Blood* Oct 11; 120(15):3048-57. ►
212. Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarrokhi A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, **Maciejewski JP** (2012). Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. *Blood* Dec 13; 120(25):4945-51. ►
213. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, Rogers JH, Sekeres MA, **Maciejewski JP**, Tiu RV (2012). *SF3B1*, a splicing factor is frequently mutated in Refractory Anemia with Ring Sideroblasts. *Leukemia* 2012 Mar;26(3):542-5. ►
214. Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Sauntharajah Y, Mooney L, **Maciejewski JP**, Sekeres MA (2012). A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). *Cancer* Aug 15;118(16):3968-76. ►
215. Gerning U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenauz P, Kelaidi C, Pfeilstocker M, Nosslinger T, Sekeres MA, **Maciejewski J**, Haase D, Schanz J, Seymour J, Kenealy M, auder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kundgen A, Haas R, Hasford J, Giagounidis A (2012). Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. *Leukemia* Jun;26(6):1286-92. ►
216. Platzbecker U, Santini V, Mufti GJ, Haferlach C, **Maciejewski JP**, Park S, Solé F, van de Loosdrecht AA, Haase D (2012). Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop. *Leuk Res.* Mar;36(3):264-70.
217. Schwele S, Fischer AM, Brestrich G, Wlodarski MW, Wagner L, Schmuck M, Roemhild A, Thomas S, Hammer MH, Babel N, Kurtz A, **Maciejewski JP**, Reinke P, Volk HD (2012). Cytomegalovirus-Specific Regulatory and Effector T Cells Share TCR Clonality-Possible Relation to Repetitive CMV Infections. *Am J Transplant* Mar;12(3):69-81.
218. Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbade NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, **Maciejewski JP**, Loughran TP Jr (2012). Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. *Leuk Res.* May;36(5):581-7.
219. Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, Mulloy JC, Hsi E, **Maciejewski J**, Sauntharajah Y (2012). CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. *Leukemia* Feb;26(2):244-254. [PM:21836612].
220. Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, **Maciejewski JP**, List AF, Epling-Burnette PK, Araten DJ (2012). Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. *Blood Cancer J.* Mar;2(3):e63.
221. Saito Y, Aoki Y, Muramatsu H, Makishima H, **Maciejewski JP**, Imaizumi M, Rikiishi T, Sasahara Y, Kure S, Niihori T, Tsuchiya S, Kojima S, Matsubara Y (2012). Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia. *Leuk Res.* Aug;36(8):1009-15.
222. Visconte V, Makishima H, **Maciejewski JP**, Tiu RV (2012). Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. *Leukemia* Dec;26(12):2447-54.

223. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP Jr, Heckman CA, **Maciejewski JP**, Mustjoki S (2012). Somatic STAT3 mutations in large granular lymphocytic leukemia. *N Engl J Med*. May 17;366(20):1905-13.
224. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, **Maciejewski JP**, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012). Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. *Blood* Sep 20;120(12):2454-65.
225. Sakaguchi H, Makishima H, Muramatsu H, Visconte V, Jerez A, Jankowska AM, Tiu RV, **Maciejewski JP**, Kojima S (2012). Mutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies. *Leuk Res*. Dec;36(12):e215-7.
226. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat T, Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultonwood J, Montagna C, Silverman L, **Maciejewski JP**, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A (2012). Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations. *Blood* Sep 6; 120(10):2076-86.
227. Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F, McMahon J, Makishima H, Szpurka H, Jankowska A, Jerez A, Sekeres MA, Sauntharajah Y, Advani AS, Copelan E, Koseki H, Isono K, Padgett RA, Osman S, Koide K, O'Keefe C, **Maciejewski JP**, Tiu RV (2012). SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. *Blood* Oct 18; 120(16):3173-86.
228. Ratajczak J, Kucia M, Mierzejewska K, Natarajan N, Sharma V, Miller DM, **Maciejewski J**, Ratajczak MZ (2012). A novel view of PNH pathogenesis: more motile PNH hematopoietic stem/progenitor cells displace normal HSPCs from their niches in bone marrow due to defective adhesion, enhanced migration and mobilization in response to erythrocyte-released sphingosine-1 phosphate gradient. *Leukemia* 26:1722-5.
229. Mailloux AW, Sugimori C, Komrokji RS, Yang L, **Maciejewski JP**, Sekeres MA, Paquette R, Loughran TP Jr, List AF, Epling-Burnette PK. Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome (2012). *J Immunol*. Sep 15; 189(6):3198-208.
230. Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P, Han Y, Hsieh FH, Sekeres MA, Mali RS, Kalaycio M, Lichtin AE, Advani AS, Duong HK, Copelan E, Kapur R, Olalla Saad ST, **Maciejewski JP**, Tiu RV (2012). Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in System Mastocytosis. *PLoS One*. 7(8):e43090.

### 2013

231. Abu Kar S, Jankowska AM, Makishima H, Visconte V, Jerez A, Sugimoto Y, Muramatsu H, Traina F, Afable M, Guinta K, Tiu RV, Przychodzen B, Sakaguchi H, Kojima S, Sekeres MA, List AF, McDevitt MA, **Maciejewski JP** (2013). Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of CMML but largely absent in JMML. *Haematologica* 98(1):107-13. ►
232. Gómez-Seguí I, Makishima H, Jerez A, Yoshida K, Przychodzen B, Miyano S, Shiraishi Y, Husseinzadeh HD, Guinta K, Clemente M, Hosono N, McDevitt MA, Moliterno AR, Sekeres MA, Ogawa S, **Maciejewski JP** (2013). Novel recurrent mutations in the RAS-LIKE GTP- Binding gene RIT1 in myeloid malignancies. *Leukemia*(9):1943-6 ►
233. Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono N, Leblanc F, Lagström S, Zhang D, Ellonen P, Tichelli A, Nissen C, Lichtin AE, Wodnar-Filipowicz A, Mufti GJ, List AF, Mustjoki S, Loughran TP Jr, **Maciejewski JP** (2013). STAT3-mutations indicate the presence of subclinical T cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. *Blood* Oct 3; 122(14):2453-9. ►
234. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, Ng KP, Gudmundsson KO, Vishwakarma BA, Jerez A, Gomez-Segui I, Takahashi M, Shiraishi Y, Nagata Y, Guinta K, Mori H, Sekeres MA, Chiba K, Tanaka H,

- Muramatsu H, Sakaguchi H, Paquette RL, McDevitt MA, Kojima S, Sauntharajah Y, Miyano S, Shih LY, Du Y, Ogawa S, **Maciejewski JP** (2013). Somatic SETBP1 mutations in myeloid malignancies. *Nat Genet.* 45(8):942-6. ►
235. Clemente MJ, Przychodzen B, Jerez A, Dienes BE, Afable MG, Husseinadeh H, Rajala HL, Wlodarski MW, Mustjoki S, **Maciejewski JP** (2013). Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. *Blood* Dec 12; 122(25):4077-85. ►
236. Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, **Maciejewski JP**, List A (2013). Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. *Oncogene* Feb 28; 32(9):1110-20. ►
237. Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat T, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, **Maciejewski JP**, Melnick AM, Grealis J, Steidl U, Moliterno A, Verma A (2013). Methyloome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. *Cancer Res.* Feb 1; 73(3):1076-85.
238. Yang L, Mailloux A, Rollison DE, Painter JS, **Maciejewski JP**, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK (2013). Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. *Leukemia* Apr; 27(4):897-906.
239. Mahfouz RZ, Jankowska A, Ebrahim Q, Gu X, Visconte V, Tabarrokhi A, Terse P, Covey JM, Chan KK, Ling Y, Engelke KJ, Sekeres M, Tiu R, **Maciejewski JP**, Radivoyevitch T, Sauntharajah Y (2013). Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5- Azacytidine or Decitabine Therapy. *Clin Cancer Res.* Feb 15;19(4):938-948.
240. Yip BH, Vuppasetty C, Attwood M, Giagounidis A, Germing U, Lamikanra AA, Roberts DJ, **Maciejewski JP**, Vandenberghe P, Mecucci C, Wainscoat JS, Pellagatti A, Boulton J. Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14- deficient erythroblasts (2013). *Leukemia* Aug; 27(8):1760-3.
241. Otrrock ZK, Tiu RV, **Maciejewski JP**, Sekeres MA (2013). The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication? *Expert Rev Hematol.* Feb; 6(1):59-68.
242. Adès L, Sekeres MA, Wolffromm A, Teichman ML, Tiu RV, Itzykson R, **Maciejewski JP**, Dreyfus F, List AF, Fenaux P, Komrokji RS (2013). Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. *Leuk Res.* Jun; 37(6):609-13.
243. Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriya V, Vatolin S, Przychodzen B, Reu FJ, Sauntharajah Y, O'Keefe C, Sekeres MA, List AF, Moliterno AR, McDevitt MA, **Maciejewski JP**, Makishima H (2013). Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. *Leukemia* Jun; 27(6):1301-9.
244. Singh H, Lane AA, Correll M, Przychodzen B, Sykes DB, Stone RM, Ballen KK, Amrein PC, **Maciejewski JP**, Attar EC (2013). Putative RNA-splicing Gene LUC7L2 on 7q34 represents a Candidate Gene in Pathogenesis of Myeloid Malignancies. *Blood Cancer Journal* May 24; 3:e117.
245. Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, **Maciejewski JP**, Schubert J, Urbano-Ispizua A, de Castro C, Socié G, Brodsky RA (2013). Long-term Safety and Efficacy of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Haemoglobinuria. *Br J Haematol.* Jul;162(1):62-73.
246. Mallo M, Del Rey M, Ibáñez M, Calasanz MJ, Arenillas L, Larráyoz MJ, Pedro C, Jerez A, **Maciejewski JP**, Costa D, Nomdedeu M, Díez-Campelo M, Lumbreras E, González- Martínez T, Marugán I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernández JM, Solé F (2013). Response to \Lenalidomide in Myelodysplastic Syndromes with del (5q): Influence of Cytogenetics and Mutations. *Br J Haematol.* Jul; 162(1):74-86.

247. Rajala HL, Eldfors S, Kuusanmäki H, van Adrichem AJ, Olson T, Lagström S, Andersson EI, Jerez A, Clemente MJ, Yan Y, Zhang D, Awwad A, Ellonen P, Kallioniemi O, Wennerberg K, Porkka K, **Maciejewski JP**, Loughran TP Jr, Heckman C, Mustjoki S (2013). Discovery of Somatic STAT5b Mutations in Large Granular Lymphocytic Leukemia. *Blood* May 30; 121(22):4541-50.
248. Mehta HM, Glaubach T, Long A, Lu H, Przychodzen B, Makishima H, McDevitt MA, Cross NC, **Maciejewski JP**, Corey SJ (2013). Granulocyte Colony Stimulating Factor Mutant Receptor T595I (T618I) Confers Vigand Independence and Enhanced Signaling. *Leukemia* Dec; 27(12):2407-10.
249. Przychodzen B, Jerez A, Guinta K, Sekeres MA, Padgett R, **Maciejewski JP**, Makishima H (2013). Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. *Blood* Aug 8; 122(6):999-1006.
250. Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortezzi A, Oliva EN, Cuzzola M, **Maciejewski JP**, Mulloy JC, Starczynowski DT (2013). Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome. *Cancer Cell* Jul 8; 24(1): 90-104.
251. Santini V, Melnick A, **Maciejewski JP**, Duprez E, Nervi C, Cocco L, Ford KG, Mufti G (2013). Epigenetics in Focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. *Crit Rev Oncol Hematol*. Nov; 88(2):231-45.
252. Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M, Kon A, Sanada M, Chiba K, Tanaka H, Makishima H, Wang X, Xu Y, Doisaki S, Hama A, Nakanishi K, Takahashi Y, Yoshida N, **Maciejewski JP**, Miyano S, Ogawa S, Kojima S (2013). Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. *Nat Genet*. Aug; 45(8):937-41.
253. Sullivan LR, Sekeres MA, Shrestha NK, **Maciejewski JP**, Tiu RV, Butler R, Mossad SB (2013). Epidemiology and risk factors for infections in myelodysplastic syndromes. *Transpl Infect Dis*. Dec; 15(6):652-7.
254. Nischal S, Bhattacharyya S, Christopheit M, Yu Y, Zhou L, Bhagat TD, Sohal D, Will B, Mo Y, Suzuki M, Pardani A, McDevitt M, **Maciejewski JP**, Melnick AM, Grealley JM, Steidl U, Moliterno A, Verma A (2013). Methyloome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. *Cancer Res*. Feb 1; 73(3):1076-85.
255. Arenillas L, Mallo M, Ramos F, Guinta K, Barragán E, Lumbreras E, Larráyoiz MJ, De Paz R, Tormo M, Abáigar M, Pedro C, Cervera J, Such E, José Calasanz M, Díez-Campelo M, Sanz GF, Hernández JM, Luño E, Saumell S, **Maciejewski JP**, Florensa L, Solé F (2013). Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. *Genes Chromosomes Cancer* Dec; 52(12):1167-77.
256. Wenzell CM, Gallagher EM, Earl , Yeh JY, Kusick KN, Advani AS, Kalaycio ME, Mukherjee S, Tiu RV, **Maciejewski JP**, Sekeres MA (2013). Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. *Am J Hematol*. Oct; 88(10):906-9.
257. Ponnaluri VK, **Maciejewski JP**, Mukherji M (2013). A mechanistic overview of TET- mediated 5-methylcytosine oxidation. *Biochem Biophys Res Commun*. Jun 28; 436(2):115-20.
258. Adès L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, **Maciejewski JP**, Dreyfus F, List AF, Fenaux P, Komrokji RS (2013). Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. *Leuk Res*. Jun; 37(6):609-13.
259. Andersson EI, Rajala HL, Eldfors S, Ellonen P, Olson T, Jerez A, Clemente MJ, Kallioniemi O, Porkka K, Heckman C, Loughran TP Jr, **Maciejewski JP**, Mustjoki S (2013). Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. *Blood Cancer J*. Dec 6; 3:e168.
260. Menezes J, Makishima H, Gomez I, Acquadro F, Gómez-López G, Graña O, Dopazo A, Alvarez S, Trujillo M, Pisano DG, **Maciejewski JP**, Cigudosa JC (2013). CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia. *Blood Cancer J*. Nov 8; 3:e158.

261. Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Gómez-Seguí I, Verma AK, McDevitt MA, Sekeres MA, Ogawa S, **Maciejewski JP** (2014). Recurrent genetic defects on chromosome 7q in myeloid neoplasms. *Leukemia* 28: 1348–1351. ►
262. Ly B, Modi A, Rogers HJ, Makishima H, Hanna R, Cook JR, Theil KS, **Maciejewski JP** (2014). Concurrent juvenile myelomonocytic leukemia and T-lymphoblastic lymphoma with a shared missense mutation in NRAS. *Pediatr Blood Cancer* May; 61(5):946-8. ►
263. Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B, Sekeres MA, Levine RL, **Maciejewski JP** (2014). Genetic alterations of the cohesin complex genes in myeloid malignancies. *Blood*. Sep 11; 124(11):1790-8. ►
264. Ornstein MC, Mukherjee S, Mohan S, Elson P, Tiu RV, Sauntharajah Y, Kendeigh C, Advani A, Kalaycio M, **Maciejewski JP**, Sekeres MA (2014). Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-related AML. *Am J Hematol*. Feb; 89(2):168-173. [PM: 24123154].
265. Advani AS, Mahfouz RZ, **Maciejewski JP**, Rybicki L, Sekeres M, Tripp B, Kalaycio M, Bates J, Sauntharajah Y (2014). Ribosomal S6 Kinase and AKT Phosphorylation as Pharmacodynamic Biomarkers in Patients with Myelodysplastic Syndrome Treated With RAD001. *Clin Lymphoma Myeloma Leuk*. Apr; 14(2):172-177.e1. [PM: 24332215]
266. Bretschneider I, Clemente MJ, Meisel C, Guerreiro M, Streitz M, Hopfenmüller W, **Maciejewski JP**, Wlodarski MW, Volk HD (2014). Discrimination of T-cell subsets and T-cell receptor repertoire distribution. *Immunol Res*. Jan; 58(1):20-7.
267. Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe CL, Sekeres MA, Advani AS, Kalaycio M, Copelan EA, Sauntharajah Y, Olalla Saad ST, **Maciejewski JP**, Tiu RV (2014). Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. *Leukemia* Jan; 28(1):78-87.
268. Visconte V, Selleri C, **Maciejewski JP**, Tiu RV (2014). Molecular pathogenesis of myelodysplastic syndromes. *Transl Med UniSa*. Feb 4; 8:19-30.
269. Mukherjee S, Reddy CA, Ciezki JP, Abdel-Wahab M, Tiu RV, Copelan E, Advani AA, Sauntharajah Y, Paulic K, Hobson S, **Maciejewski JP**, Bolwell BJ, Kalaycio M, Dreicer R, Klein EA, Sekeres MA (2014). Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. *J Natl Cancer Inst*. Mar; 106(3):djt462.
270. Mehta HM, Futami M, Glaubach T, Lee DW, Andolina JR, Yang Q, Whichard Z, Quinn M, Lu HF, Kao WM, Przychodzen B, Sarkar CA, Minella A, **Maciejewski JP**, Corey SJ (2014). Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition. *Leukemia* May; 28(5):1041-51.
271. Rajala HL, Porkka K, **Maciejewski JP**, Loughran TP Jr, Mustjoki S (2014). Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. *Ann Med*. May; 46(3):114-22.
272. Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, **Maciejewski JP**, Brodsky RA, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P (2014). Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. *Haematologica* May; 99(5):922-9.
273. Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, **Maciejewski JP**, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF (2014). ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. *Blood* Jun 5; 123(23):3675-7.
274. Komrokji RS, Mailloux AW, Chen DT, Sekeres MA, Paquette R, Fulp WJ, Sugimori C, Paleveda-Pena J, **Maciejewski JP**, List AF, Epling-Burnette PK (2014). A phase 2 multicenter rabbit anti-thymocyte globulin trial in patient's with myelodysplastic syndromes identifying a novel model for response prediction. *Haematologica* Jul; 99(7):1176-83.
275. Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Christie S, Chen X, Rao DS, Grimes HL, Komurov K, Weirauch MT, Cancelas JA, **Maciejewski JP**, Starczynowski DT (2014). Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-κB Gene Network. *Cell Rep*. Sep 11; 8(5):1328-38.

276. Shen W, Clemente MJ, Hosono N, Yoshida K, Przychodzen B, Yoshizato T, Shiraishi Y, Miyano S, Ogawa S, **Maciejewski JP**, Makishima H (2014). Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. *J Clin Invest*. Oct; 124(10):4529-38.
  277. Askar M, Sun Y, Rybicki L, Zhang A, Thomas D, Kalaycio M, Pohlman B, Dean R, Duong H, Hanna R, **Maciejewski J**, Majhail NS, Bolwell B, Sobecks R (2014). Synergistic Effect of Major Histocompatibility Complex Class I-Related Chain A and Human Leukocyte Antigen-DPB1 Mismatches in Association with Acute Graft-versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant* Nov; 20(11):1835-40.
  278. Molenaar RJ, Radivoyevitch T, **Maciejewski JP**, van Noorden CJ, Bleeker FE (2014). The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. *Biochim Biophys Acta*. Dec; 1846(2) 326-341.
- 2015**
279. Sauntharajah Y, Sekeres M, Advani A, Mahfouz R, Durkin L, Radivoyevitch T, Englehaupt R, Juersivich J, Cooper K, Hussein Zadeh H, Przychodzen B, Rump R, Reu F, Tiu R, Hamilton B, Hsi E, Kalaycio M, **Maciejewski JP** (2015). Evaluation of non-cytotoxic DNMT1-depleting treatment of myelodysplastic syndromes. *J Clin Invest*. Mar 2; 125(3):1043-55. doi: 10.1172/JCI78789. Epub 2015 Jan 26. PMID: 2562149 ►
  280. Polprasert CH, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N., Padgett RP, Phillips JG, Clemente M, Dienes B, Du Y, Mukherjee S, Krug U, Klein HU, Berdel W, Yoshida K, Shiraishi Y, Chiba K, Ogawa S, Müller-Tidow C, **Maciejewski JP** (2015). Inherited and somatic defects in DDX41 in myeloid neoplasms. *Cancer Cell* May 11;27(5):658-70. doi: 10.1016/j.ccell.2015.03.017. Epub 2015 Apr 23. PMID: 25920683 ►
  281. Viny AD, **Maciejewski JP** (2015). High Rate of Both Hematopoietic and Solid Tumors Associated with Large Granular Lymphocyte Leukemia. *Leuk Lymphoma*. Feb; 56(2):503-4. doi: 10.3109/10428194.2014.927459. Epub 2014 Jul 17. PMID: 24882263 ►
  282. Patel B, Hirsch C, Clemente M, Sekeres M, Makishima H, **Maciejewski JP** (2015). Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms. *Int J Hematol*. Mar; 101(3):213-8. doi: 10.1007/s12185-015-1747-7. Epub 2015 Feb 18. PMID: 25690487 ►
  283. Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Hirsh C, Viny AD, Hosono N, Bleeker FE, Meggendorfer M, Alpermann T, Shiraishi Y, Chiba K, Tanaka H, van Noorden CJ, Radivoyevitch T, Carraway H, Makishima H, Miyano S, Sekeres MA, Ogawa S, Haferlach T, **Maciejewski JP** (2015). Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. *Leukemia* Nov; 29(11):2134-42. doi: 10.1038/leu.2015.91. Epub 2015 Apr 3. PMID: 2583658 ►
  284. Nazha A, Seastone D, Radivoyevitch T, Przychodzen B, Carraway HE, Patel BJ, Carew J, Makishima H, Sekeres MA, **Maciejewski JP** (2015). Genomic Patterns Associated with Hypoplastic Compared to Hyperplastic Myelodysplastic Syndromes. *Haematologica* Nov; 100(11):e434-7. doi: 10.3324/haematol.2015.130112. Epub 2015 Aug 13. PMID: 26273060 ►
  285. Bilori B, Thota S, Clemente MJ, Patel B, Jerez A, Afable M, **Maciejewski JP** (2015). Tofacitinib as a novel salvage therapy for refractory T cell large granular lymphocytic leukemia. *Leukemia* Dec; 29(12):2427-9.:/Leu.2015.280. Epub 2015 Oct 9. PMID: 26449659 ►
  286. Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, Kalaycio ME, Carraway HE, Mukherjee S, Sekeres MA, **Maciejewski JP** (2015). Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. *Leukemia* 2016 Feb;30(2):285-94. ►
  287. Kurtovic-Kozaric A, Przychodzen B, Singh J, Konarska MM, Clemente MJ, Otrrock ZK, Nakashima M, Hsi ED, Yoshida K, Ogawa S, Boultonwood J, **Maciejewski JP**, Padgett RA, Makishima H (2015). PRPF8 defects cause missplicing in myeloid malignancies. *Leukemia* Jan; 29(1):126-36. ►
  288. A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javid-Sharifi N, **Maciejewski JP**, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA (2015). Mutations in G protein  $\beta$  subunits promote transformation and kinase inhibitor resistance. *Nat Med*. Jan; 21(1):71-5. ►

289. Nawrocki ST, Kelly KR, Smith PG, Keaton M, Carraway H, Sekeres MA, **Maciejewski JP**, Carew JS (2015). The NEDD8-activating enzyme inhibitor MLN4924 ► disrupts nucleotide metabolism and augments the efficacy of cytarabine. *Clin Cancer Res*. Jan 15; 21(2):439-47.
290. McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, **Maciejewski JP**, Sokol L, Epling-Burnette PK, Wei S, List AF (2015). The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. *Blood Cancer J*. 2015 Mar 13; 5:e291. doi: 10.1038/bcj.2015.11. PMID: 25768405
291. Nazha A, Seastone D, Keng M, Hobson S, Kalaycio M, **Maciejewski JP**, Sekeres MA. The Revised International Prognostic Scoring System (IPSS-R) is not Predictive of Survival in Patients with Secondary Myelodysplastic Syndromes. *Leuk Lymphoma*. 2015 Apr 24:1-12.
292. Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, **Maciejewski J**, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). *Leukemia* 2015 Feb 27. Doi: .1038/leu.2015.5
293. Hobfoll SE1, Gerhart JI, Zalta AK, Wells K, **Maciejewski J**, Fung H. Posttraumatic stress symptoms predict impaired neutrophil recovery in stem cell transplant recipients. *Psychooncology* 2015 Jan 27.doi;1002/pon.376
294. Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjan JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, **Maciejewski J**, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF; MDS/MPN International Working Group. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. *Blood* 2015 Mar 19; 125(12):1857-65. doi: 10.1182/blood-2014-10- 607341. Epub 2015 Jan 26.
295. Ornstein MC, Mukherjee S, Keng M, Elson P, Tiu RV, Sauntharajah Y, Maggiorotto A, Schaub M, Banks D, Advani A, Kalaycio M, **Maciejewski JP**, Sekeres MA. Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. *Leuk Lymphoma*. 2015 Feb 20:1-7.
296. Ratajczak MZ, Borkowska S, Mierzejewska K, Kucia M, Mendek-Czajkowska E, Suszynska M, Sharma VA, Deptala A, Song W, Platzbecker U, Larratt L, Janowska-Wieczorek A, **Maciejewski J**, and Ratajczak J. Further evidence that paroxysmal nocturnal haemoglobinuria is a disorder of defective cell membrane lipid rafts. *J. Cell Mol Med*. 2015 May 29 DOI: 10.1111/jcmm.12605.
297. Visconte V, Tabarrok A, Hasrouni E, **Maciejewski JP**, Hsi ED, Tiu RV, Rogers HJ. Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. *Leuk Lymphoma*. 2015 Apr 29:1-11.
298. Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, Sato-Otsubo A, Sato Y, Liu D, Suzuki H, Wu CO, Shiraishi Y, Clemente MJ, Kataoka K, Shiozawa Y, Okuno Y, Chiba K, Tanaka H, Nagata Y, Katagiri T, Kon A, Sanada M, Scheinberg P, Miyano S, **Maciejewski JP**, Nakao S, Young NS, Ogawa S. Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. *N Engl J Med*. 2015 Jul 2; 373(1):35-47. doi: 10.1056/NEJMoa1414799.
299. Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, Przychodzen B, Sahgal N, Kanapin AA, Lockstone H, Scifo L, Vandenberghe P, Papaemmanuil E, Smith CW, Campbell PJ, Ogawa S, **Maciejewski JP**, Cazzola M, Savage KI, Boultonwood J. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. *Leukemia* 2015 Aug; 29(8):1798. doi: 10.1038/leu.2015.178. No abstract available.
300. Vishwakarma BA, Nguyen N, Makishima H, Hosono N, Gudmundsson KO, Negi V, Oakley K, Han Y, Przychodzen B, **Maciejewski JP**, Du Y. Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development. *Leukemia* 2015 Jul 24. doi: 10.1038/leu.2015.200.



301. Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, **Maciejewski JP**, List AF, Komrokji RS; MDS Clinical Research Consortium. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? *Am J Hematol*. 2015 Aug 18. doi: 10.1002/ajh.24173. PMID: 26284571
302. Sinyuk M, Alvarado AG, Nesmiyanov P, Shaw J, Mulkearns-Hubert EE, Eurich JT, Hale JS, Bogdanova A, Hitomi M, **Maciejewski J**, Huang AY, Sauntharajah Y, Lathia JD. Cx25 contributes to leukemia cell communication and chemosensitivity. *Oncotarget* 2015 Aug 19. PMID: 26375552.
303. Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A, Beausoleil SA, Han Y, Carraway HE, Nazha A Advani AS, **Maciejewski JP**, Sekeres MA, Carew JS. Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. *Leukemia* 2015 Sep 15. doi: 10.1038/leu.2015.250. PMID: 26369982.
304. Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J, Henneman P, Khurshed M, Lenting K, Mul AN, Dimitrakopoulou D, van Drunen CM, Hoebe RA, Radivoyevitch T, Wilmink JW, **Maciejewski JP**, Vandertop WP, Leenders WP, Bleeker FE, Van Noorden CJ. Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198. *Cancer Res*. 2015 Sep 11. pii: canres.3603.2014. [Epub ahead of print] PMID: 26363012.
305. Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjan JJ, Garcia-Manero G, Orazi A, Mesa R, **Maciejewski JP**, Fenaux P, Itzykson R, Mufti G, Solary E, List AF. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. *Haematologica*. 2015 Sep; 100(9):1117-30. doi: 10.3324/haematol.2014.114660. PMID: 26341525.
306. Hurtado AM, Chen-Liang TH, Przychodzen B, Hamed C, Muñoz-Ballester J, Dienes B, García-Malo MD, Antón AI, de Arriba F, Teruel-Montoya R, Ortuño FJ, Vicente V, **Maciejewski JP**, Jerez A. Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia. *Blood Cancer J*. 2015 Aug 28; 5:e342. doi: 10.1038/bcj.2015.65. PMID: 26314984
307. Andersson E, Kuusanmäki H, Bortoluzzi S, Lagström S, Parsons A, Rajala H, van Adrichem A, Eldfors S, Olson T, Clemente MJ, Laasonen A, Ellonen P, Heckman C, Loughran TP, **Maciejewski JP**, Mustjoki S. Activating somatic mutations outside the SH2-domain of STAT3 in LGL-leukemia. *Leukemia* 2015 Sep 30. doi: 10.1038/leu.2015.263. PMID: 26419508.
308. McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, **Maciejewski JP**, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. *Oncotarget* 2015 Sep 25. PMID: 26416416
309. Viny AD, Ott CJ, Spitzer B, Rivas M, Meydan C, Papalexi E, Yelin D, Shank K, Reyes J, Chiu A, Romin Y, Boyko V, Thota S, **Maciejewski JP**, Melnick A, Bradner JE, Levine RL. Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. *J Exp Med*. 2015 Oct 5. pii: jem.20151317.
310. Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faeltsh-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopheit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, **Maciejewski JP**, Verma A, Steidl U. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. *Nat Chem Biol*. 2015 Oct 5. doi: 10.1038/nchembio.1930. PMID: 26436839
311. Ruffalo M, Husseinazadeh H, Makishima H, Przychodzen B, Ashkar M, Koyutürk M, **Maciejewski JP**, LaFramboise T. Whole-Exome Sequencing Enhances Prognostic Classification of Myeloid Malignancies. *J Biomed Inform*. 2015 Oct 7. pii: S1532-464(15)00225-7. doi: 10.1016/j.jbi.2015.10.003. PMID: 26453823
312. Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Al Ali N, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, **Maciejewski JP**, List A, Komrokji R. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. *Leukemia* 2015 Oct 14. doi: 10.1038/leu.2015.283. PMID: 26464171

313. Varney ME, Niederkorn M, Konno H, Matsumura T, Gohda J, Yoshida N, Akiyama T, Christie S, Fang J, Miller D, Jerez A, Karsan A, **Maciejewski JP**, Meetei RA, Inoue JI, Starczynowski DT. Loss of Tifab, a Del (5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. *J Exp Med*. 2015 Oct 12. pii: jem.20141898. PMID: 26458771
  314. Sakaguchi H, Muramatsu H, Okuno Y, Makishima H, Xu Y, Furujawa-Hibi Y, Wang X, Narita A, Yoshida K, doisaki S, Yoshida N, Hama A, Takahashi Y, Yamada K, Miyano S, Ogawa S, **Maciejewski J**, Kojima S. Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia. *PLoS One* 2015 Dec 31; 10(12):e0145394.
- 2016**
315. Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch- C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, **Maciejewski JP**. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. *Leukemia* 2016 Aug, doi: 10.1038/leu.2016.228 PMID: 27560106 ►
  316. Visconte V, Tabarroki A, Hasrouni E, **Maciejewski JP**, Hsi ED, Tiu RV, Rogers HJ (2016). Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. *Leuk Lymphoma*. Jan; 57(1):212-5.
  317. Vishwakarma BA, Nguyen N, Makishima H, Hosono N, Gudmundsson KO, Negi V, Oakley K, Han Y, Przychodzen B, **Maciejewski JP**, Du Y (2016). Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development. *Leukemia* Jan; 30(1):200-8.
  318. Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, **Maciejewski J**, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson-MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. *BMC Cancer*, 2016 Aug 19; 16:652,
  319. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole'F, Bennett Jm, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, **Maciejewski J**, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van-de Loosdrecht AA, Germing U, Haase D. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. *Blood* 2016 Aug 17, pii: blood-2016-07-728766 PMID: 27535995
  320. Pfeilstocker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sole' F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, **Maciejewski J**, Machherndi-Spandi S, Magalhaes SM, Miyazaki Y, Sekkerr MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de-Loosdrecht AA, Germing U, Haase D, Greenberg PL. Time-dependent changes in mortality and transformation risk in MDS. *Blood* 2016 Aug 18; 128(7):902-10. Doi: 10.1182/blood-2016-02-700054.
  321. Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, Mukherjee S, Kalaycio M, Advani A, Przychodzen B, Carraway HE, **Maciejewski J**, Sekeres MA. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patient is with myelodysplastic syndromes. *Leukemia* 2016 30(11):2214-2220
  322. Botezatu L, Michel LC, Heiness A, Vadnais C, Makishima H, Hones JM, Robert F, Vassen L, Thivakaran A, Al-Matary Y, Lams RF, Schutte J, Giebel B, Gorgens A, Heuser M, Medyouf H, **Maciejewski J**, Duhrsen U, Moroy T, Khandanpour C. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. *Exp Hematol*. 2016 Aug; 44(8):713-726.e14.

323. Goel S, hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hfidh J, Wang Y, Halmos B, Steidi U, **Maciejewski J**, Braunschweig I, Verma A. High precalence and allele burden-independent prognostic importance of p53 mutations in an innercity MDS/AML cohort. *Leukemia* 2016 Aug; 30 (8):1793-5.
324. Botezatu L, Michel LC, Makishima H, Schroeder T, Germing U, Haas R, van der Reijden B, Marneth AE, Bergevoet SM, Jansen JH, Przychodzen B, Wlodarski M, Niemeyer C, Platzbecker U, Ehninger G, Unnikrishnan A, Beck D, Pimanda J, Hellstrom-Lindberg E, Malcovati L, Boulwood J, Pellagatti A, Papaemmanuil E, Le Coutre P, Kaeda J, Opalka B, Moroy T, Duhrsen U, **Maciejewski J**, Khansanpour C. GF11(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome. *Exp Hematol*. 2016 Jul; 44(7):590-595.
325. Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, **Maciejewski J**, List AF, Sekeres MA; MDS Clinical Research Consortium. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. *Haematologica* 2016 Jun; 101(6):e224-7. Doi: 10.3324/haematol.2015.140962. Epub 2016 Mar 18. PMID: 26992944
326. Hones JM, Botezatu L, Helness A, Vadnais C, Vassen L, Robert F, Hergenhan SM, Thivakaran A, Schutte J, Al-Matary YS, Lams RF, Fraszczak J, Makishima H, Radivoyevitch T, Przychodzen B, da Conceicao Castro SV, Gorgens A, Giebel B, Klein-Hitpass L, Lennartz K, Heuser M, Thiede C, Ehninger G, Duhrsen U, **Maciejewski J**, Moroy T, Khandanpour C. GF11 as a novel prognostic and therapeutic factor for AML/MDS. *Leukemia* 2016 Jun;30 (6):1237-45.
327. Hamilton BK, Visconte V, Jia X, Tabarrokhi A, Makishima H, Hasrouni E, Abounader D, Kalaycio M, Sekeres MA, Sobecks R, Duong Liu H, Bolwell B, **Maciejewski J**, Copelan E, Tiu RV. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying splicingosomal mutations. *AM J Hematol*. 2016 Jun;91 (4) 406-9
328. Naza A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, **Maciejewski J**, Komrokji RS, MDS Clinical Research Consortium. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. *Leuk Res*. 2016 Feb; 41:43-7,
329. Wlodarski MW, Hirabayashi S, Pastor V, Stary J, Hasle H, Masetti R, Dworzak M, Schmutge M, van den Heuvel-Eibrink M, Ussowicz M, DeMoerloose B, Catala A, Smith OP, Sedlacek P, Lankester AC, Zecca M, Bordon V, Matthes-Martin S, Abrahamsson J, Kuhl JS, Sykora KW, Albert NH, Przychodzen B, **Maciejewski J**, Schwarz S, Gohring G, Schlegelberger B, Cseh A, Noellke P, Yoshimi A, Locatelli F, Baumann I, Strahm B, Niemeyer CM, EWOG\_MDS. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. *Blood* 2016 Mar 17; 127(11):1387-97;
330. Ondrejka SL, Grzywacz B, Bodo J, Makishima H, Polprasert C, Said JW, Przychodzen B, **Maciejewski J**, His, ED. Angioimmunoblastic T-cell Lymphomas with the RHOA p. Gly17Val Mutation Have Classic Clinical and Pathologic Features. *AM J Surg Pathol*. 2016 Mar;40(3):335- 41.
331. Palomo L, Xicoy B, Garvia O, Mallo M, Adema V, Cabezon M, Arnau M, Pomares H, Jose Larrayoz M, Jose Calasanz M, **Maciejewski J**, Huang D, Shih LY, Ogawa S, Cervera J, Such E, Coll R, Grau J, Sole F, Zamora L. Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. *Am J Hematol*. 2016 Feb; 9 (2): 185-92. doi:10.1002/ajh.24227. Epub 2015 Dec 9 PMID: 26509444
332. Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway HE, Hirsch CM, Przychodzen B, Patel BJ, Clemente M, Sanikommu SR, Kalaycio M, **Maciejewski JP**, Sekeres MA. The complexity of interpreting genomic data in patients with acute myeloid leukemia. *Blood Cancer J*. 2016 Dec 16;6(12):e510

333. Nguyen N, Vishwakarma BA, Oakley K, Han Y, Przychodzen B, **Maciejewski JP**, Du Y. Myb expression is critical for myeloid leukemia development induced by Setbp1 activation. *Oncotarget* 2016 Dec 27;7(52):86300-86312
  334. Andersson EI, Tanahashi T, Sekiguchi N, Gasparini VR, Bortoluzzi S, Kawakami T, Matsuda K, Mitsui T, Eldfors S, Bortoluzzi S, Coppe A, Binatti A, Lagström S, Ellonen P, Fukushima N, Nishina S, Senoo N, Sakai H, Nakazawa H, Kwong YL, Loughran TP, **Maciejewski JP**, Mustjoki S, Ishida F. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. *Blood*. 2016 Nov 17;128(20):2465-2468.
  335. Makishima H, Yoshida K, Ruffalo R, Przychodzen B, LaFramboise T, Hosono H, Gómez- Seguí I, Husseinzadeh HD, Thota S, Clemente MJ, Shiraishi M, Sanada M, Nagata Y, Okuno Y, Sato Y, Sauntharajah Y, Sekeres MA, Shih L-Y, Ogawa S, **Maciejewski JP**. Landscape of somatic mutations in whole exomes of myelodysplastic and related myeloid neoplasms. *Nat Med*. Nat Genet. 2017 Feb; 49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec
- 2017**
336. Visconte V, Przychodzen B, Han Y, Nawrocki ST, Thota S, Kelly KR, Patel BJ, Hirsch C, Advani AS, Carraway HE, Sekeres MA, **Maciejewski JP**, Carew JS Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms. *Leukemia*. 2017 Feb;31(2):505-510
  337. Balasubramanian SK, Aly M, Nagata Y, Bat T, Przychodzen BP, Hirsch CM, Adema V, Visconte V, Kuzmanovic T, Radivoyevitch T, Nazha A, Mukherjee S, Sekeres MA, **Maciejewski JP**. (2017) distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. *Leukemia* 2017 Sep 22. doi: 10.1038/leu.2017. ►
  338. Thota S, Patel BJ, Sadaps M, Balasubramanian S, Sanikommu S, Hirsch C, Marotta S, Sekeres MA, Risitano AM, **Maciejewski JP**. (2017) Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. *Br J Haematol*. 2017 ►
  339. Negoro E, Nagata Y, Clemente MJ, Hosono N, Shen W, Nazha A, Yoshizato T, Hirsch C, Przychodzen B, Mahfouz RZ, Kuzmanovic T, Sekeres MA, Makishima H, Ogawa S, **Maciejewski JP**. (2017) Origins of myelodysplastic syndromes after aplastic anemia. *Blood* 2017 Oct 26; 130(17):1953-1957. ►
  340. Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML. Przychodzen B, Makishima H, Sekeres MA, Balasubramanian SK, Thota S, Patel BJ, Clemente M, Hirsch C, Dienes B, **Maciejewski JP**. *Oncotarget*. 2017 Dec 16;9(2):2050-2057. doi: 10.18632/oncotarget.23328.. ►
  341. Molenaar RJ, Radivoyevitch T, Nagata Y, Khurshed M, Przychodzen B, Makishima H, Xu M, Bleeker FE, Wilmink JW, Carraway HE, Mukherjee S, Sekeres MA, van Noorden CJF, **Maciejewski JP**. IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. *Clin Cancer Res*. 2018 Apr 1;24(7):1705-1715. doi: 10.1158/1078-0432.CCR-17-2796. Epub 2018 Jan 16. ►
  342. **Maciejewski JP**, Balasubramanian SK. Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age. *Hematology Am Soc Hematol Educ Program*. 2017 Dec 8; 2017(1):66-72. doi: 10.1182/asheducation-2017.1.66. ►
  343. Thota S, Patel BJ, Sadaps M, Balasubramanian S, Sanikommu S, Hirsch C, Marotta S, Sekeres MA, Risitano AM, **Maciejewski JP** Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. *Br J Haematol*. 2017 Sep 14. ►
  344. Patel BJ, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Kuzmanovic T, Clemente M, Hirsch C, Morawski A, Souaid R, Saygin C, Nazha A, Demarest B, LaFramboise T, Sakaguchi H, Kojima S, Carraway HE, Ogawa S, Makishima H, Sekeres MA, **Maciejewski JP**. (2017) Genomic determinants of chronic myelomonocytic leukemia. *Leukemia* 2017 Dec;31(12):2815-2823. doi: 10.1038/leu.2017.164. Epub 2017 May 30 ►
  345. Bat T, Abdelhamid ON, Balasubramanian SK, Mai A, Radivoyevitch T, Clemente M, **Maciejewski JP**. (2017) The

- evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy. *Br J Haematol.* 2017 Aug 14. doi: 10.1111/bjh.14862 ►
346. Sanikommu SR, Clemente MJ, Chomczynski P, Afable MG 2nd, Jerez A, Thota S, Patel B, Hirsch C, Nazha A, Desamito J, Lichtin A, Pohlman B, Sekeres MA, Radivoyevitch T, **Maciejewski JP**. (2017) Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). *Leuk Lymphoma.* Feb; 59(2):416-422. doi: 10.1080/10428194.2017.1339880. Epub 2017 Jun 20.
  347. Nazha A, Al-Issa K, Przychodzen B, Abuhadra N, Hirsch C, **Maciejewski JP**, Sekeres MA. (2017) Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes. *Blood Cancer J.* 2017 Sep 1; 7(9):e602
  348. Nazha A, Al-Issa K, Hamilton BK, Radivoyevitch T, Gerds AT, Mukherjee S, Adema V, Zarzour A, Abuhadra N, Patel BJ, Hirsch CM, Advani A, Przychodzen B, Carraway HE, **Maciejewski JP**, Sekeres MA. (2017) Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. *Leukemia*
  349. Enane FO, Shuen WH, Gu X, Quteba E, Przychodzen B, Makishima H, Bodo J, Ng J, Chee CL, Ba R, Seng Koh L, Lim J, Cheong R, Teo M, Hu Z, Ng KP, **Maciejewski JP**, Radivoyevitch T, Chung A, Ooi LL, Tan YM, Cheow PC, Chow P, Chan CY, Lim KH, Yerian L, Hsi E, Toh HC, Sauntharajah Y. (2017) GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. *JCI* 2017 Sep b1;127(9):3527-3542.
  350. Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Goldely A, Advani AS, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein D, Nasr C, Angelini D, **Maciejewski JP**, Majhail N, Sekeres MA, Mukherjee S. (2017) Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. *Leukemia* Nov 6. doi: 10.1038/leu.2017.323. PMID: 29104287
  351. Sakai H, Hosono N, Nakazawa H, Przychodzen B, Polprasert C, Carraway HE, Sekeres MA, Radivoyevitch T, Yoshida K, Sanada M, Yoshizato T, Kataoka K, Nakagawa MM, Ueno H, Nannya Y, Kon A, Shiozawa Y, Takeda J, Shiraishi Y, Chiba K, Miyano S, Singh J, Padgett RA, Ogawa S, **Maciejewski JP**, Makishima H. A novel genetic and morphologic phenotype of ARID2- mediated myelodysplasia. *Leukemia* 2017 Nov 3. doi: 10.1038/leu.2017.319.
  352. Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, Angelini D, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, **Maciejewski JP**, Majhail NS, Sekeres MA, Mukherjee S. (2017) Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. *J Clin Oncol.* 2017 Dec 18; JCO2017750232. Doi: 10.1200/JCO.2017.75.0232
  353. Nazha A, Al-Issa K, Przychodzen B, Abuhadra N, Hirsch C, **Maciejewski JP**, Sekeres MA. (2017) Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes. *Blood Cancer J.* 2017 Sep 1;7(9):e602.
  354. Nazha A, Al-Issa K, Hamilton BK, Radivoyevitch T, Gerds AT, Mukherjee S, Adema V, Zarzour A, Abuhadra N, Patel BJ, Hirsch CM, Advani A, Przychodzen B, Carraway HE, **Maciejewski JP**, Sekeres MA. (2017) Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. *Leukemia* 2017 Dec;31(12):2848-2850.
  355. Enane FO, Shuen WH, Gu X, Quteba E, Przychodzen B, Makishima H, Bodo J, Ng J, Chee CL, Ba R, Seng Koh L, Lim J, Cheong R, Teo M, Hu Z, Ng KP, **Maciejewski J**, Radivoyevitch T, Chung A, Ooi LL, Tan YM, Cheow PC, Chow P, Chan CY, Lim KH, Yerian L, Hsi E, Toh HC, Sauntharajah Y. (2017) GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. *J Clin Invest.* 2017 Sep 1;127(9):3527-3542.
  356. Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, **Maciejewski JP**, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow

- C. (2017) AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. *Nat Cell Biol.* 2017 Jul; 19(7):844-855.
357. Pan F, Wingo TS, Zhao Z, Gao R, Makishima H, Qu G, Lin L, Yu M, Ortega JR, Wang J, Nazha A, Chen L, Yao B, Liu C, Chen S, Weeks O, Ni H, Phillips BL, Huang S, Wang J, He C, Li GM, Radivoyevitch T, Aifantis I, **Maciejewski JP**, Yang FC, Jin P, Xu M. (2017) Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. *Nat Commun.* 2017 Apr 25; 8:15102. doi: 10.1038/ncomms15102.
  358. Varney ME, Choi K, Bolanos L, Christie S, Fang J, Grimes HL, **Maciejewski JP**, Inoue JI, Starczynowski DT. (2017) Epistasis between TIFAB and miR-146a: neighboring genes in del (5q) myelodysplastic syndrome. *Leukemia* 2017 Jul; 31(7):1659. doi: 10.1038/leu.2017.95. Epub 2017 Apr 7
  359. Hira VVV, Van Noorden CJF, Carraway HE, **Maciejewski JP**, Molenaar RJ. (2017) Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. *Biochim Biophys Acta.* 2017 Aug; 1868(1):183-198.
  360. Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis KD, Stoilov P, Filippi MD, **Maciejewski JP**, Garcia-Manero G, Weirauch MT, Salamonis N, Geiger H, Zheng Y, Starczynowski DT. (2017) Corrigendum: Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. *Nat Immunol.* 2017 Mar 22; 18(4):474. doi: 10.1038/ni0417-474a.
  361. Visconte V, Shetty S, Przychodzen B, Hirsch C, Bodo J, **Maciejewski JP**, Hsi ED, Rogers HJ. (2017) Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34). *Int J Lab Hematol.* 2017 Aug; 39(4):409-417. doi: 10.1111/ijlh.12641. Epub 2017 Mar 20.
  362. Stanley RF, Piszczatowski RT, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari S, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, **Maciejewski JP**, Kitis RN, Steidl U. (2017) A myeloid tumor suppressor role for NOL3. *J Exp Med.* 2017 Mar 6; 214(3):753-771. doi: 10.1084/jem.20162089. Epub 2017 Feb 23
  363. Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, **Maciejewski J**, Auberger P, Wei S, Fenaux P, Santini V, List A Pro-inflammatory proteins S100A9 and tumor necrosis factor- $\alpha$  suppress erythropoietin elaboration in myelodysplastic syndromes. *Haematologica* 2017 Dec;102(12):2015-2020
  364. Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Suzuki H, Nagata Y, Sato Y, Kakiuchi N, Matsuo K, Onizuka M, Kataoka K, Chiba K, Tanaka H, Ueno H, Nakagawa MM, Przychodzen B, Haferlach C, Kern W, Aoki K, Itonaga H, Kanda Y, Sekeres MA, **Maciejewski JP**, Haferlach T, Miyazaki Y, Horibe K, Sanada M, Miyano S, Makishima H, Ogawa S. (2017) Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. *Blood* 2017 Apr 27; 129(17):2347-2358. doi: 10.1182/blood-2016-12-754796. Epub 2017 Feb 21
  365. Coppe A, Andersson EI, Binatti A, Gasparini VR, Bortoluzzi S, Clemente M, Herling M, **Maciejewski J**, Mustjoki S, Bortoluzzi S. (2017) Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach. *Leukemia* 2017 May;31(5):1243-1246.
  366. Jobe F, Patel B, Kuzmanovic T, Makishima H, Yang Y, Przychodzen B, Hutchison RE, Bence KK, **Maciejewski JP**, Mohi G. (2017) Deletion of Ptpn1 induces myeloproliferative neoplasm. *Leukemia* 2017 May;31(5):1229-1234. doi: 10.1038/leu.2017.31.
  367. Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Sauntharajah Y, Sekeres MA, Boultonwood J, Ogawa S, **Maciejewski JP**. (2017) Recurrent genetic defects on chromosome 5q in myeloid neoplasms. *Oncotarget* 2017 Jan 24;8(4):6483-6495. ►

368. Przychodzen B, Makishima H, Sekeres MA, Balasubramanian SK, Thota S, Patel BJ, Clemente M, Hirsch C, Dienes B, **Maciejewski JP**, Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS, and AML. *Oncotarget* 2017 Dec 16;9(2): 2050-2057. Doi:10.18632/oncotarget.23328.eCollection 2018 Jan 5.
- 2018**
369. Hu Y, Lin J, Fang H, Fang J, Li C, Chen W, Liu S, Ondrejka S, Gong Z, Reu F, **Maciejewski JP**, Yi Q, Zhao JJ. Targeting the MALAT1? PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. *Leukemia* 2018 Oct; 32(10):2250-2262.doi:10.1038/s41375-018-0104-2. Epub 2018 Mar 22. ►
370. Balasubramanian SK, Aly M, Nagata Y, Bat T, Przychodzen BP, Hirsch CM, Adema V, Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. Visconte V, Kuzmanovic T, Radivoyevitch T, Nazha A, Mukherjee S, Sekeres MA, **Maciejewski JP**. *Leukemia* 2018 Feb; 32(2):550-553. ►
371. Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, **Maciejewski JP**. Consequences of mutant TET2 on clonality and subclonal hierarchy. *Leukemia* 2018 May 24. doi: 10.1038/s41375-018-0150-9. ►
372. Clemente MJ, Przychodzen B, Hirsch CM, Nagata Y, Bat T, Wlodarski MW, Radivoyevitch T, Makishima H, **Maciejewski JP**. Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. *Leukemia* 2018 Apr 25. doi: 10.1038/s41375-018-0138-5. ►
373. Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, Angelini D, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, **Maciejewski JP**, Majhail NS, Sekeres MA, Mukherjee S. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. *J Clin Oncol*. 2018 Jun 20; 36(18):1831-1839. doi:10.1200/JCO.2017.75.0232. Epub 2017 Dec 18. PubMed PMID: 29252123.
374. Balasubramanian SK, Sadaps M, Thota S, Aly M, Przychodzen BP, Hirsch CM, Visconte V, Radivoyevitch T, **Maciejewski JP**. Rational management approach to pure red cell aplasia. *Haematologica*. 2018 Feb; 103(2):221-230. doi: 10.3324/haematol.2017.175810. Epub 2017 Dec 7. PubMed PMID: 29217782; PubMed Central PMCID: PMC5792266.. ►
375. Lee JW, Peffault de Latour R, Brodsky RA, Jang JH, Hill A, Röth A, Schrezenmeier H, Wilson A, Marantz JL, **Maciejewski JP**. Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry. *Am J Hematol*. 2019 Jan; 94(1):E37-E41. doi: 10.1002/ajh.25334. Epub 2018 Nov 25. PubMed PMID: 30370949. ►
376. Chu Y, Zhao Z, Sant DW, Zhu G, Greenblatt SM, Liu L, Wang J, Cao Z, Tho JC, Chen S, Liu X, Zhang P, **Maciejewski JP**, Nimer S, Wang G, Yuan W, Yang FC, Xu M. Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC). *Genomics Proteomics Bioinformatics* 2018 Jun 13. pii: S1672-0229(18)30106-2
377. Hurtado AM, Luengo-Gil G, Chen-Liang TH, Amaral F, Batta K, Palomo L, Lumberras E, Przychodzen B, Caparros E, Amigo ML, Diez-Campelo M, Zamora L, Salido Fierrez EJ, **Maciejewski JP**, Ortuño FJ, Vicente V, Del Canizo M, Sole F, Ferrer-Marin F, Wiseman DH, Jerez A, Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia. *Br J Haematol*. 2018 May 24. doi: 10.1111/bjh.15408.
378. Molenaar RJ, Sidana S, Radivoyevitch T, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, **Maciejewski JP**, Majhail NS, Sekeres MA, Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al Mukherjee S. *J Clin Oncol*. 2018 Jun 20; 36(18):1889-1892.
379. Röth A, **Maciejewski J**, Nishimura JI, Jain D, Weitz JI. Screening and diagnostic clinical algorithm for paroxysmal

- nocturnal hemoglobinuria: Expert consensus. *Eur J Haematol.* 2018 Jul; 101(1):3-11.
380. Molenaar RJ, Maciejewski JP, Wilmink JW, Noorden CJF. Wild-type and mutated IDH1/2 enzymes and therapy responses. *Oncogene* 2018 Apr; 37(15):1949-1960. Review.
  381. Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, Carraway HE, Gerds AT, Mukherjee S, Nazha A, Sobecks R, Goebel C, Abounader D, Maciejewski JP, Advani AS. Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1 *Blood Cancer J.* 2018 Jan 10; 8(1):4.
  382. Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Angelini D, Maciejewski JP, Majhail N, Sekeres MA, Mukherjee S. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. *Leukemia.* 2018 Apr; 32(4):952-959. 6.
  383. Sakai H, Hosono N, Nakazawa H, Przychodzen B, Polprasert C, Carraway HE, Sekeres MA, Radivoyevitch T, Yoshida K, Sanada M, Yoshizato T, Kataoka K, Nakagawa MM, Ueno H, Nannya Y, Kon A, Shiozawa Y, Takeda J, Shiraishi Y, Chiba K, Miyano S, Singh J, Padgett RA, Ogawa S, Maciejewski JP, Makishima H. A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia. *Leukemia* 2018 Mar; 32(3):839-843.
  384. Nagata Y, Narumi S, Guan Y, Przychodzen BP, Hirsch CM, Makishima H, Shima H, Aly M, Pastor V, Kuzmanovic T, Radivoyevitch T, Adema V, Awada H, Yoshida K, Li S, Sole F, Hanna R, Jha BK, LaFramboise T, Ogawa S, Sekeres MA, Wlodarski MW, Cammenga J, Maciejewski JP. Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. *Blood* 2018 Nov 22; 132(21):2309-2313. doi: 10.1182/blood-2017-05-787390. Epub 2018 Oct 15. PubMed PMID: 30322869; PubMed Central PMCID: PMC6251008 u8695853 ►
  385. Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. *Blood* 2018 Nov 8 132(19):2100-2103. doi: 10.1182
  386. Kotani S, Yoda A, Kon A, Kataoka K, Ochi Y, Shiozawa Y, Hirsch C, Takeda J, Ueno H, Yoshizato T, Yoshida K, Nakagawa MM, Nannya Y, Kakiuchi N, Yamauchi T, Aoki K, Shiraishi Y, Miyano S, Maeda T, Maciejewski JP, Takaori-Kondo A, Ogawa S, Makishima H. Molecular pathogenesis of disease progression in MLL-rearranged AML. *Leukemia* 2018 Sep 12. doi: 10.1038/s41375-018-0253-3. PubMed PMID: 30209403. ►
  387. Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, WoodWA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. *Leuk Res.* 2018 Nov; 74:130-136. doi: 10.1016/j.leukres.2018.07.016. Epub 2018 Jul 19. PubMed PMID: 30055822; PubMed Central PMCID: PMC6219911.
  388. Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. *Blood Adv.* 2018 Jul 24; 2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414. PubMed PMID: 30037803; PubMed Central PMCID: PMC6058241



389. Gu X, Ebrahim Q, Mahfouz RZ, Hasipek M, Enane F, Radivoyevitch T, Rapin N, Przychodzen B, Hu Z, Balusu R, Cotta CV, Wald D, Argueta C, Landesman Y, Martelli MP, Falini B, Carraway H, Porse BT, **Maciejewski JP**, Jha BK, Sauntharajah Y. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. *J Clin Invest*. 2018 Oct 1; 128(10):4260-4279. doi: 10.1172/JCI97117. Epub 2018 Jul 17. PubMed PMID: 30015632; PubMed CentralPMCID: PMC6159976.
390. Chu Y, Zhao Z, Sant DW, Zhu G, Greenblatt SM, Liu L, Wang J, Cao Z, Tho JC, Chen S, Liu X, Zhang P, **Maciejewski JP**, Nimer S, Wang G, Yuan W, Yang FC, Xu M. Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC). *Genomics Proteomics Bioinformatics* 2018 Jun;16(3):172-186. doi: 10.1016/j.gpb.2018.04.005. Epub 2018 Jun 13. PubMed PMID: 29908294; PubMed Central PMCID: PMC6076382.
391. Hurtado AM, Luengo-Gil G, Chen-Liang TH, Amaral F, Batta K, Palomo L, Lumbreras E, Przychodzen B, Caparros E, Amigo ML, Diez-Campelo M, Zamora L, Salido Fierrez EJ, **Maciejewski JP**, Ortuño FJ, Vicente V, Del Canizo M, Sole F, Ferrer-Marin F, Wiseman DH, Jerez A. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia. *Br J Haematol*. 2018 May 24. doi: 10.1111/bjh.15408. PubMed PMID: 29797327.
392. Molenaar RJ, Radivoyevitch T, Nagata Y, Khurshed M, Przychodzen B, Makishima H, Xu M, Bleeker FE, Wilmink JW, Carraway HE, Mukherjee S, Sekeres MA, vanNoorden CJF, **Maciejewski JP**. IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. *Clin Cancer Res*. 2018 Apr 1;24(7):1705-1715. doi: 10.1158/1078-0432.CCR-17-2796. Epub 2018 Jan 16 PubMed PMID: 29339439; PubMed Central PMCID: PMC5884732. ►

## 2019

393. Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, Kuzmanovic T, Guan Y, Przychodzen BP, Aly M, Adema V, Shen W, Williams L, Nazha A, Abazeed ME, Sekeres MA, Radivoyevitch T, Haferlach T, Jha BK, Visconte V, **Maciejewski JP**. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. *Blood Adv*. 2019 Feb 12;3(3):339-349. doi: 10.1182/bloodadvances.2018024216. PMID: 30709865 ►
394. Vatolin S, Radivoyevitch T, **Maciejewski JP**. New drugs for pharmacological extension of replicative life span in normal and progeroid cells. *NPJ Aging Mech Dis*. 2019 Jan 16; 5:2. doi: 10.1038/s41514-018-0032-4. eCollection 2019. PMID: 30675378 ►
395. Hamilton BK, Rybicki L, Hirsch C, Przychodzen B, Nazha A, Gerds AT, Hanna R, Kalaycio M, Sekeres MA, Sobecks R, de Lima M, Majhail NS, **Maciejewski JP**. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. *Bone Marrow Transplant* 2019 Jan 17. doi: 10.1038/s41409-019-0444-1. PMID: 30655603 ►
396. Radivoyevitch T, Jorgensen TN, Lindner DJ, **Maciejewski JP**, Miyazaki Y, Gale RP. Chronic myeloid leukemia: Two mysteries. *Leuk Res*. 2019 Apr;79:3-5 doi: 10.1016/j.leukres.2019.02.003. Epub 2019 Feb 12. PMID: 30780032
397. Shen W, Kerr CM, Przychozen B, Mahouz RZ, LaFramboise T, Nagat Y, Hanna R, Radivoyevitch T, Nazha A, Sekeres Ma, **Maciejewski JP**. Impact of germline CTC1 alterations of telomere length in acquired bone marrow failure. *BR J haematol*. 2019 June; 185(5):935-939. doi: 10.1111/bjh.15862. Epub 2019 Mar 19. PMID: 30891747 ►
398. Kerr CM, Clemente MJ, Chomczynski PW, Przychodzen B, Nagata Y, Adema V, Visconte V, Lichtin AE, Mustjoki S, Radivoyevitch T, Sekeres MA, **Maciejewski JP**. Subclonal STAT3 mutations solidify clonal dominance. *Blood Adv*. 2019 Mar 26;3(6): 917-921 doi: 10.1182/bloodadvances.2018027862 PMID: 30898763
399. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, **Maciejewski J**, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. *Blood Adv*. 2019 Mar 26;3(6):922-933. doi: 10.1182/bloodadvances.2018026989. PMID: 30902805 ►

400. Advani AS, Cooper B, Visconte V, Elson P, Chan R, Carew J, Wei W, Mukherjee S, Gerds A, Carraway H, Nazha A, Hamilton B, Sobecks R, Caimi P, Tomlinson B, Malek E, Little J, Miron A, Pink J, **Maciejewski J**, Unger A, Kalaycio M, de Lima M, Sekeres MA. A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. *Clin Cancer Res*. 2019 Jul 15;25(14):4231-4237. doi: 10.1158/1078-0432.CCR-18-3886. Epub 2019 Apr 16 PMID: 30992301
401. Kishtagari A, Jha BK, **Maciejewski JP**. TET2 mutations and clonal dynamics. *Oncotarget* 2019 Mar 12;10(21):2010-2011. doi: 10.18632/oncotarget.26779. eCollection 2019 Mar 12 PMID: 31007843 ►
402. Nandakumar SK, McFarland SK, Mateyka LM, Lareau CA, Ulirsch JC, Ludwig LS, Agarwal G, Engreitz JM, Przychodzen B, McConkey M, Cowley GS, Doench JG, **Maciejewski JP**, Ebert BL, Root DE, Sankaran VG. Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis. *Elife*. 2019 May 9;8. pii: e44080. doi: 10.7554/eLife.44080. PMID: 31070582
403. Singhal D, Wee LYA, Kutyna MM, Chhetri R, Geoghegan J, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Hiwase S, Edwards S, Moore S, Branford S, Kuzmanovic T, Singhal N, Gowda R, Brown AL, Arts P, To LB, Bardy PG, Lewis ID, D'Andrea RJ, **Maciejewski JP**, Scott HS, Hahn CN, Hiwase DK. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. *Leukemia* 2019 May 14. doi: 10.1038/s41375-019-0479-8. PMID 31089247
404. Bowler TG, Pradhan K, Kong Y, Bartenstein M, Morrone KA, Sridharan A, Kessel RM, Shastri A, Giricz O, Bhagat TD, Gordon-Mitchell S, Rohanizadegan M, Hooda L, Datt I, Przychodzen BP, Parmar S, Maqbool S, **Maciejewski JP**, Steidl U, Grealley JM, Verma A. Misidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions. *Leuk Lymphoma*. 2019 Jul 10:1-6. doi: 10.1080/10428194.2019.1630620. PMID 31288594
405. Aly M, Ramdhan ZM, Nagata Y, Balasubramanian SK, Hosono N, Makishima H, Visconte V, Kuzmanovic T, Adema V, Nazha A, Przychodzen BP, Kerr CM, Sekeres MA, Abazeed ME, Nepveu A, **Maciejewski JP**. Distinct clinical and biological implications of CUX1 in myeloid neoplasms. *Blood Adv*. 2019 Jul 23;3(14):2164-2178. doi: 10.1182/bloodadvances.2018028423 PMID 31320321 ►
406. Nawrocki ST, Han Y, Visconte V, Przychodzen B, Espitia CM, Phillips J, Anwer F, Advani A, Carraway HE, Kelly KR, Sekeres MA, **Maciejewski JP**, Carew JS. The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine. *Leukemia* 2019 Jul 29. doi: 10.1038/s41375-019-0529-2. PMID: 31358855
407. Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, Przychodzen BP, Jha BK, Hiwase D, Singhal D, Advani AS, Nazha A, Gerds AT, Carraway HE, Sekeres MA, Mukherjee S, **Maciejewski JP**, Radivoyevitch T. Genomics of therapy-related myeloid neoplasms. *Haematologica* 2019 Aug 14. pii: haematol.2019.219352. doi: 10.3324/haematol.2019.219352. PMID: 31413096
408. Poh W, Dilley RL, Moliterno AR, **Maciejewski JP**, Pratz KW, McDevitt MA, Herman JG. BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies. *Clin Cancer Res*. 2019 Jan 28. doi: 10.1158/1078-0432.CCR-18-0179. PMID: 30692098
409. Haase D, Stevenson KE, Neuberg D, **Maciejewski JP**, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boulwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. International Working Group for MDS Molecular Prognostic Committee. *Leukemia*. 2019 Jan 11. doi: 10.1038/s41375-018-0351-2. PMID: 30635634
410. Abuhadra N, Mukherjee S, Al-Issa K, Adema V, Hirsch CM, Advani A, Przychodzen B, Makhoul A, Awada H, **Maciejewski JP**, Sekeres MA, Nazha A. BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. *Leuk Lymphoma*. 2019 Jan 8:1-4. doi: 10.1080/10428194.2018.1543885 PMID: 3061830
411. Awada H, Rahman S, Durrani J, Asad MF, Kerr CM, Adema V, Kishtagari A, Graham A, Snider CA, Kongkiatkamon

- Nagata Y, Patel BJ, Carraway HE, Sekeres MA, **Maciejewski JP**, Visconte V. Leukemia evolving from paroxysmal nocturnal hemoglobinuria. *Leukemia* 2019 Aug 20. doi: 10.1038/s41375-019-0555-0. PMID 31431736
412. Gackowski D, Gawronski M, Kerr C, Radivoyevitch T, Zarakowska E, Starczak M, Abakir A, Ruzov A, **Maciejewski JP**, Olinski R. 5-Formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively. *Haematologica* 2019 Sep 5. pii: haematol.2019.224030. doi: 10.3324/haematol.2019.224030. PMID: 31488558
413. Nagata Y, **Maciejewski JP**. The functional mechanisms of mutations in myelodysplastic syndrome, *Leukemia* 2019 Oct31, doi:10.1038/s41375-019-0617-3
414. Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garic-Manero G, Erba H, Ebert BL, **Maciejewski JP**. Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients with Myelodysplastic Syndromes using Artificial Intelligence. *JCO Precis Oncol*. 2019; 3 doi:10.1200/po.19.00119. Epub2019 September 20
415. Durrani J, Awada H, Kishtagari A, Visconte V, Kerr C, Adema V, Nagata Y, Kuzmanovic T, Hong s, Patel B, Nazha A, Mukherjee S, Sauntharajah Y, Carraway H, Sekeres M, **Maciejewski JP**. Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. *Leukemia* 2019 Oct 17. Doi: 10.1038/s41375-019-0601-y
416. McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, Sokol L, Moreilhon C, Raynaud S, Tien HF, Boultonwood J, Ebert BL, Sole F, Fenaux P, Mufti GJ, **Maciejewski JP**, Kanetsky PA, List AF. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis *Blood Adv*. 2019 Nov 26;3(22):3579-3589. doi: 10.1182/bloodadvances.2019000922. PMID: 31738830
417. Awada H, Mahfouz RZ, Kishtagari A, Kuzmanovic T, Durrani J, Kerr CM, Patel BJ, Visconte V, Radivoyevitch T, Lichtin A, Carraway HE, **Maciejewski JP**, Sauntharajah Y. Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. *Br J Haematol*. 2019 Nov 17. doi: 10.1111/bjh.16281. PMID: 31736067
418. Nagata Y, Makishima H, Kerr CM, Przychodzen BP, Aly M, Goyal A, Awada H, Asad MF, Kuzmanovic T, Suzuki H, Yoshizato T, Yoshida K, Chiba K, Tanaka H, Shiraishi Y, Miyano S, Mukherjee S, LaFramboise T, Nazha A, Sekeres MA, Radivoyevitch T, Haferlach T, Ogawa S, **Maciejewski JP**. Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes *Nat Commun*. 2019 Nov 26;10(1):5386. doi: 10.1038/s41467-019-13001-
419. Patel BJ, Barot SV, Waldron M, Billings S, ViJ A, Sekeres MA, **Maciejewski JP**, Carraway HE. Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria *Leuk Lymphoma* 2019 Dec. 28:1-4 doi: 10.1080/10428194.2019.1706734
420. Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, **Maciejewski JP**, Advani AS. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse features and clinical outcomes. *Blood Adv*. 2019 Dec 23;3(24):4228-4237. doi: 10.1182/bloodadvances.2019000925
421. Radivoyevitch T, Weaver D, Hobbs B, **Maciejewski JP**, Hehlmann R, Jiang Q, Hochhaus A, Gale RP. Do persons with chronic myeloid leukaemia have normal or near normal survival? *Leukemia* 2019 Dec 20. 10.1038/s41375-019-0699-y
422. Nagata Y, **Maciejewski JP**, The function mechanisms of mutations in myelodysplastic syndrome. *Leukemia* 201-Dec;33 (12):2779-2794 doi: 10.1038/s41375-019-0617-3
- 2020
423. Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, **Maciejewski JP**, Pollyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. *Int J Lab Hematol*. 2020 Nov 21. doi: 10.1111/ijlh.13400. PMID: 33220019

424. Adema V, Khouri J, Ni Y, Rogers HJ, Kerr CM, Awada H, Nagata Y, Kuzmanovic T, Advani AS, Gerds AT, Mukherjee S, Nazha A, Sauntharajah Y, Madanat Y, Patel BJ, Solé F, Nawrocki ST, Carew JS, Sekeres MA, **Maciejewski JP**, Visconte V, Carraway HE. Analysis of distinct *SF3B1* hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. *Leuk Lymphoma*. 2020 Nov 3:1-4. doi: 10.1080/10428194.2020.1839647. PMID: 33140678
425. Risitano AM, Kulasekararaj AG, Lee JW, **Maciejewski JP**, Notaro R, Brodsky R, Huang M, Geffner M, Browett P. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. *Haematologica*. 2020 Oct 29; doi: .3324/haematol.2020.261826. PMID: 33121236
426. Norris EJ, Patel YC, Klotz KE, Steuerwald N, Jones WD, **Maciejewski JP**, Ganapathi RN, Ganapathi MK. Dexrazoxane enhances efficacy of all-*trans* retinoic acid in acute myeloid leukemia patient blast cells and cell lines. *Leuk Lymphoma*. 2020 Oct 16:1-5. doi: 10.1080/10428194.2020.1827245. PMID: 33064055
427. Haferlach T, **Maciejewski JP**. Progress in the molecular diagnostics of hematologic neoplasia. *Best Pract Res Clin Haematol*. 2020 Sep;33(3):101198. doi: 10.1016/j.beha.2020.101198. PMID: 33038987 ►
428. Nagata Y, Zhao R, Awada H, Kerr CM, Mirzaev I, Kongkiatkamon S, Nazha A, Makishima H, Radivoyevitch T, Scott JG, Sekeres MA, Hobbs BP, **Maciejewski JP**. Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. *Blood*. 2020 Nov 12;136(20):2249-2262. doi: 10.1182/blood.2020005488. PMID: 32961553 ►
429. Guan Y, Greenberg EF, Hasipek M, Chen S, Liu X, Kerr CM, Gackowski D, Zarakowska E, Radivoyevitch T, Gu X, Willard B, Visconte V, Makishima H, Nazha A, Mukherji M, Sekeres MA, Sauntharajah Y, Oliński R, Xu M, **Maciejewski JP**, Jha BK. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. *Nat Commun Biol*. 2020 Sep 7;3(1):493. doi: 10.1038/s42003-020-01220-9. PMID: 32895473
430. Zhang L, Chen JY, Kerr C, Cobb BA, **Maciejewski JP**, Lin F. Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria. *Leukemia*. 2020 Aug 19. doi: h10.1038/s41375-020-1008-5. PMID: 32814838
431. Gu X, Tohme R, Tomlinson B, Sakre N, Hasipek M, Durkin L, Schuerger C, Grabowski D, Zidan AM, Radivoyevitch T, Hong C, Carraway H, Hamilton B, Sobecks R, Patel B, Jha BK, Hsi ED, **Maciejewski J**, Sauntharajah Y. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. *Leukemia*. 2020 Aug 7. doi: 10.1038/s41375-020-1003-x. PMID: 32770088
432. Hershberger CE, Moyer DC, Adema V, Kerr CM, Walter W, Hutter S, Meggendorfer M, Baer C, Kern W, Nadarajah N, Twardziok S, Sekeres MA, Haferlach C, Haferlach T, **Maciejewski JP**, Padgett RA. Complex landscape of alternative splicing in myeloid neoplasms. *Leukemia*. 2020 Aug 4. doi: 10.1038/s41375-020-1002-y. PMID: 32753690
433. Röth A, Araten DJ, Larratt L, Kulasekararaj AG, **Maciejewski JP**, Wilson A, Gustovic P, Kanakura Y. Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry. *Eur J Haematol*. 2020 Jul 8. doi: 10.1111/ejh.13485. PMID: 32640047
434. Palomo L, Meggendorfer M, Hutter S, Twardziok S, Adema V, Fuhrmann I, Fuster-Tormo F, Xicoy B, Zamora L, Acha P, Kerr CM, Kern W, **Maciejewski JP**, Solé F, Haferlach C, Haferlach T. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. *Blood*. 2020 Oct 15;136(16):1851-1862. doi: 10.1182/blood.2019004229. PMID: 32573691
435. Takeda R, Asada S, Park SJ, Yokoyama A, Becker HJ, Kanai A, Visconte V, Hershberger C, Hayashi Y, Yonezawa T, Tamura M, Fukushima T, Tanaka Y, Fukuyama T, Matsumoto A, Yamasaki S, Nakai K, Yamazaki S, Inaba T, Shibata T, Inoue D, Honda H, Goyama S, **Maciejewski JP**, Kitamura T. HHEX promotes myeloid transformation in cooperation with mutant ASXL1. *Blood*. 2020 Oct 1;136(14):1670-1684. doi: 10.1182/blood.2019004613. PMID: 32492700
436. Schrezenmeier H, Röth A, Araten DJ, Kanakura Y, Larratt L, Shammo JM, Wilson A, Shayan G, **Maciejewski JP**. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. *Ann Hematol*. 2020 Jul;99(7):1505-1514. doi: 10.1007/s00277-020-04052-z. Epub 2020 May 10. PMID: 32390114 ►

437. Fagnan A, Bagger FO, Piqué-Borràs MR, Ignacimoutou C, Caulier A, Lopez CK, Robert E, Uzan B, Gelsi-Boyer V, Aid Z, Thirant C, Moll U, Tauchmann S, Kurtovic-Kozaric A, **Maciejewski J**, Dierks C, Spinelli O, Salmoiraghi S, Pabst T, Shimoda K, Deleuze V, Lapillonne H, Sweeney C, De Mas V, Leite B, Kadri Z, Malinge S, de Botton S, Micol JB, Kile B, Carmichael CL, Iacobucci I, Mullighan CG, Carroll M, Valent P, Bernard OA, Delabesse E, Vyas P, Birnbaum D, Anguita E, Garçon L, Soler E, Schwaller J, Mercher T. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. *Blood*. 2020 Aug 6;136(6):698-714. doi: 10.1182/blood.2019003062.PMID: 32350520
438. Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boulton J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, **Maciejewski JP**, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. *Blood*. 2020 Jul 9;136(2):157-170. doi: 10.1182/blood.2020004850.PMID: 3234792
439. Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, **Maciejewski JP**, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. *Clin Lymphoma Myeloma Leuk*. 2020 Sep;20(9):e597-e605. doi: 10.1016/j.clml.2020.03.005.PMID: 32303488
440. Hu Y, Liu H, Fang C, Li C, Xhyliu F, Dysert H, Bodo J, Habermehl G, Russell BE, Li W, Chappell M, Jiang X, Ondrejka SL, Hsi ED, **Maciejewski JP**, Yi Q, Anderson KC, Munshi NC, Ao G, Valent JN, Lin J, Zhao Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. *J. Cancer Res*. 2020 May 15;80(10):2031-2044. doi: 10.1158/0008-5472.CAN-19-1077. PMID: 32193289
441. Adema V, Palomo L, Toma A, Kosmider O, Fuster-Tormo F, Benito R, Salgado R, Such E, Larrayoz MJ, Xicoy B, Hernandez-Sanchez JM, Maietta P, Neef A, Fontenay M, Ibañez M, Diez-Campelo M, Alvarez S, **Maciejewski JP**, Fenaux P, Sole F. Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide. *Br J Haematol*. 2020 May;189(4):e133-e137. doi: 10.1111/bjh.16558.PMID: 32147816
442. Gurnari C, Voso MT, **Maciejewski JP**, Visconte V. From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. *Cancers (Basel)*. 2020 Feb 4;12(2):357. doi: 10.3390/cancers12020357.PMID: 32020357
443. Patel BJ, Barot SV, Kuzmanovic T, Kerr C, Przychodzen BP, Thota S, Lee S, Patel S, Radivoyevitch T, Lichtin A, Advani A, Kalaycio M, Sekeres MA, Carraway HE, **Maciejewski JP**. Distinctive and common features of moderate aplastic anaemia. *Br J Haematol*. 2020 Jun;189(5):967-975. doi: 10.1111/bjh.16460. PMID: 32004386
444. Awada H, Mahfouz RZ, Durrani J, Kishtagari A, Jagadeesh D, Lichtin AE, Hill BT, Hamilton BK, Carraway HE, Nazha A, Majhail NS, Sobecks R, Visconte V, Kalaycio M, Sekeres MA, **Maciejewski JP**. Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. *Br J Haematol*. 2020 Apr;189(2):318-322. doi: 10.1111/bjh.16336. Epub 2020 Jan 20.PMID: 31958160
445. Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, Hillmen P, **Maciejewski JP**, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. *Haematologica*. 2020 Jan 16;haematol.2019.236877. doi: 10.3324/haematol.2019.236877. PMID: 31949012
446. Li ST, Wang J, Wei R, Shi R, Adema V, Nagata Y, Kerr CM, Kuzmanovic T, Przychodzen B, Sole F, **Maciejewski JP**, LaFramboise T. Rare germline variant contributions to myeloid malignancy susceptibility. *Leukemia*. 2020 Jun;34(6):1675-1678. doi: 10.1038/s41375-019-0701-8. PMID: 31911633
447. Patel BJ, Barot SV, Waldron M, Billings S, Vij A, Sekeres MA, **Maciejewski JP**, Carraway HE. Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. *Leuk Lymphoma*. 2020 May;61(5):1242-1245. doi: 10.1080/10428194.2019.1706734.PMID: 31885297
448. Radivoyevitch T, Weaver D, Hobbs B, **Maciejewski JP**, Hehlmann R, Jiang Q, Hochhaus A, Gale RP. Do persons with chronic myeloid leukaemia have normal or near normal survival? *Leukemia*. 2020 Feb;34(2):333-335. doi: 10.1038/s41375-019-0699-y.PMID: 31862960.

449. Awada H, Mahfouz RZ, Kishtagari A, Kuzmanovic T, Durrani J, Kerr CM, Patel BJ, Visconte V, Radivoyevitch T, Lichtin A, Carraway HE, **Maciejewski JP**, Sauntharajah Y. Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. *Br J Haematol*. 2020 Mar;188(6):924-929. doi: 10.1111/bjh.16281. PMID: 31736067
450. Durrani J, Awada H, Kishtagari A, Visconte V, Kerr C, Adema V, Nagata Y, Kuzmanovic T, Hong S, Patel B, Nazha A, Lichtin A, Mukherjee S, Sauntharajah Y, Carraway H, Sekeres M, **Maciejewski JP**. Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. *Leukemia* 2020 Mar;34(3):957-962. doi: 10.1038/s41375-019-0601-y. PMID: 31624375►
451. Gackowski D, Gawronski M, Kerr C, Radivoyevitch T, Zarakowska E, Starczak M, Abakir A, Ruzov A, **Maciejewski JP**, Olinski R 5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively. *Haematologica*. 2020 May;105(5):e213-e215. doi: 10.3324/haematol.2019.224030. PMID: 31488558
452. Awada H, Rahman S, Durrani J, Asad MF, Kerr CM, Adema V, Kishtagari A, Graham A, Snider CA, Kongkiatkamon S, Nagata Y, Patel BJ, Carraway HE, Sekeres MA, **Maciejewski JP**, Visconte V Leukemia evolving from paroxysmal nocturnal hemoglobinuria. *Leukemia*. 2020 Jan;34(1):327-330. doi: 10.1038/s41375-019-0555-0. PMID: 31431736
453. Guan Y, Tiwari AD, Phillips JG, Hasipek H, Grabowski DR, Pagliuca S, Gopal P, Kerr MC, Adema V, Radivoyevitch T, Parker Y, Daniel J Lindner, Meggendorfer M, Abazeed M, Sekeres M, Mian OY, Haferlach T, **Maciejewski JP**, Jha JB. A therapeutic strategy for preferential targeting of TET2 mutant and TET-dioxygenase deficient cells in myeloid neoplasms. *Blood Cancer Discovery*, 2020 (on line ahead of print) DOI: 10.1158/2643-3230.BCD-20-0173  
Vacuolization of hematopoietic precursors: an enigma with multiple etiologies.

**2021**

454. Gurnari C, Pagliuca S, Durkin L, Terkawi L, Awada H, Kongkiatkamon S, Zawit M, Hsi ED, Carraway HE, Rogers HJ, Visconte V, **Maciejewski JP** Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. *Blood*. 2021 Mar 9;blood.2021010811. doi: 10.1182/blood.2021010811. PMID: 33690844 ►
455. Gurnari C, **Maciejewski JP**. How I manage acquired pure red cell aplasia in adults. *Blood*. 2021 Mar 3;blood.2021010898. doi: 10.1182/blood.2021010898. PMID: 33657207
456. Awada H, Kerr CM, Durmaz A, Adema V, Gurnari C, Pagliuca S, Zawit M, Kongkiatkamon S, Rogers HJ, Sauntharajah Y, Sekeres MA, Carraway H, **Maciejewski JP**, Visconte V. Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. *Leukemia*. 2021 Feb 18. doi: 10.1038/s41375-021-01176-7. PMID: 33603144
457. Pleyer L, Leisch M, Kourakli A, Padron E, **Maciejewski JP**, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jimenez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Muñoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro MJ, Cortés A, Avendaño Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. *Lancet Haematol*. 2021 Feb;8(2):e135-e148. doi: 10.1016/S2352-3026(20)30374-4. PMID: 33513373
458. GuanY, HasipekM, TiwariAD, **Maciejewski JP**, Jha BK. TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics. *Semin Hematol*. 2021 Jan;58(1):27-34. doi: 10.1053/j.seminhematol.2020.12.002. Epub 2020 Dec 28. PMID: 33509440
459. Gurnari C, Pagliuca S, Patel BJ, Awada H, Kongkiatkamon S, Terkawi L, Zawit M, Corey S, Lichtin AE, Carraway HE, Wahida A, Visconte V, **Maciejewski JP** Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. *Leukemia*. 2021 Jan 22. doi: 10.1038/s41375-020-01113-0. PMID: 33483614
460. List AF, Sun Z, Verma A, Bennett JM, Komrokji RS, McGraw K, **Maciejewski J**, Altman JK, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar TR, Artz AS, Schiffer CA, Litzow MR, Tallman MS. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin *J Clin Oncol*. 2021 Mar 20;39(9):1001-1009. doi: 10.1200/JCO.20.01691. Epub 2021 Jan 13. PMID: 33439748

461. Advani AS, Tse W, Li H, Jia X, Elson P, Cooper B, Ali-Osman F, Park J, Rao AV, Rizzieri DA, Wang ES, Cotta CV, Kalaycio M, Sobecks RM, Roupail B, **Maciejewski JP**, Fensterl J, Carew JS, Foster B, Rush ML, Tripp B, Adams D, Corrigan D, Griffiths EA, Sekeres MA. A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. 2021 Feb;21(2):113-118 doi: 10.1016/j.clml.2020.11.018. Epub 2020 Dec 3. PMID: 33422470
462. Gurnari C, Durrani J, Pagliuca S, Kishtagari A, Awada H, Kerr CM, Adema V, Kongkiatkamon S, Lichtin AE, Patel BJ, Visconte V, Sekeres MA, Cook JR, **Maciejewski JP**. Novel invariant features of Good syndrome. *Leukemia*. 2021 Jan 7. doi: 10.1038/s41375-020-01114-z. PMID: 33414481 ►
463. Gurnari C, Graham AC, Efanov A, Pagliuca S, Durrani J, Awada H, Patel BJ, Lichtin AE, Visconte V, Sekeres MA, **Maciejewski JP**. Frequency and perturbations of various peripheral blood cell populations before and after ecilizumab treatment in paroxysmal nocturnal hemoglobinuria. *Blood Cells Mol Dis*. 2021 Mar;87:102528. doi: 10.1016/j.bcmd.2020.102528. Epub 2020 Dec 8. PMID: 33341510 ►
464. Adema V, Khouri J, Ni Y, Rogers HJ, Kerr CM, Awada H, Nagata Y, Kuzmanovic T, Advani AS, Gerds AT, Mukherjee S, Nazha A, Sauntharajah Y, Madanat Y, Patel BJ, Solé F, Nawrocki ST, Carew JS, Sekeres MA, **Maciejewski JP**, Visconte V, Carraway HE. Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. *Leuk Lymphoma*. 2021 Mar;62(3):735-738. doi: 10.1080/10428194.2020.1839647. Epub 2020 Nov 3. PMID: 33140678 ►
465. Norris EJ, Patel YC, Klotz KE, Steuerwald N, Jones WD, **Maciejewski JP**, Ganapathi RN, Ganapathi MK. Dexamethasone enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines. *Leuk Lymphoma*. 2021 Feb;62(2):473-477. doi: 10.1080/10428194.2020.1827245. Epub 2020 Oct 16. PMID: 33064055
466. Brodsky RA, Peffault de Latour R, Rottinghaus ST, Röth A, Risitano AM, Weitz IC, Hillmen P, **Maciejewski JP**, Szer J, Lee JW, Kulasekararaj AG, Volles L, Damokosh AI, Ortiz S, Shafner L, Liu P, Hill A, Schrezenmeier H. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus ecilizumab in adults with paroxysmal nocturnal hemoglobinuria. *Haematologica*. 2021 Jan 1;106(1):230-237. doi:10.3324/haematol.2019.236877. PMID: 31949012
467. Gu X, Tohme R, Tomlinson B, Sakre N, Hasipek M, Durkin L, Schuerger C, Grabowski D, Zidan AM, Radivoyevitch T, Hong C, Carraway H, Hamilton B, Sobecks R, Patel B, Jha BK, Hsi ED, **Maciejewski J**, Sauntharajah Y. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. *Leukemia*. 2021 Apr;35(4):1023-1036. doi: 10.1038/s41375-020-1003-x. Epub 2020 Aug 7. PMID: 3277008
468. Gurnari C, Pagliuca S, **Maciejewski JP**. Pegcetacoplan versus Ecilizumab in PNH. *N Engl J Med*. 2021 Oct 28;385(18):1725. doi: 10.1056/NEJMc2106424. PMID: 34706184 ►
469. Gurnari C, Colak C, Zawit M, **Maciejewski JP**. Lancet. Chronic Budd-Chiari syndrome in paroxysmal nocturnal haemoglobinuria. *Lancet*. 2021 Sep 11;398(10304):e14. doi: 10.1016/S0140-6736(21)01542-7. PMID: 34509232
470. Adema V, Khouri J, Ni Y, Rogers HJ, Kerr CM, Awada H, Nagata Y, Kuzmanovic T, Advani AS, Gerds AT, Mukherjee S, Nazha A, Sauntharajah Y, Madanat Y, Patel BJ, Solé F, Nawrocki ST, Carew JS, Sekeres MA, **Maciejewski JP**, Visconte V, Carraway HE. Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. *Leuk Lymphoma*. 2021 Mar; 62(3):735-738. doi: 10.1080/10428194.2020.1839647. Epub 2020 Nov 3. PMID: 33140678
471. Radakovich N, Meggendorfer M, Malcovati L, Hilton CB, Sekeres MA, Shreve J, Roupail Y, Walter W, Hutter S, Galli A, Pozzi S, Elena C, Padron E, Savona MR, Gerds AT, Mukherjee S, Nagata Y, Komrokji RS, Jha BK, Haferlach C, **Maciejewski JP**, Haferlach T, Nazha. Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. *Blood Adv*. 2021 Nov 9;5(21):4361-4369.
472. Chlon TM, Stepanchick E, Hershberger CE, Daniels NJ, Hueneman KM, Kuenzi Davis A, Choi K, Zheng Y, Gurnari C, Haferlach T, Padgett RA, **Maciejewski JP**, Starczynowski DT. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. *Cell Stem Cell*. 2021 Nov 4;28(11):1966-1981.
473. Tiwari AD, Guan Y, Grabowski DR, **Maciejewski JP**, Jha BK, Phillips JG. SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates. *Bioorg Med Chem*. 2021 Jun 1;39:116141.

474. Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, **Maciejewski JP**, Pollyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. *Int J Lab Hematol* 2021 Jun;43(3):426-432.
475. Gurnari C, Yeane GA, Kalinowski M, Cotta CV, **Maciejewski JP** T-cell large granular lymphocytic leukemia associated with inclusion body myositis. *Int J Lab Hematol* 2021 Sep 25. doi: 10.1111/ijlh.13719.PMID: 34562064 ►
476. Hasipek M, Grabowski D, Guan Y, Alugubelli RR, Tiwari AD, Gu X, DeAvila GA, Silva AS, Meads MB, Parker Y, Lindner DJ, Sauntharajah Y, Shain KH, **Maciejewski JP**, Reu FJ, Phillips JG, Jha BK. Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. *Cancers (Basel)* 2021 May 28;13(11):2649.
477. Gurnari C, Yeane GA, Kalinowski M, Cotta CV, **Maciejewski JP**. T-cell large granular lymphocytic leukemia associated with inclusion body myositis. *Int J Lab Hematol* 2021 Sep 25. doi: 10.1111/ijlh.13719.PMID: 34562064 ►
478. Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, Hilton CB, Nagata Y, Hamilton BK, Mukherjee S, Al Ali N, Walter W, Hutter S, Padron E, Sallman D, Kuzmanovic T, Kerr C, Adema V, Steensma DP, Dezern A, Roboz G, Garcia-Manero G, Erba H, Haferlach C, **Maciejewski JP**, Haferlach T, Sekeres MA.J. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. *J. Clin Oncol* 2021 Aug 18;JCO2002810. doi: 10.1200/JCO.20.02810. PMID: 34406850
479. Lundgren S, Keränen MAI, Kankainen M, Huuhtanen J, Walldin G, Kerr CM, Clemente M, Ebeling F, Rajala H, Brück O, Lähdesmäki H, Hannula S, Hannunen T, Ellonen P, Young NS, Ogawa S, **Maciejewski JP**, Hellström-Lindberg E, Mustjoki S. Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. *Leukemia* 2021 May;35(5):1365-1379. doi: 10.1038/s41375-021-01231-3. Epub 2021 Mar 30.PMID: 33785863
480. Komrokji R, Melody M, Al Ali N, Chan O, Klimek V, Ball BJ, Sekeres MA, Lucas G, **Maciejewski JP**, Sallman DA, Padron E, Kuykendall A, Lasho T, Al-Kali A, Naqvi K, Steensma DP, Garcia-Manero G, Patnaik MM. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. *Leuk Lymphoma* 2021 Aug 27:1-6. doi: 10.1080/10428194.2021.1971217.PMID: 34448437
481. Gurnari C, Pagliuca S, Awada H, Zawit M, Patel BJ, Visconte V, Valent J, Rogers HJ, **Maciejewski JP**. Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander? *Blood Cells Mol Dis* 2021 Nov;91:102595. doi: 10.1016/j.bcmd.2021.102595. Epub 2021 Jul 14.PMID: 34280665 ►
482. Pagliuca S, Gurnari C, Hong S, Zhao R, Kongkiatkamon S, Terkawi L, Zawit M, Guan Y, Awada H, Kishtagari A, Kerr CM, LaFramboise T, Patel BJ, Jha BK, Carraway HE, Visconte V, Majhail NS, Hamilton BK, **Maciejewski JP**. Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. *JCI Insight* 2021 Jul 8;6(13):e149080. doi: 10.1172/jci.insight.149080.PMID: 34236054 ►
483. Zawit M, Gurnari C, Pagliuca S, Awada H, **Maciejewski JP**, Sauntharajah Y. A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia. *Clin Case Rep* 2021 Sep 15;9(9):e04533. doi: 10.1002/ccr3.4533. eCollection 2021 Sep.PMID: 34552731
484. Daniels NJ, Hershberger CE, Gu X, Schueger C, DiPasquale WM, Brick J, Sauntharajah Y, **Maciejewski JP**, Padgett RA. Functional analyses of human LUC7-like proteins involved in splicing regulation and myeloid neoplasms. *Cell Rep* 2021 Apr 13;35(2):108989. doi: 10.1016/j.celrep.2021.108989.PMID: 33852859
485. Awada H, Durmaz A, Gurnari C, Kishtagari A, Meggendorfer M, Kerr CM, Kuzmanovic T, Durrani J, Shreve J, Nagata Y, Radivoyevitch T, Advani AS, Ravandi F, Carraway HE, Nazha A, Haferlach C, Sauntharajah Y, Scott JG, Visconte V, Kantarjian HM, Kadia TM, Sekeres MA, Haferlach T, **Maciejewski JP**. Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia. *Blood*. 2021 Jun 1;blood.2020010603. doi: 10.1182/blood.2020010603 PMID: 34075412 ►
486. Hong S, Rybicki L, Zhang A, Thomas D, Kerr CM, Durrani J, Rainey MA, Mian A, Behera TR, Carraway HE, Nazha A, Mukherjee S, Advani AS, Patel B, Kalaycio M, Bolwell BJ, Hanna R, Gerds AT, Pohlman B, Hamilton BK, Sekeres MA, Majhail NS, **Maciejewski JP**, Askar M, Sobecks R. Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. *Transplant Cell Ther*. 2021 Nov;27(11):917.



487. Dermawan JK, Wensel C, Visconte V, **Maciejewski JP**, Cook JR, Bosler DS. Clinically Significant CUX1 Mutations Are Frequently Subclonal and Common in Myeloid Disorders With a High Number of Co-mutated Genes and Dysplastic Features. *Am J Clin Pathol*. 2021 Oct 18;aqab157. doi: 10.1093/ajcp/aqab157.PMID: 34661647
488. Kulesekararaj A, Risitano AM, **Maciejewski JP**, Notaro R, Browett PJ, Lee JW, Huang M, Geffner M, Brodsky RA. Phase 2 Study of Danicopan in Paroxysmal Nocturnal Hemoglobinuria Patients with an Inadequate Response to Eculizumab. *Blood*. 2021 Jul 27;blood.2021011388. doi: 10.1182/blood.2021011388. Online ahead of print.PMID: 34314483
489. Pagliuca S, Gurnari C, Awada H, Kishtagari A, Kongkiatkamon S, Terkawi L, Zawit M, Guan Y, LaFramboise T, Jha BK, Patel BJ, Hamilton BK, Majhail NS, Lundgren S, Mustjoki S, Sauntharajah Y, Visconte V, Chan T, Yang CY, Lenz T, **Maciejewski JP**. The Similarity of Class II HLA Genotypes Defines Patterns of Autoreactivity in Idiopathic Bone Marrow Failure Disorders. *Blood*. 2021 Nov 5;blood.2021012900. doi: 10.1182/blood.2021012900. PMID: 34748628 ►

**2022**

490. Gurnari C, Pagliuca S, Guan Y, Adema V, Hershberger CE, Ni Y, Awada H, Kongkiatkamon S, Zawit M, Coutinho DF, Zalberg IR, Ahn JS, Kim HJ, Kim DDH, Minden MD, Jansen JH, Meggendorfer M, Haferlach C, Jha BK, Haferlach T, **Maciejewski JP**, Visconte V. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. *Blood Adv*. 2022 Jan 11;6(1):100-107.
491. Semin Hematol. Gurnari C, **Maciejewski JP**. Aplastic anemia: Quo vadis? 2022 Jan;59(1):54-55. doi: 10.1053/j.seminhematol.2021.12.001. Epub 2021 Dec 31.PMID: 35491060. ►
492. Kongkiatkamon S, Terkawi L, Guan Y, Adema V, Hasipek M, Dombrovski T, Co M, Walter W, Awada H, Parker Y, Hutter S, Pagliuca S, Gurnari C, Rogers HJ, Meggendorfer M, Lindner DJ, Haferlach T, Visconte V, LaFramboise T, Jha BK, **Maciejewski JP**. Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms. *Leukemia*. 2022. Epub ahead of print. PMID: 35761024. ►
493. Visconte V, **Maciejewski JP**. Semin Hematol. Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia. 2022 Jan;59(1):47-53. Epub 2022 Jan 5. PMID: 35491059. ►
494. Kongkiatkamon S, Pagliuca S, Adema V, Nagata Y, Kerr CM, Walter W, Awada H, Hutter S, Gurnari C, Rogers HJ, Meggendorfer M, Sauntharajah Y, Haferlach T, Visconte V, **Maciejewski JP**. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia *Leukemia*. 2022 Apr;36(4):1185-1188. ►
495. Gurnari C, Wahida A, Pagliuca S, Durmaz A, Zawit M, Haferlach T, **Maciejewski JP**, Visconte V. A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia. *Hematol Oncol*. 2022 Feb 1. doi: 10.1002/hon.2967. Epub ahead of print.
96. Adema V, Palomo L, Walter W, Mallo M, Hutter S, La Framboise T, Arenillas L, Meggendorfer M, Radivoyevitch T, Xicoy B, Pellagatti A, Haferlach C, Boulwood J, Kern W, Visconte V, Sekeres M, Barnard J, Haferlach T, Solé F, **Maciejewski JP**. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q. *EBioMedicine*. 2022 Jun;80:104059. ►
497. Nguyen N, Gudmundsson KO, Soltis AR, Oakley K, Roy KR, Han Y, Gurnari C, **Maciejewski JP**, Crouch G, Ernst P, Dalgard CL, Du Y. Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation. *iScience*. 2021 Dec 25;25(1):103679.
498. Balasubramanian SK, Azmi AS, **Maciejewski J**. Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms. *Leukemia*. 2022 Mar;36(3):601-612. doi: 10.1038/s41375-021-01483-z. Epub 2022 Jan 29. PMID: 35091658; PMCID: PMC8885406.
499. Guan Y, Hasipek M, Jiang D, Tiwari AD, Grabowski DR, Pagliuca S, Kongkiatkamon S, Patel B, Singh S, Parker Y, LaFramboise T, Lindner D, Sekeres MA, Mian OY, Sauntharajah Y, **Maciejewski JP**, Jha BK. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. *J Clin Invest*. 2022 Feb 15;132(4):e149856.

500. Woerner J, Huang Y, Hutter S, Gurnari C, Sánchez JMH, Wang J, Huang Y, Schnabel D, Aaby M, Xu W, Thorat V, Jiang D, Jha BK, Koyuturk M, **Maciejewski JP**, Haferlach T, LaFramboise T. Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes. *Nat Commun.* 2022 Feb 24;13(1):1038.
501. Huuhtanen J, Bhattacharya D, Lönnberg T, Kankainen M, Kerr C, Theodoropoulos J, Rajala H, Gurnari C, Kasanen T, Braun T, Teramo A, Zambello R, Herling M, Ishida F, Kawakami T, Salmi M, Loughran T, **Maciejewski JP**, Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. Lähdesmäki H, Kelkka T, Mustjoki S. *Nat. Commun.* 2022 Apr. 11;13(1):1981.
502. Balasubramanian SK, Azmi AS, **Maciejewski J**. Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms. *Leukemia.* 2022. Mar;36(3):601-612. ►
503. Hine C, Treviño-Villarreal JH, Mejia P, Longchamp A, Brace LE, Harputlugil E, Mitchell SJ, Yang J, Guan Y, **Maciejewski JP**, Jha BK, Mitchell JR. Restriction for enhancing bone marrow regrowth following ionizing Radiation. Sulfur amino acid supplementation abrogates protective effects of caloric nutrients. 2022 Apr 6;14(7):1529.

**Guest Editor:**

**Maciejewski JP** and Haferlach T, "Molecular advances in myeloid malignancies Issue." *Sem of Onc* 2011 (In press)

**Book Chapters:**

1. Wachter M, Elstner E, **Maciejewski JP**, Volk HD, Ihle R. (1992) In vitro effects of GM-CSF and interferon-gamma on the establishment of stromal layer and hematopoiesis in human Dexter cultures. IN: Neth R., Frolowa E., Gallo R.C. (eds.) *Modern Trends in Human Leukemia*, IX. New York: Springer, pp. 97-100.
2. St. Jeor S, **Maciejewski JP**. (1993) Human cytomegalovirus. IN: Young N.S. (ed.) *Viruses and Bone Marrow: Basic Research and Clinical Practice*. New York: Marcel Dekker, pp.181-203.
3. St. Jeor S, **Maciejewski JP**, Young NS. (1993) Replication of human cytomegalovirus in monocytes and the effect of cytokines on virus protein expression. In: *Progress in cytomegalovirus research*. Landini MP (eds). Excerpta medica, Amsterdam.
4. St. Jeor S, **Maciejewski JP**, Bruening E, Young NS. (1993) Human cytomegalovirus: the potential role of hematopoietic cells in the pathogenesis of cytomegalovirus infection. IN: Lvov D.K., Many B.W.J. (eds.) *Current Concepts in Virology: From Ivanavsky to Present*. Switzerland: Hardwood Academic Publishers gmbh.
5. Young NS, **Maciejewski JP**, Selleri C, Sato T, Nisticò A, Brown KE, Green SW, Wong S, Anderson S. (1995) The pathophysiology of acquired aplastic anemia. IN: Gluckman E, Coulombel L. (eds.) *Ontogeny of Hematopoiesis Aplastic Anemia*. Montrouge, France: Colloques INSERM/John Libbey Eurotext Ltd, pp. 193-201.
6. Young NS, **Maciejewski JP**. (2000) Aplastic anemia. In: Hoffman R., Benz E.J., Shattil S.J., Cohen H.J., Furie B., Sibertstein L.E., McGlave P. (eds.) *Hematology: Basic Principles and Practice*, 3rd edition. New York: Churchill-Livingstone.
7. Sloand E and **Maciejewski JP**. (2003). Bone marrow failure syndromes. IN Furie, B., Cassileth P, Aktins GM, Mayer RJ. *Clinical Hematology and Oncology* pp. 443-454. Churchill-Livingstone.
8. **Maciejewski JP**, Selleri, C and Risitano, A. (2005). *Molecular diagnostics in hematology*. (ed). Rogers, G and Young, NS. Bethesda Handbook of Hematology. 1<sup>st</sup> edition
9. Young NS, **Maciejewski JP**. (2005) Aplastic anemia. IN: Hoffman R., Benz E.J., Shattil S.J., Cohen H.J., Furie B., Sibertstein L.E., McGlave P. (eds.) *Hematology: Basic Principles and Practice*, 4rd edition. New York: Churchill-Livingstone.
10. **Maciejewski JP**, Torrelli G. (2005) Human cytomegalovirus and other herpes viruses in hematology. IN: Gerson S, Young NS (eds) *Handbook of Hematology*. Saunders.
11. **Maciejewski JP**. (2006) Aplastic Anemia. IN: Bolwell B, Sekeres M, Kalaycio M (eds). *Clinical Neoplastic Hematology*, McGraw-Hill Companies.
12. **Maciejewski JP**, Selleri C and Risitano AM. (2007). *Molecular diagnostics in Hematology*. Bethesda Handbook of

Clinical Hematology. 2<sup>nd</sup> edition.

13. Young NS, **Maciejewski JP**. (2008) Aplastic anemia. In: Hoffman R., Benz E.J., Shattil S.J., Cohen H.J., Furie B., Sibertstein L.E., McGlave P. (eds.) Hematology: Basic Principles and Practice, 5th edition. New York: Churchill-Livingstone.
14. **Maciejewski JP**, Tiu R (2008) Single lineage cytopenias. In: Hoffman R., Benz E.J., Shattil S.J., Cohen H.J., Furie B., Sibertstein L.E., McGlave P. (eds.) Hematology: Basic Principles and Practice, 5th edition. New York: Churchill-Livingstone.
15. Young NS, **Maciejewski JP**. (2008) Aplastic anemia. In: Hoffman R., Benz E.J., Shattil S.J., Cohen H.J., Furie B., Sibertstein L.E., McGlave P. (eds.) Hematology: Basic Principles and Practice, 6th edition. New York: Churchill-Livingstone.
16. **Maciejewski JP**, Loughran T. Leblanc F (2008) Pure red cell aplasia single lineage cytopenias. In: Hoffman R., Benz E.J., Shattil S.J., Cohen H.J., Furie B., Sibertstein L.E., McGlave P. (eds.) Hematology: Basic Principles and Practice, 6th edition. New York: Churchill-Livingstone.
17. **Maciejewski JP**, Steensma D (2010) American Society of Hematology SAP in Hematology. "Bone marrow failure syndromes".
18. Young NS, **Maciejewski JP**. (2012) Aplastic anemia. In: Hoffman R., Benz E.J., Shattil S.J., Cohen H.J., Furie B., Sibertstein L.E., McGlave P. (eds.) Hematology: Basic Principles and Practice, 7th edition. New York: Churchill-Livingstone.
19. **Maciejewski JP**, Tiu R (2012) Pure red cell aplasia Single lineage cytopenias. In: Hoffman R., Benz E.J., Shattil S.J., Cohen H.J., Furie B., Sibertstein L.E., McGlave P. (eds.) Hematology: Basic Principles and Practice, 3rd edition. New York: Churchill-Livingstone.
20. **Maciejewski JP**, Przychodzen B, and Risitano AM (2012). Molecular diagnostics in Hematology. Bethesda Handbook of Clinical Hematology. 3rd edition.
21. Bupathi M, Tiu RV, and **Maciejewski JP** (2013). Myelodysplastic/Myeloproliferative Neoplasms. In: Deeg HJ, Bowen DT, Gore SD, Haferlach T, LeBeau MM, Niemeyer C. Myelodysplastic Syndromes, 2<sup>nd</sup> Edition. Heidelberg, New York, Dordrecht, London: Springer.
22. Young NS, **Maciejewski JP**. (2021) Aplastic anemia. In: Hoffman R., Benz E.J., Shattil S.J., Cohen H.J., Furie B., Sibertstein L.E., McGlave P. (eds.) Hematology: Basic Principles and Practice, 7th edition. New York: Churchill-Livingstone. (in press)
23. **Maciejewski JP**, Loughran T. Leblanc F. (2021) pure red cell aplasia Single lineage cytopenias. In: Hoffman R., Benz E.J., Shattil S.J., Cohen H.J., Furie B., Sibertstein L.E., McGlave P. (eds.) Hematology: Basic Principles and Practice, 6th edition. New York: Churchill-Livingstone

### Invited Speaker

2006. Current Research and Emerging Treatments in MDS Symposium, James P. Wilmot Cancer Center, Rochester, NY, "Molecular Approaches to the Pathogenesis of Some Forms of MDS."
2006. NIH RFA Awardees Meeting, Bethesda, MD, "Chromosomal Instability in MDS."
2006. ASH Review Meeting, Cleveland, Ohio. "Aplastic Anemia."
2006. Hematology/Medical Oncology Core Curriculum Conference, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, "Overview of Myelodysplastic Syndrome."
2006. Grand Rounds, University of Iowa, Iowa City, Iowa, "New Molecular Approaches to Study Bone Marrow Failure Syndromes."
2006. International Workshop on Immune-Mediated Marrow Failure Meeting, Naples, Italy, "Pathogenetic Mechanisms in

Aplastic Anemia.”

- 2006. Revlimid Promotional Speakers Bureau Meeting, Cleveland, Ohio, “The Role of Revlimid (lenalidomide) in del 5q Myelodysplastic Syndromes.”
- 2006. Grand Rounds, University of Illinois at Chicago, Chicago IL, Myelodysplastic Syndromes.”
- 2006. Grand Rounds, Memorial Sloan-Kettering, New York, NY, “New Molecular Approaches to Study Bone Marrow Failure Syndromes.”
- 2007. 10<sup>th</sup> Annual Meeting of the Regional Cancer Center Consortium for Biological Therapy of Cancer, Cleveland, OH, “Myelodysplastic Syndromes.”
- 2007. Grand Rounds, Yale University School of Medicine, New Haven, CT, “New Molecular Diagnostic Approaches in Bone Marrow Failure Syndromes.”
- 2007. Hematology/Medical Oncology Core Curriculum Conference, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, “Overview of Myelodysplastic Syndrome.”
- 2007. Grand Rounds, University of Kentucky, Louisville, KY, “New DNA Array-based Approaches to the Analysis of Myelodysplastic Syndromes.”
- 2007. Cancer and Aging Symposium, Case Western Reserve University, Cleveland, OH, “Cryptic Cytogenetic Abnormalities in MDS.”
- 2007. Grand Rounds, Roswell Park Cancer Institute, Buffalo, NY, “SNP Array-based diagnostics in MDS.”
- 2007. Roswell Park Cancer Institute, Buffalo, NY, “New DNA Array-based Approaches to the Analysis of Myelodysplastic Syndromes.”
- 2007. 12<sup>th</sup> Congress of the European Hematology Association, Vienna, Austria. “Mechanisms of T-cell Activation in Aplastic Anemia.”
- 2007. Pediatric Grand Rounds, Mt. Sinai Hospital, New York, NY, “Molecular Pathogenesis of Bone Marrow Failure Syndromes.”
- 2007. AA & MDS International Foundation, Patient Conference, Las Vegas, NY, “Causes of BMFD & Epidemiology” and “PNH.”
- 2007. MDS Summit, Cleveland Clinic, Cleveland, OH, “Molecular Diagnostics in MDS.”
- 2007. Leukemia Grand Rounds, University of Texas, MD Anderson Cancer Center, Houston, TX, “Genomics of MDS.”
- 2007. 49<sup>th</sup> Annual Meeting of American Society of Hematology, New Trends in MDS Symposium. Atlanta, GA, “Immune pathogenesis of MDS.”
- 2007. Hematology/Medical Oncology Core Curriculum Conference, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH. “Overview of Aplastic Anemia.”
- 2008. Division of Internal Medicine Grand Rounds, Cleveland Clinic, Cleveland, OH, “Bone Marrow Failure Syndromes.”
- 2008. Blood Club Lectures, Case Western Reserve University, Cleveland, OH, “Genomics of Myeloid Malignancies.”
- 2008. St. Vincent Medical Center, Internal Medicine Grand Rounds, South Bend, IN, “Pathogenesis and Treatment of PNH.”
- 2008. NIH, NHLBI, Hematology Branch, Clinical Grand Rounds, Bethesda, MD, “Single Nucleotide Polymorphism Arrays as a Karyotyping Tool in the Diagnosis of Myeloid Malignancies.”
- 2008. Alpena Regional Cancer Center, Clinical Grand Rounds, Alpena, MI, “Newest Advances in the Diagnosis and Treatment of MDS.”
- 2008. Patients conference of AA and MDS International Foundation, Washington DC, “Current State of the Art, PNH” and “Achievements of Bone Marrow Failure Research Consortium.”
- 2008. International Neutropenia Symposium, Heraclion, Greece, “Management of Autoimmune Neutropenia.”

- 2008. International Society of Cytology and Immunohistochemistry Annual Meeting, Gdansk, Poland, "Normal and Malignant Hematopoietic Stem Cells, Clonality of Stem Cell Compartment."
- 2008. 50<sup>th</sup> Annual ASH Meeting, Invited Speaker Corporate Friday Symposium, San Francisco, CA, "Novel Cytogenetic Tools for Detection of Cryptic Cytogenetic Abnormalities in MDS."
- 2009. Case Western Reserve Cancer Energetics Series, Cleveland, OH, "Homozygous Mutations Revealed by the Presence of Somatic Uniparental Disomy."
- 2009. Member of Organizing Committee, AA and MDS International Foundation Patients Conference, Indianapolis, IN, "Complement System and PNH" and "Pathogenesis of PNH."
- 2009. International MDS Symposium, Patras, Greece, "Genomics of MDS."
- 2009. MDS Minisymposium, Kings College of Medicine, London, UK, "New Pathogenic Mutations in MDS"
- 2009. Annual ASCO Meeting, Orlando, FL, "Classification and Diagnosis of MDS."
- 2009. Australian Hematology Symposium, Melbourne, Australia, "Indication for Bone Marrow Transplantation in Aplastic Anemia" and "Molecular Diagnosis of MDS."
- 2009. European School of Hematology, Nice, France, "Molecular Diagnostics of MDS."
- 2009. Spanish Society of Hematology Meeting, Barcelona, Spain, "SNP-karyotyping in MDS."
- 2009. European Aplastic Anemia Working Party, Basel, Switzerland, "New Research Results in Aplastic Anemia."
- 2009. 51<sup>st</sup> Annual American Society of Hematology Meeting, Corporate Friday Symposium, New Orleans, LA, "Therapeutic Implications of Molecular Lesions in MDS."
- 2009. Cleveland Clinic's Taussig Cancer Institute Core Curriculum Lecture Series, Cleveland, OH, "Aplastic Anemia."
- 2009. Grand Rounds, Mayo Clinic, Jacksonville, FL, "MDS to AML."
- 2009. Medical Grand Rounds, Huron Hospital (now Stephanie Tubbs Jones Health Center), Cleveland Clinic, Cleveland, OH, "Aplastic Anemia."
- 2009. Cleveland Clinic's Pathology & Laboratory Medicine Institute's Grand Rounds, Cleveland, OH, "Genomics of Myeloid Malignancies."
- 2010. Annual meeting of Italian Society of Cytogenetics, Turin, Italy, "Principles of Karyotyping Using SNP-Arrays."
- 2010. Annual MDA MDS and MPD Symposium, Houston, TX, "TET2 and c-Cbl Mutations in MDS."
- 2010. Cancer Center Grand Rounds University of Cincinnati, Cincinnati, OH, "New Molecular Lesions in MDS and Related Myeloid Malignancies."
- 2010. Session Chairmen, German Kidney Symposium, Berlin, Germany, "Malignancies in Renal Transplant."
- 2010. International Aplastic Anemia Consensus Conference, Hamamatsu Japan, "Clonal Chromosomal Defects in Aplastic Anemia."
- 2010. Marioka University Hematology Department Grand Rounds, Takizawa, Iwate, Japan "Molecular Pathogenesis of MDS."
- 2010. Del5q Consensus Conference, London, UK, "Molecular Consequences of Haploinsufficiency in del5q."
- 2010. 1<sup>st</sup> Annual Controversies in Hematology Conference, Rome, Italy, "Therapy choices in PNH."
- 2010. MDA International Leukemia Conference, Houston, TX, "New Mutations in MDS."
- 2010. 5q-Advisory Board, Munich, Germany, "Pathogenesis, Diagnosis and Molecular Biology of 5q-Syndrome".
- 2010. 52<sup>nd</sup> Annual ASH Meeting, Invited Speaker Corporate Friday Symposium, Orlando, FL, "Molecular Biology of Malignant Evolution in MDS."
- 2010. International Workshop on Epigenetic Therapy in MDS, Florence, Italy, "Molecular and Cytogenetic Factors

Predicting Response to Hypomethylating Agents.”

2011. Hematology/Oncology Grand Rounds-University of WV, Charleston, WV, “Pathogenesis and Diagnosis and Therapy of PNH.”
2011. International 5q- Symposium, Duisburg, Germany, “Molecular Pathogenesis of 5q- Syndrome.”
2011. International State of the Art Symposium, Bethesda MD, Session Chair, “Molecular Advances in the Understanding of MDS” and New Somatic Mutations in MDS.”
2011. MDA MDS/MPD International Symposium, Houston, TX. “TET2 Mutations, Recent Advances.”
2011. MDS International Symposium, Meet the Expert, Edinburgh, UK, “Molecular Testing in MDS.”
2011. Cancer Rounds, Queen Margaret Hospital, University of Toronto, Canada, “Molecular Pathogenesis of MDS.”
2011. Hematology/Oncology Grand Rounds, Swedish Covenant Hospital, Chicago, IL, “Pathogenesis of PNH.”
2011. Northwestern University, Cancer Center Grand Rounds, Chicago, IL, “Genomics of MDS.”
2011. 53<sup>rd</sup> ASH Annual Meeting, San Diego, CA, Educational Session, “Clonal Transformation of Aplastic Anemia.”
2012. Genomics in Hematology, Perugia, Italy. "Are SNPs able to differentiate Aplastic Anemia from MDS?"
2012. Florence, Italy. "Genomics of Bone Marrow Failure"
2012. American Society of Hematology, Best of ASH, Orlando FL, “Bone Marrow Failure Syndromes.”
2012. American Society of Hematology, Best of ASH, New York, NY, “Bone Marrow Failure Syndromes.”
2012. American Society of Hematology, Highlights of ASH North America, Iguassu Fall, Brazil, “Bone Marrow Failure Syndromes.”
2012. AA&MDS International Foundation, Bone Marrow Failure International Symposium, Bethesda, MD, “Molecular Pathogenesis of Aplastic Anemia.”
2012. AA&MDS International Foundation, Bone Marrow Failure International Symposium, Bethesda, MD, “Molecular Genetics of MDS: Introduction.”
2012. Australian Society of Pathology Annual Meeting, Sydney, Australia, “Molecular Pathogenesis of MDS.”
2012. Australian Society of Pathology Annual Meeting, Sydney, Australia, “Immune-mediated Aplastic Anemia.”
2012. Cincinnati Children’s Cancer & Blood Diseases Institute, Cincinnati, OH, “The Genomics of MDS.”
2012. EEMG 2012 Meeting, Warsaw, Poland, “Mutations in Spliceosomal Machinery Genes in Myeloid Neoplasms; a Novel Pathway of Leukemogenesis.”
2012. Hematologic Malignancies 2012 Meeting, Houston, TX, “State of the Art on Epigenetic Lesions in MDS-Significance.”
2012. Medical College of Wisconsin, Grand Rounds, Milwaukee, WI, “Pathogenesis in PNH.”
2013. Global Iron Summit, Copenhagen, Denmark, "Spliceosomal Mutations in RARS" and "Aplastic Anemia."
2013. Advanced Research in Medicine seminar for CCLCM students, Cleveland, OH, “Various Instructive Research Aspects in Aplastic Anemia: a Prototypic Stem Cell Disease.”
2013. Great Debates and Updates in Hematologic Malignancies, New York, NY, “Aplastic Anemia in the Adult: Diagnosis, Prognosis, and Management.”
2013. The 12<sup>th</sup> International Symposium on Myelodysplastic Syndromes, Berlin, Germany, “Overlap of BMF and MDS.”
2013. MD Anderson Cancer Center, Grand Rounds, Houston, TX, “Genomics of MDS, Implications from Whole Exome Sequencing Studies.”
2013. The Ohio State University-The James Cancer Center, Grand Rounds, Columbus, OH, “MDS Mutatome: from Discovery to Diagnostics.”

- 2013. 33<sup>rd</sup> Annual Cleveland Clinic Research Day, Cleveland, OH, "Genomics of Myeloid Leukemias: from Discovery to Diagnostics."
- 2013. University of Illinois-Chicago, Grand Rounds, Chicago, IL, "PNH."
- 2013. 55<sup>th</sup> Annual ASH Meeting, New Orleans, LA, "Turning the Tide against MDS and Other Bone Marrow Failure Syndromes."
- 2014. Albert Einstein College of Medicine, New York, NY, Oncology Grand Rounds: "Genomics of MDS."
- 2014. Japanese Society of Hematology International Symposium. Hammamatsu, Japan 1) "New Insights into Molecular Pathogenesis of MDS". 2) "Treatment of MDS."
- 2014. University of Nagoya, Research Lecture. Nagoya, Japan, "Next Generation Sequencing in MDS."
- 2014. University of Kyoto, Clinical Research Presentation, Kyoto, Japan, "Rational Approaches to the Treatment of MDS: New Therapies."
- 2014. University of Nagasaki, Invited Speaker-Hematology Lecture, "Molecular Pathogenesis of MDS."
- 2014. Rush University, Grand Rounds, Chicago, IL, "From Aplastic Anemia to Paroxysmal Nocturnal Hemoglobinuria."
- 2015. Acute Leukemias XV International Symposium, Munich, Germany, "The Role of Ancestral Mutations in Myeloid Neoplasms."
- 2015. Northwestern University, Grand Rounds, Chicago, IL, "Role of Ancestral versus Secondary Molecular Lesions in Myeloid Neoplasms."
- 2015. Northwestern University, Grand Rounds, Chicago, IL, "Molecular Genetics of MDS; Implications for Discovery and Treatment."
- 2015. H. Lee Moffitt Cancer Center, Grand Rounds, Tampa, FL, "Founder vs. Ancestral Events in Myeloid Neoplasms."
- 2015. US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Conference, Alexandria, VA, "Current understanding of a genetic/epigenetic basis of MDS."
- 2015. *FasterCures* Chronic Myelomonocytic Leukemia Retreat, New York, NY, "CMML Gene Discovery" Session Moderator.
- 2015. Society of Hematologic Oncology Annual Meeting, Houston, TX, "Somatic Mutations-A Powerful Tool Characterizing Disease Pathogenesis, Diagnosis to Prognosis and Treatment."
- 2015. Leukemia Predisposing Genes Conference, Perugia, Italy, "Familial mutations in RNA DDX41 Helicase."
- 2016. Japanese Society of Bone marrow transplantation. Nagoya, Japan "Genomic determinants of outcomes of BMT in MDS"
- 2016. Oncology Grand Rounds, University of Fukui, Fukui, Japan "Genomics of bone marrow Failure"
- 2016. International Bone Marrow Failure Symposium, Rockville, MD, "Inherited and somatic alterations in aplastic anemia and myelodysplastic syndrome"
- 2017. International Meeting on Childhood MDS and SAA EWOG-MDS/SAA, Rome, Italy, "Inherited mutational landscape of AA and MDS."
- 2017. The 14<sup>th</sup> International symposium Myelodysplastic Syndromes, Valenica, Spain "Meet the Expert: Genomics of MDS."
- 2017. 59<sup>th</sup> Annual American Society of Hematolog Meeting, Atlanta, GA, Meeting Educational Session. "Genomic diagnosis of Bone Marrow Failure."
- 2017. Warren Alpert Medical School, Providence, Rhode Island, Myeloid Neoplasm Symposium, "Clonal chierocky of myeloid neoplasm."
- 2018. MDS/MPN IWG Meeting, Charlotte, NC, "Targeting TET2 in MDS/MPN"

- 2018. Madelieu, France, International Conference on Myelodysplastic Syndromes, “Walk this way: The Multiple acquired clonal steps to MDS discussion”
- 2018. Medical Grand Rounds, Rosewell Park, Buffalo, NY, “Random and Deterministic Aspects of Clonal Hierachy in Myeloid Neoplasm.”
- 2018. The 9<sup>th</sup> Internaional Symposuim, Kyoto, Japan, “Epigenetic abnormalitites of hematological malignancies: Basic studies.”
- 2018. Tokyo, Japan. Tokyo University, Hemeatology Mini Symposuim.
- 2019. Tokyo, Japan. Aplastic Anemia Mini Symposuim: “Newest Advances in the treatment of aplastic anemia”
- 2019. Rochester, Minnesota, Mayo Clinic Ground Rounds: “Germline and somatic genomics of myelodysplastic syndromes”
- 2019. Naples, Italy, International PNH conference: “Is PNH a myeloid neoplasm?”
- 2019. Bethesda, Maryland, National Institute of Health Aging Stem Cell symposium: “Interventions in aging hematopoiesis “
- 2019. Rochester, MN. Mayo Clinic Division of Hematology “Somatic and germ line genetics of bone marrow failure”
- 2019. New York, NY, Columbia Univeristy Medical Grand Rounds: “Genomic clues to the therapy of MDS”
- 2019. Detroit, MI, Henry Ford Cancer Institute. Medical Grand Rounds: “Genomic clues to the therapy MDS”
- 2019. New York, NY, Memorial Sloan-Kettering Cancer Center, Grand Rounds. “National new molecular targeting in MDS”
- 2019. Orlando Florida, Annual American Society of Hematology Meeting, Education Session Bone Marrow Failure “Clonal complications of aplastic anemia in genomic era”
- 2020. Washington DC, AA&MDS Int Foundation Bone Barrow Failure Symposium. “Somatic mutations in aplastic anemia and paroxysmal nocturnal hemoglobinuria” (Virtual)
- 2020. Paris, France, EHA Bone marrow Failure Symposium “Clonal hematopoiesis in aplastic anemia” (Virtual)
- 2020. San Diego, CA, Annual American Society of Hematology Meeting, Satellite Bone marrow Failure Symposium “Management of apastic anemia in 2020” (Virtual)
- 2020. Durham, NC. Duke Cancer Institute Grand Rounds “Research and Vision” (Vitual)
- 2020. New York, NY. Perlmutter Cancer Center Grand Rounds “From Immunobiology to molecular hematology”
- 2020. Seattle, WA. Washington University Fred Huchinson Cancer Center grand rounds Inhibition of DNA dioxgenoses in myeloid neoplasia.
- 2022. Mondelieu, France ESH 8<sup>th</sup> Translational Research Conference on Myelodysplastic Syndromes: “Germline vs. Semactic genetic lesions in MDS”
- 2022. Int. Virtual Conference PNH Registry Patient Conference AA&MDS Int Foundation, “What’s new in PNH”
- 2022. Sarajero Bosnia, BHAAS Conference. Molecular pathogenesis of AML

### **Organized Symposia**

Bone Marrow Failure Symposium 2007 (NIH R13-sponsored) Washington DC, **Maciejewski JP** and Young NS, Co- organizers

MDS Summit 2007 Cleveland Clinic, Cleveland, OH, **Maciejewski JP** and M Sekeres, Co-organizers



**Oral and Poster Presentations since 2010 (328)**

1. O'Keefe CL, Sugimori C, Afable M, Clemente M, List A, Shain K, Araten D, Epling-Burnette PK, **Maciejewski JP** (2010). Deletions of Xp22.2 Including the PIG-A Locus Can Lead to a Paroxysmal Nocturnal Hemoglobinuria Phenotype in Patients without PIG-A mutations: MDS with PNH Phenotype? 52<sup>nd</sup> American Society of Hematology Annual Meeting.
2. Clemente M, Wlodarski M, Viny A, Shaik M, Bejanyan N, Makishima H, Lichtin A, Hsi E, Paquette R, Loughran T, **Maciejewski JP** (2010). Clonotype Switching Indicates Propensity for Clonal Outgrowth from Diverse Components of the T Cell Repertoire in T Cell Large Granular Lymphocyte Leukemia. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
3. Brodsky R, Risitano A, Schrezenmeier H, Schubert J, **Maciejewski JP**, Dührsen U, Luzzatto L, Muus P, Szer J, De Castro C, Socié G, Hillmen P (2010). Long Term Safety and Efficacy of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). 52<sup>nd</sup> American Society of Hematology Annual Meeting.
4. Afable M, Shaik M, Sugimoto Y, Clemente M, Tiu R, Mohan S, Bejanyan N, Elson P, Kalaycio M, Advani A, Sobecks R, Lichtin A, Sekeres M, **Maciejewski JP** (2010). Efficacy of Rabbit Anti-thymocyte Globulin (ATG) Compared to Horse ATG in Severe Aplastic Anemia. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
5. Szpurka H, Jankowska A, Przychodzen B, Hu Z, Sauntharajah Y, McDevitt M, **Maciejewski JP** (2010). UTX Mutations and Epigenetic Changes in MDS/MPN and Related Myeloid Malignancies. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
6. Makishima H, Jankowska A, Tiu R, Szpurka H, Sugimoto Y, Hu Z, Ebrahim Q, Sauntharajah Y, Guinta K, Keddache M, O'Keefe C, Sekeres M, List A, McDevitt M, **Maciejewski JP** (2010). Identification of Oncogenic EZH2 Mutations in MDS and Related Myeloid Malignancies. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
7. Makishima H, Jankowska A, McDevitt M, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, Harish S, Shaik M, Hsi E, Advani A, Paquette R, **Maciejewski JP** (2010). CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations as well as additional chromosomal aberrations constitute molecular events contributing to malignant progression in advanced Philadelphia chromosome-positive disorders. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
8. Makishima H, Muramatsu H, Hama A, Tiu R, Sugimoto Y, Sekeres M, Sauntharajah Y, McDevitt M, Kojima S, **Maciejewski JP** (2010). A high resolution analysis of chromosome 21 amplification in myeloid malignancies reveals an association with a specific cytogenetic subgroup and enhanced ERG gene expression. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
9. Hama A, Makishima H, Muramatsu H, Sugimoto Y, Doisaki S, Nishio N, Shimada A, Takahashi Y, Kojima S, **Maciejewski JP** (2010). Gene alterations of acute megakaryoblastic leukemia (AMKL): a comparison of AMKL with and without Down syndrome. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
10. Traina F, Jankowska A, Makishima H, Hsieh FH, Han Y, O'Keefe C, Sugimoto Y, Mohan SR, Szpurka H, Prince C, Guinta K, Sekeres MA, Kalaycio M, Lichtin A, Advani AS, Copelan E, Sobecks R, **Maciejewski JP**, Tiu RV (2010). New TET2, ASXL1 and CBL mutations have poor prognostic impact in Systemic Mastocytosis and related disorders. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
11. Sugimoto Y, Makishima H, Szpurka H, Jankowska A, Guinta K, Tiu R, O'Keefe C, Moliterno A, McDevitt M, Muramatsu H, Kojima S, Keddache M, **Maciejewski JP** (2010). Next Generation Exome Sequencing for Identification of the Gene Mutations Associated with Loss of Heterozygosity on Chromosome 7 In Myeloid Malignancies. 52<sup>nd</sup> American Society of Hematology Annual Meeting.

12. Sugimoto Y, Sekeres M, Makishima H, O'Keefe C, Guinta K, Afable M, Rocha McGraw K, List A **Maciejewski JP** (2010). Cytogenetic Predictors of Response to Lenalidomide In Myeloid Malignancies without Del(5q). 52<sup>nd</sup> American Society of Hematology Annual Meeting.
13. McGraw K, Zhang LM, Rollison D, Lin HY, Rawal B, Billingsley D, Kurtin S, Caceres G, Clark J, Sokol L, Burnette PK, Guinta K, **Maciejewski JP**, Mallo M, Sole F, Jose Calasanz M, Cervera J, Such E, Gonzalez T, Sung S, Nevill T, Karsan A, List A (2010). Predisposition to Myelodysplastic Syndrome with Deletion 5q Is Associated with TP53 Codon 72 Genotype. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
14. Jankowska A, Makishima H, Tiu R, Szpurka H, Huang Y, Sugimoto Y, Prince C, O'Keefe C, Hsi E, List A, Sekeres M, Rao A, McDevitt M, **Maciejewski JP** (2010). Mutational Spectrum in Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such As UTX and EZH2. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
15. Jankowska A, Ko M, Huang Y, Pape U, Szpurka H, Tahiliani M, Bandukwala H, An J, Lamperti E, Koh KP, Liu X, Aravind L, Agarwal S, Rao A, **Maciejewski JP** (2010). Impaired hydroxylation of 5-methylcytosine in TET2 mutated patients with myeloid malignancies. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
16. Mohan S, Elson P, Tiu R, Advani A, Sauntharajah Y, Sobecks R, Kalaycio M, Copelan E, **Maciejewski JP**, Sekeres M (2010). Duration of Antecedent Complete Blood Cell Count (CBC) Abnormalities Predicts Response and Survival Rates in De Novo and Secondary AML. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
17. Mohan S, Fu A, Tiu R, Copelan E, Sauntharajah Y, Advani A, Sobecks R, Afable M, Englehaupt R, Paulic K, Earl M, Kalaycio M, **Maciejewski JP**, Sekeres M (2010). Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival in Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
18. Earl M, Fu A, Kalaycio M, Advani A, Sauntharajah Y, Peks C, Tripp B, Grimes K, Sobecks R, Copelan E, **Maciejewski JP**, Sekeres M (2010). Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and Without Bone Marrow Involvement. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
19. Sekeres M, Mohan S, **Maciejewski JP**, Lundberg A, Erba H (2010). A retrospective multi-center analysis of prognostic factors determining outcomes in patients with secondary AML. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
20. Sekeres M, Narang M, Rami S, Komrokji R, **Maciejewski JP**, List A, Street T, Swern A, Sullivan K, Grinblatt D (2010). Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
21. Epling-Burnette PK, Komrokji R, **Maciejewski JP**, Sekeres M, Paquette R, Wei S, Painter J, Bai F, Fulp W, Paleveda-Pena J, Chen DT, List A (2010). Phase 2 Multicenter Trial of Rabbit Anti-Thymocyte Serotherapy in Myelodysplastic Syndrome: Rate of Hematological Improvement Associated with Pre-Treatment Disease Duration. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
22. Sekeres M, Arevalo-Araujo R, Shelekhova T, Bennett J, Steensma D, List A, Lu M Ivo Nnane, Varsos H, Wan Y, Bowers P, **Maciejewski JP** (2010). A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa (EPO) at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Patients with Myelodysplastic Syndromes (MDS) at Risk for Transfusion. 52<sup>nd</sup> American Society of Hematology Annual Meeting.
23. Stein B, Williams D, McDevitt M, O'Keefe C, **Maciejewski JP**, Rogers O, Spivak J, Moliterno A (2011). Disruption of the ASXL1 gene is prevalent in PMF: Analysis of molecular genetics and clinical phenotypes. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
24. Mukherjee S, Fu AZ, Mansour MG, Kalaycio ME, Copelan E, Advani A, Tiu RC, Sauntharajah Y, **Maciejewski JP**, and Mikkael A. Sekeres (2011). Cigarette Smoking Significantly Increases the risk of Invasive Fungal Disease in AML Patients Undergoing Induction Chemotherapy. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
25. Mukherjee S, Reddy C, Ciezki J, Tiu R, Copelan E, Advani A, Sauntharajah Y, Paulic K, **Maciejewski JP**,<sup>1</sup> Bolwell BB, Klein E and Sekeres M, (2011). Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS) 53<sup>rd</sup> American Society of Hematology Annual Meeting.

26. Sekeres MA, Elson P, Tiu RV, Sauntharajah Y, Advani A, Paulic K, Chan J, Pierce S, Jabbour E, Kantarjian H, **Maciejewski JP**,<sup>1</sup> Garcia-Manero G (2011). Validating the Lower-risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
27. Sekeres MA, Komrokji R, Lancet J, Tiu RV, Advani A, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Palveda J, Paquette R, Smith, Strozniak L, List AF, **Maciejewski JP**,<sup>1</sup> (2011). Final Results from the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-risk Myelodysplastic Syndromes (MDS) 53<sup>rd</sup> American Society of Hematology Annual Meeting.
28. Urbano-Ispizua A, Schrezenmeier H, Muus P, **Maciejewski JP**, Socie G, Szer J, Brodsky R, Bessler M, Rosse W, Kanakura W, Khursigara G, Bedrosian C, Hillmen P (2011). Clinical Characteristics of Classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pediatric Patients: A Comparison with Classic PNH in Adults. An International PNH Registry study. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
29. Mailloux AW, Sugimori X, **Maciejewski JP**, Paquette R, Loughran TP, List AF, Epling-Burnette PK (2011). A Switch in Regulatory T-cell Memory Phenotype is an Independent Prognostic Indicator for Poor Survival in Lower Risk Myelodysplastic Syndrome Patients 53<sup>rd</sup> American Society of Hematology Annual Meeting.
30. Sauntharajah Y, Mahfouz R, Englehaupt E, Juersivich J, Durkin L, Radivoyevitch T, Cooper K, Afable M, Dean R, Advani A, Kalaycio M, Sobecks R, Copelan E, His E, **Maciejewski JP**, Sekeres M (2011). A proof of principle clinical trial in myelodysplastic syndrome of decitabine rationalized for non-cytotoxic differentiation therapy. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
31. Yang L, Mailloux, AW, Rollison DE, Park J, Painter, JS, Komrokji RS, **Maciejewski JP**, Paquette R, Loughran TP, Wei S, List AF and Epling-Burnette PK (2011). Human Telomerase Reverse Transcriptase (hTERT) Deficiency in Myelodysplastic Syndrome (MDS) Demonstrates Mechanistic Linkage to Aplastic Anemia Pathophysiology. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
32. Mahfouz R, Jankowska A, Ebrahim Q, Hu Z, Terse P, Covey J, Chan J, Sekeres M, Lavelle D, DeSimone J, Sekeres RV, Tiu RV, **Maciejewski JP**, Yogen Sauntharajah (2011). Gender is a major determinant of cytidine analogue metabolism and may contribute to differences in treatment outcomes. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
33. McDevitt MA, Dilley R; Pratz J, Smith D, Moliterno A, Yen Y, Malick L, Gore S, Jones R, **Maciejewski JP**, Espinoza-Delgado I, Karp JE (2011). Final results from a phase II trial of Triapine® plus fludarabine for Adults with aggressive myeloproliferative disorders. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
34. McDevitt MA, Koh B, Patel A, Moliterno A, Poh W, Herman J, Dilley R, Smith RB, Karp JE, **Maciejewski JP**, Kaufmann S, Pratz K (2011). Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
35. Jankowska AM, Szpurka H, Venugopalan C, Peng K, Hu Z, Michael MA, Sauntharajah Y and **Maciejewski JP** (2011). Consequences of UTX Dysfunction in Myelodysplastic Syndrome. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
36. Jankowska AM, Huang, Ko M, Pape, Makishima H, Szpurka H, Traina F, Visconte V, Tiu RV, Sekeres MA, Rao A, **Maciejewski JP** (2011). Mechanisms of defective hydroxylation of 5-methylcytosine in MDS include pathways other than *TET2* and *IDH1/2*. (2011) 53<sup>rd</sup> American Society of Hematology Annual Meeting.
37. Clemente MJ, Afable MG, Lichtin AE, and **Maciejewski JP** (2011). Glycophosphatidylinositol Deficiency as Assessed by Flow Cytometry is a Biomarker for Chronic Natural Killer Lymphoproliferative Disorder and has Implications for Therapy with Alemtuzumab. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
38. Clemente MJ, Przychodzen B, Makishima M, Afable M, Lichtin AR, **Maciejewski JP** (2011). T-Cell Receptor Repertoire Landscape Mapping: A Novel Paradigm for T-Cell Mediated Autoimmune Disorders Based on Deep Vβ Chain Sequencing. 53<sup>rd</sup> American Society of Hematology Annual Meeting.

39. Makishima H, Khan NS, Jankowska AM, Sugimoto Y, Hu Z, Cheriya V, Mahfouz R, Ebrahim Q, Vatolin S, Sauntharajah Y, Sekeres MA, and **Maciejewski JP** (2011). Pathogenesis of *EZH2* Is Either Mutated or Downregulated in Patients with Loss of Heterozygosity of Chromosome 7/7q and Leads to Epigenetic Dysregulation Via Histone H3K27. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
40. Y Sugimoto, Guinta KM, Sakaguchi H, O'Keefe C, Muramatsu M, Kojima S and **Maciejewski JP** (2011). Monosomy 7 in Bone Marrow Failure Syndromes." 53<sup>rd</sup> American Society of Hematology Annual Meeting.
41. Makishima H, Sakaguchi H, Visconte V, Jerez A, Jankowska AM, Guinta KM, Muramatsu H, Sekeres MA, Kojima S, Tiu RV, and **Maciejewski JP** (2011). Acquired Molecular Defects in Spliceosome Machinery: Novel Pathogenetic Pathways in Myeloid Leukemogenesis. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
42. Makishima H, Jankowska AM, Visconte V, Tiu RV, Kathryn G, Szpurka H, Sugimoto S, O'Keefe CH, List A, Sekeres MA, McDevitt MA, **Maciejewski JP** (2011). Spliceosome gene mutations are also present in the diverse mutational spectrum of CMML. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
43. Afable M, Makishima H, Sakaguchi H, Jerez A, Jankowska AM, Guinta KM, Abu Kar S, Traina F, Sugimoto Y, O'Keefe CH, Tiu RV, Sekeres MA, **Maciejewski JP** (2011). Distinction of Early and Late Molecular Events In Patients with Myelodysplastic Syndromes (MDS) Who Progressed to Acute Myeloid Leukemia (AML). 53<sup>rd</sup> American Society of Hematology Annual Meeting.
44. Przychodzen B, Jerez A., Guinta K, Wodnar-Filipowicz B, **Maciejewski JP** (2011). Mass Screening for Non-Synonymous SNPs Using Custom Cancer Microarrays Directly Reveals Possible Pathogenic Predisposition Factors in AA. 53<sup>rd</sup> American Society of Hematology Annual Meeting.
45. Afable MG, Guo T, Przychodzen BP, Rybicki L, Clemente MJ, Jerez A, Husseinadeh H, Evans EP, Lichtin AE, Wodnar-Filipowicz A, Sekeres MA, **Maciejewski JP** (2012). Identifying Immunogenetic Features That Distinguish Immune Mediated, Immunosuppression-Sensitive Disease in Aplastic Anemia (AA). 54<sup>th</sup> American Society of Hematology Annual Meeting.
46. Gómez-Seguí I, Przychodzen BP, Yoshida K, Ruffalo M, Jerez A, Makishima H, Miyano S, Shiraishi Y, Husseinadeh H, Hosono N, Guinta K, LaFramboise T, Ogawa S, Sautharajah Y, Sekeres MA, **Maciejewski JP** (2012). Mutational spectrum of myelodysplastic syndrome malignancies revealed by whole exome sequencing. 54<sup>th</sup> American Society of Hematology Annual Meeting.
47. Gómez-Seguí I, Makishima H, Jerez A, Yoshida K, Przychodzen BP, Miyano S, Shiraishi Y, Husseinadeh H, Guinta K, Hosono N, McDevitt M, Moliterno AR, Sekeres MA, Ogawa S, **Maciejewski JP** (2012). Novel recurrent mutations in the RAS-like GTP-binding gene *Rit1* in myeloid malignancies. 54<sup>th</sup> American Society of Hematology Annual Meeting.
48. Makishima H, Yoshida K, Clemente MJ, Afable MG, Jerez A, Shiraishi Y, Miyano S, Ogawa S, **Maciejewski JP** (2012). Karyotypic and genetic abnormalities associated with clonal evolution paroxysmal nocturnal. 54<sup>th</sup> American Society of Hematology Annual Meeting.
49. Makishima H, Yoshida K, Nguyen N, Sanada M, Okuno Y, Ng KP, Przychodzen BP, Gudmundsson K, Vishwakarma B, Jerez A, Gómez-Seguí I, Takahashi M, Shiraishi Y, Nagata Y, Guinta K, Mori H, Sekeres MA, Chiba K, Muramatsu H, Sakaguchi H, Paquette R, McDevitt M, Kojima S, Sautharajah Y, Miyano S, Shih L, Du Y, Ogawa S, **Maciejewski JP** (2012). Somatic mutations in Schinzel-Giedion syndrome gene *SETBP1* determine progression in myeloid malignancies. 54<sup>th</sup> American Society of Hematology Annual Meeting.
50. Hosono N, Makishima H, Jerez A, Gómez-Seguí I, Przychodzen BP, Sekeres MA, Miyano S, Shiraishi Y, Ogawa S, **Maciejewski JP** (2012). Mutation screening associated with chromosome 7 abnormalities using next generation whole exome sequencing. 54<sup>th</sup> American Society of Hematology Annual Meeting.
51. Husseinadeh HD, Evans EP, Yoshida K, Makishima H, Jerez A, Ruffalo M, Shiraishi Y, Miyano S, Sanada M, Chiba K, Nagata Y, Gómez-Seguí I, Przychodzen B, Wenzell C, Afable MG, Sautharajah Y, Advani A, Sekeres MA, Ogawa S, **Maciejewski JP** (2012). Whole Exome Sequencing to Predict Response to Hypomethylating Agents in MDS. 54<sup>th</sup> American Society of Hematology Annual Meeting.
52. Przychodzen BP, Makishima H, Jerez A, Padgett R, **Maciejewski JP** (2012). Downstream consequences of U2AF1

- mutations in MDS are a result of a specific misplicing pattern due to faulty recognition of 3' acceptor splice site. 54<sup>th</sup> American Society of Hematology Annual Meeting.
53. Hosono N, Rehman H, Przychodzen BP, Gómez-Seguí I, Guinta K, Yoshida K, Miyano S, Shiraishi Y, Ogawa S, **Maciejewski JP**, Makishima H (2012). Various germline congenital disorder genes are somatically mutated in myeloid malignancies. 54<sup>th</sup> American Society of Hematology Annual Meeting.
  54. Rouphail B, Yoshida K, Husseinazadeh H, Evans E, Miyano S, Nagata Y, Shiraishi Y, Chiba K, Sanada M, Przychodzen BP, Gómez-Seguí I, Guinta K, Afafe MG, Sauntharajah Y, Sekeres MA, **Maciejewski JP**, Ogawa S, Makishima H (2012). Molecular diversity detected by whole exome sequencing in chronic myelomonocytic leukemia. 54<sup>th</sup> American Society of Hematology Annual Meeting.
  55. Andersson E, Eldfors S, Koskela H, Ellonen P, Olson T, Jerez A, Clemente MJ, Kallioniemi O, Porkka K, Loughran Jr T, **Maciejewski JP**, Heckman C, Mustijoki S (2012). Somatic PTPRT and ANGPT2 mutations in large granulocyte leukemia. 54<sup>th</sup> American Society of Hematology Annual Meeting.
  56. Fang J, Jerez A, Rasch C, Bolanos L, **Maciejewski JP**, Starczynowski DT (2012). Haploinsufficiency of Mir-146a in High-Risk Del(5q) MDS/AML Requires an Intrachromosomal Gene Network Involving p62/TRAF6/NF- $\kappa$ B. 54<sup>th</sup> American Society of Hematology Annual Meeting.
  57. Varney M, Jerez A, Fang J, Miller D, Bolanos L, Karsan A, **Maciejewski JP**, Starczynowski DT (2012). Tifab, a Novel Candidate Gene in Deletion Chromosome 5q, Contributes to Deregulation of NF- $\kappa$ B Signaling in MDS/AML. 54<sup>th</sup> American Society of Hematology Annual Meeting.
  58. Mehta H, Maskishima H, Futami M, Kao W, Przychodzen BP, Cheng C, **Maciejewski JP**, Corey SJ (2012). Profound Signaling Abnormalities Due to Cytoplasmic Variants of CSF3R in Patients with Myelodysplastic/Myeloproliferative Syndromes Associated with CSF3R Mutations or Mutations of Splicing Factor U2AF1. 54<sup>th</sup> American Society of Hematology Annual Meeting.
  59. Koskela/Rajala HLM, Eldfors S, Kuusanmäki H, Andersson EI, van Adrichem AJ, Lagström S, Olson T, Jerez A, Clemente, Zhang D, Awwad A, Pihlman M, Ellonen P, Kallioniemi O, Wennerberg K, Porkka K, **Maciejewski JP**, MD, Loughran Jr. TP, Heckman C, Mustjoki S (2012). Discovery of STAT5b mutations and small subclones of STAT3 mutations in large granular lymphocytic (LGL) leukemia. 54<sup>th</sup> American Society of Hematology Annual Meeting.
  60. Muramatsu H, Okuno Y, Sakaguchi H, Yoshida K, Shiraishi Y, Sanada M, Chiba K, Tanaka H, Makishima H, Wang X, Xu Y, Doiaki S, Hama A, Nakanishi K, Takahashi Y, Yoshida N, **Maciejewski JP**, Miyano S, Ogawa S, Kojima S (2012). Whole exome analysis reveals spectrum of gene mutations in juvenile myelomonocytic leukemia. 54<sup>th</sup> American Society of Hematology Annual Meeting.
  61. Hasrouni E, Visconte V, Tabarroki A, Rogers HJ, Traina F, Jankowska A, Liu Y, Hamilton BK, Bupathi M, Makishima H, Jerez A, Copelan E, Advani A, McDevitt MA, Kalaycio M, Sauntharajah Y, Sekeres MA, **Maciejewski JP**, Tiu RV (2012). Pathway Analysis of Molecular Mutations Can Modify Morphologic, and Prognostic Risk Stratification Schemes in Myelodysplastic Syndromes (MDS), Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN), and Secondary Acute Myeloid Leukemia (AML). 54<sup>th</sup> American Society of Hematology Annual Meeting.
  62. Hamilton BK, Tabarroki A, Visconte V, Hasrouni E, Makishima H, Tench S, Kalaycio M, Sekeres MA, Sobecks R, Duong HK, Hill BT, **Maciejewski JP**, Bolwell BJ, Copelan E, Tiu RV (2012). Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in patients with Myeloid Malignancies who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation. 54<sup>th</sup> American Society of Hematology Annual meeting.
  63. Visconte V, Rogers HJ, Tabarroki A, Hasrouni E, Traina F, Liu, O'Keefe CL, **Maciejewski JP**, Sekeres MA, Hsieh FH, Tiu RV (2012). SF3B1, a Splicing Factor Gene, Is Infrequently Mutated in Rare Bone Marrow Failure Diseases but Still Associated with Ring Sideroblast Phenotype. 54<sup>th</sup> American Society of Hematology Annual Meeting.
  64. Visconte V, Mahfouz RZ, Tabarroki A, Rogers HJ, Juraj B, Hasrouni E, Sharghi-Moshtaghin R, Avishai N, Bupathi M, Hamilton BK, Liu Y, Makishima H, Jankowska A, Barnard J, Traina F, Sauntharajah Y, Copelan E, Heuer A, Lindner D, **Maciejewski JP**, Sekeres MA, Tiu RV (2012). Biological Rationale for the Favorable Clinical Outcomes of Patients Carrying SF3B1 Mutations in Myelodysplastic Syndromes with Ring Sideroblasts. 54<sup>th</sup> American Society of Hematology Annual Meeting.

65. Moliterno AR, Williams DM, McDevitt MA, Stein BL, Gerber JM, Rogers O, Streiff MB, Lanzkron S, Resar L, O'Keefe C, **Maciejewski JP**, Spivak JL (2012). Polycythemia Vera: Redefinition in the Genomic Era. 54<sup>th</sup> American Society of Hematology Annual Meeting.
66. Ornstein M, Mukherjee S, Mohan S, Elson P, Tiu RV, Sauntharajah Y, Farhat L, Kendeigh C, Advani A, Kalaycio M, **Maciejewski JP**, Sekeres MA. A multicomponent prognostic model to predict outcome in therapy-related AML. 54<sup>th</sup> American Society of Hematology Annual Meeting.
67. Ornstein MC, Mukherjee S, Keng M, Elson P, Tiu RV, Sauntharajah Y, Farhat L, Banks D, Advani A, Kalaycio M, **Maciejewski JP**, Sekeres MA (2012). Vancomycin-resistant Enterococcus (VRE) Bacteremia during Induction for Acute Myeloid Leukemia (AML) is an Independent Predictor of Poor Outcome. 54<sup>th</sup> American Society of Hematology Annual Meeting.
68. Socié G, Schrezenmeier H, Muus P, Szer J, Urbano-Ispizua A, **Maciejewski JP**, Brodsky R, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P (2012). Eculizumab Protects against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study. 54<sup>th</sup> American Society of Hematology Annual Meeting.
69. Jerez A, Clemente M, Makishima H, Koskela H, Gomez-Segui I, Olson T, McGraw K, Przychodzen B, Kulasekararaj AG, Afable M, Husseinadeh H, Hosono N, LeBlanc F, Lagström S, Zhang D, Ellonen P, Lichtin AE, Wodnar-Filipowicz A, Mufti GJ, List A, Mustjoki S, Loughran TP, **Maciejewski JP** (2012). STAT3-mutations indicate the presence of subclinical self-reactive cytotoxic T cell clones in Aplastic Anemia and Myelodysplastic Syndromes. 54<sup>th</sup> American Society of Hematology Annual Meeting.
70. Clemente MJ, Przychodzen B, Makishima H, Afable MG, Wlodarski MW, Lichtin AE, **Maciejewski JP** (2012). Identification and Monitoring of Pathogenic T cell Clones Using Deep TCR Sequencing in T-Large Granular Lymphocyte Leukemia and Aplastic Anemia. 54<sup>th</sup> American Society of Hematology Annual Meeting.
71. Portell CA, Visconte V, Clemente M, Tabarroki A, Traina F, Liu Y, Hamilton BK, Manojkumar B, Advani AS, Horwitz L, Lichtin AE, Sekeres MA, **Maciejewski JP**, Tiu RV (2012). Anemia associated with Increased IL-6 and IL-8 expression predicts for worse progression free survival in T-cell and NK-cell Large Granular Lymphocyte (LGL) Leukemia but improved by treatment with Cyclophosphamide. 54<sup>th</sup> American Society of Hematology Annual Meeting.
72. Mahfouz RZ, Englehaupt R, Juersivich JA, Cooper K, Durkin L, Radivoyevitch T, Tiu RV, Reu FJ, Dean RM, Sobecks R, Kalaycio M, Copelan EA, Advani AS, Hsi ED, Sekeres MA, **Maciejewski JP**, Sauntharajah Y (2012). Non-Cytotoxic Differentiation Therapy Based on Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics. 54<sup>th</sup> American Society of Hematology Annual Meeting.
73. Ornstein M, Mukherjee S, Mohan SR, Elson P, Tiu RV, Sauntharajah Y, Farhat L, Kendeigh C, Advani AS, Kalaycio M, **Maciejewski JP**, Sekeres MA (2012). Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-Related AML. 54<sup>th</sup> American Society of Hematology Annual Meeting.
74. McGraw, KL, Zhang LM, Fulp W, Lin H, Jerez A, Basiorka AA, Caceres G, Rollison DE, Billingsley D, Kurtin SE, Sokol L, Epling-Burnette PK, Mallo M, Sole F, Calasanz MJ, Cervera J, Such E, Gonzalez T, **Maciejewski JP**, List AF (2012). Association of MDM2 Gene Polymorphisms SNP285 and 309 with MDS Susceptibility and Outcomes. 54<sup>th</sup> American Society of Hematology Annual Meeting.
75. Scopim-Ribeiro R, Machado-Neto J, de Melo Campos P, Favaro P, Duarte AS, Visconte V, Lorand-Metze I, Ferreira Costa F, **Maciejewski JP**, Tiu RV, Olalla Saad ST, Traina F (2012). Reduced TET2 Expression in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. 54<sup>th</sup> American Society of Hematology Annual Meeting.
76. Advani, AS, Cooper B, Sowunmi O, Elson P, Ali-Osman F, Park J, Rao A, Rizzieri DA, Wang ES, Cotta C, Sekeres MA, Kalaycio M, Sobecks R, Roupail B, **Maciejewski JP**, Davis R, Bailey L (2012). A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML). 54<sup>th</sup> American Society of Hematology Annual Meeting.
77. Szer J, Muus P, Roeth A, Elebute MO, Risitano AM, Schrezenmeier H, **Maciejewski JP**, Urbano-Ispizua A, Manuel de Castro III C, Socie G, Brodsky RA (2012). Long-Term Safety of Sustained Eculizumab Treatment in Patients with PNH. 54<sup>th</sup> American Society of Hematology Annual Meeting.

78. Mierzejewska K, Rodriguez C, Sharma, VR, Kucia M, **Maciejewski JP**, Ratajczak J, Ratajczak MZ (2012). A Novel Evidence that PNH Affected Cells Residing in Bone Marrow (BM) Due to Impaired Incorporation of CXCR4 and VLA-4 into Membrane Lipid Rafts Show Defective and Impaired Interaction with the BM Stem Cell Niches. 54<sup>th</sup> American Society of Hematology Annual Meeting.
79. Muus P, Schrezenmeier H, Socié G, **Maciejewski JP**, Szer J, Brodsky RA, Urbano-Ispizua A, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P (2013). Improved Fatigue and Quality-of-Life in Patients with Paroxysmal Nocturnal Hemoglobinuria during Treatment with Eculizumab: Data from the Global PNH Registry. 18<sup>th</sup> Congress of the European Hematology Association Annual Meeting.
80. Rajala HLM, Olson T, Lagström S, Ellonen P, Arshi Uz Zaman S, Andersson EI, Clemente MJ, Jerez A, Porkka K, **Maciejewski JP**, Loughran TP, Mustjoki S (2013). Multiple STAT3 Mutations in Different Lymphocyte Clones of Large Granular Lymphocytic Leukemia Patients. 55<sup>th</sup> American Society of Hematology Annual Meeting.
81. Sakaguchi H, Muramatsu H, Wang X, Xu Y, Hibi Y, Kawashima N, Narita A, Doi S, Yoshida N, Hama A, Takahashi Y, Makishima H, Yamada K, **Maciejewski JP**, Kojima S. (2013). Aberrant DNA Methylation Is Associated With Poor Outcomes In Juvenile Myelomonocytic Leukemia. 55<sup>th</sup> American Society of Hematology Annual Meeting.
82. Clemente MJ, Bilori B, Thota S, Afable MG, Hussein Zadeh HD, Lichtin AE, **Maciejewski JP** (2013). Inhibition of the JAK/STAT Signaling Pathway as a Novel Therapy in CD8+ T-Large Granular Lymphocyte Leukemia. 55<sup>th</sup> American Society of Hematology Annual Meeting.
83. Kozaric AK, Makishima H, Przychodzen BP, Singh J, Konarska MM, Otrrock ZK, Nakashima M, Hsi ED, Yoshida K, Ogawa S, **Maciejewski JP** (2013). PRPF8 Defects Cause Missplicing In Myeloid Malignancies. 55<sup>th</sup> American Society of Hematology Annual Meeting.
84. Polprasert C, Makishima H, Przychodzen BP, Hosono N, Shen W, Huang D, Shiraishi Y, Miyano S, Yoshida K, Ogawa S, **Maciejewski JP** (2013). Whole Exome Sequencing Detecting Kinesin Family Defects in Myeloid Neoplasm. 55<sup>th</sup> American Society of Hematology Annual Meeting.
85. Polprasert C, Sekeres M, Makishima H, Przychodzen BP, Hosono N, Padgett RA, Singh J, Otrrock ZK, Mukherjee S, Afable MG, Hussein Zadeh HD, McMahon S, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, **Maciejewski JP** (2013). Novel Pathogenic Defects of Dead/H-Box Helicases in Myeloid Neoplasms. 55<sup>th</sup> American Society of Hematology Annual Meeting.
86. Yoshizato T, Bogdan D, Hosokawa K, Makishima H, Yoshida K, Okuno Y, Chiba K, Tanaka H, Shiraishi Y, Nagata Y, Katagiri T, Kon A, Clemente M, Sanada M, Miyano S, **Maciejewski JP**, Nakao S, Young N, Ogawa S (2013). Spectrum of genetic alterations in acquired aplastic anemia. 55<sup>th</sup> American Society of Hematology Annual Meeting.
87. Shen W, Przychodzen B, Clemente M, Dienes B, Yoshisato T, Sanada M, Yoshida K, Ogawa S, **Maciejewski JP**, Makishima H (2013). The Presence of Leukemogenic Mutational Events in Paroxysmal Nocturnal Hemoglobinuria Suggests that Clonal Architecture of Bone Marrow Failure is Similar to Myelodysplastic Syndrome. 55<sup>th</sup> American Society of Hematology Annual Meeting.
88. Hosono N, Makishima H, Przychodzen B, Jerez A, Polprasert C, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Yoshida K, Sanada M, Boulwood J, List A, Sekeres M, Ogawa S, **Maciejewski JP** (2013). Whole Exome Sequencing ("Mutatome") of Deletion 5q. 55<sup>th</sup> American Society of Hematology Annual Meeting.
89. Hosono N, Makishima H, Przychodzen B, Singh J, Padgett R, Sekeres M, Jerez A, Yoshida K, Shiraishi Y, Miyano S, Sanada M, Ogawa S, **Maciejewski JP** (2013). 55<sup>th</sup> American Society of Hematology Annual Meeting. Spliceosomal Gene LUC7L2 Mutation Causes Missplicing and Alteration of Gene Expression in Myeloid Neoplasms. 55<sup>th</sup> American Society of Hematology Annual Meeting.
90. Hosono N, Ramdhan ZM, Pal R, Makishima H, Przychodzen B, Sekeres M, Yoshida K, Shiraishi Y, Miyano S, Ogawa S, Nepveu A, **Maciejewski JP** (2013). Somatic Mutations and Loss-of-Heterozygosity Impair the DNA Repair Functions of CUX1 in Myelodysplastic Syndromes (MDS). 55<sup>th</sup> American Society of Hematology Annual Meeting.
91. Makishima H, LaFramboise T, Przychodzen B, Yoshida K, Ruffalo M, Gómez-Seguí I, Hussein Zadeh HD, Shiraishi Y, Sanada M, Nagato Y, Sato Y, Sato-Otsubo A, Chiba K, Tanaka H, Nakamaki T, Hoffman W, Miyawaki S, Shih L, Chiba

- S, Miyano S, Hosono N, Polprasert C, Thota S, Dienes B, Guinta K, Sauntharajah Y, Sekeres M, Ogawa S, **Maciejewski JP** (2013). Clinical "MUTATOME" of Myelodysplastic Syndrome; Comparison to Primary Acute Myelogenous Leukemia. 55th American Society of Hematology Annual Meeting.
92. Shen W, Przychodzen B, Polprasert C, Hosono N, Dienes B, Miyano S, Shiraishi Y, Yoshida K, Ogawa S, Sauntharajah Y, **Maciejewski JP**, Makishima H (2013). Somatic PHF6 Mutations in Myeloid Malignancies. 55th American Society of Hematology Annual Meeting.
  93. Pfeilstöcker M, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, **Maciejewski JP**, Magalhaes SMM, Miyazaki Y, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL (2013). Changes in Prognostic Power of MDS Prognostic Scoring Systems with Time from Diagnosis – Effects on Revised Scores such as the IPSS-R, Impact of Age. 55th American Society of Hematology Annual Meeting.
  94. Gu X, Mahfouz R, Enane F, Hu Z, Clemente M, Przychodzen B, Sekeres M, Advani A, Kalaycio M, **Maciejewski JP**, Sauntharajah Y (2013). A specific mechanism by which NPM1 mutations impede myeloid differentiation also explains the link with DNMT3A mutation. 55th American Society of Hematology Annual Meeting.
  95. Komrokji RS, Wang X, Ali NA, Garcia-Manero G, Steensma DP, Roboz G, Gore S, Hobson S, Padron E, **Maciejewski JP**, List AF, Sekeres MA (2013). Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes (MDS): Is one model better? 55th American Society of Hematology Annual Meeting.
  96. Huang D, Makishima H, Du Y, Hosono N, Shen W, Polprasert C, Sekeres MA, Przychodzen B, Padgett RA, Singh J, Guinta KM, Clemente MJ, Dienes B, Aifale MG, Husseinzadeh HD, McMahon S, Sauntharajah Y, Yoshida K, Shiraishi Y, Chiba T, Tanaka H, Miyano S, Ogawa S, **Maciejewski JP** (2013). Molecular Defects in BRCC3 Complex, a Novel Pathogenic Pathway in MDS. 55th American Society of Hematology Annual Meeting.
  97. Bilori B, Makishima H, Przychodzen BP, Ashkar M, Garje R, Thota S, Dienes B, Guinta KM, Tiu RV, Sekeres MA, **Maciejewski JP** (2013). Clinical and Molecular Features of Young Patients with Myelodysplastic Syndromes (MDS). 55th American Society of Hematology Annual Meeting.
  98. Thota S, Lakin P, Husseinzadeh HD, Makishima H, Przychodzen B, Dienes B, Guinta KM, Hosono N, Radivoyevitch T, Sekeres MA, Sauntharajah Y, **Maciejewski JP** (2013). Somatic Mutational Screen for Improved Prediction of the Outcomes of Epigenetic Therapy in MDS. 55th American Society of Hematology Annual Meeting.
  99. Thota S, McMahon S, Przychodzen B, LaFramboise T, Makishima H, Sekeres MA, **Maciejewski JP** (2013). Comprehensive Identification of Germline Alterations in Telomerase Complex Genes by Whole Exome Sequencing of MDS and Related Myeloid Neoplasms. 55th American Society of Hematology Annual Meeting.
  100. Thota S, McMahon S, Makishima H, Przychodzen B, Guinta KM, Dienes B, Hosono N, Sekeres MA, **Maciejewski JP** (2013). Germline Events in GF11 in Myelodysplastic Syndrome. 55th American Society of Hematology Annual Meeting.
  101. McMahon S, Przychodzen BP, Makishima H, Yoshida K, Shiraishi Y, Sanada M, Nagata Y, Sato Y, Sato-Otsubo A, Chiba K, Tanaka H, Miyano S, Ogawa S, LaFramboise T, **Maciejewski JP** (2013). Whole exome analysis of germline alterations associated with myelodysplastic syndrome. 55th American Society of Hematology Annual Meeting.
  102. Otrrock ZK, Przychodzen BP, Husseinzadeh HD, Makishima H, Dienes B, Hosono N, Sekeres MA, **Maciejewski JP** (2013). Molecular Predictors of Response To Lenalidomide In Myeloid Malignancies. 55th American Society of Hematology Annual Meeting.
  103. Makishima H, Yoshida K, LaFramboise T, Przychodzen BP, Ruffalo M, Gómez-Seguí I, Shiraishi Y, Sanada M, Nagata Y, Sato Y, Sato-Otsubo A, Chiba K, Tanaka H, Nakamaki T, Hofmann W-K, Miyawaki S, Chiba S, Miyano S, Husseinzadeh H, Hosono N, Polprasert C, Patel BJ, Thota S, Dienes B, Guinta KM, Shih L-Y, Sauntharajah Y, Okuno Y, Sekeres MA, Ogawa S, **Maciejewski JP** (2014). In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  104. Polprasert C, Schulze I, Sekeres MA, Makishima H, MD, Przychodzen BP, Hosono N, Singh J, Padgett RA, Gu X, Jankowsky E, Clemente M, Dienes B, Mukherjee S, Krug U, Klein H-U, Dugas M, Berdel WE, Yoshida K, Shiraishi Y,



- Chiba K, Tanaka H, Miyano S, Ogawa S, Müller-Tidow C, **Maciejewski JP** (2014). DDX41 Is a Tumor Suppressor Gene Associated with Inherited and Acquired Mutations. 56<sup>th</sup> American Society of Hematology Annual Meeting.
105. Hosono N, Mahfouz R, Przychodzen BP, Polprasert C, Zekri L, Clemente MJ, Tazi J, Sauntharajah Y, Sekeres MA, **Maciejewski JP**, and Makishima H (2014). Haploinsufficiency and Deletions of G3BP1 on Chromosome 5q Result in Induction of TP53. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  106. Patel BJ, Huang D, Thota S, Przychodzen BP, Sakaguchi H, Kojima S, Ogawa S, Sekeres MA, Makishima H, **Maciejewski JP** (2014). Chronic Myelomonocytic Leukemia (CMML) can be Categorized by Ancestral Mutational Events. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  107. Dienes B, Przychodzen BP, Clemente M, Shen W, Polprasert C, Hosono N, Miyano S, Shiraishi Y, Yoshida K, Ogawa S, Sekeres MA, Sauntharajah Y, **Maciejewski JP**, and Makishima H (2014). Impact and Function of Somatic PHF6 Mutations in Myeloid Neoplasms. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  108. Hosono N, Makishima H, Przychodzen BP, LaFramboise T, Polprasert C, Clemente MJ, Boultonwood J, Sekeres MA, **Maciejewski JP** (2014). Analysis of Clonal Hierarchy Shows That Other Ancestral Events May Precede Evolution of Del(5q) in Myeloid Neoplasms. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  109. Polprasert C, Radivoyevitch T, Hosono N, Makishima H, Przychodzen BP, Dienes B, McGraw K, Mukherjee S, Carraway HE, Sekeres MA, List AF, **Maciejewski JP** (2014). Molecular Predictors of Response in Patients with Myeloid Neoplasms Treated with Lenalidomide. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  110. Sakai H, Hosono N, Przychodzen BP, Carraway HE, Sekeres MA, **Maciejewski JP**, Makishima H (2014). Multiple Mechanisms Leading to ARID2 defects in Myeloid Neoplasms. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  111. Nazha A, Seastone DJ, Radivoyevitch T, Gerds AT, Mukherjee S, Carraway HE, Advani AS, Kalaycio ME, Rupp G, Colaluca K, Hobson S, **Maciejewski JP**, Sekeres MA (2014). A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS). 56<sup>th</sup> American Society of Hematology Annual Meeting.
  112. Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Sato A, Okuno Y, Kataoka K, Chiba K, Tanaka H, Shiraishi Y, Nagata Y, Suzuki H, Sato Y, Shiozawa Y, Katagiri T, Kon A, Clemente M, Sanada M, Miyano S, **Maciejewski JP**, Nakao S, Young NS, Ogawa S (2014). Chronological Analysis of Clonal Evolution in Acquired Aplastic Anemia. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  113. Gondek LP, Lim Y, Makishima H, Wang Q, **Maciejewski JP**, Aplan PD, DeZern AE, Matsui W (2014). Aberrant Hedgehog Pathway Activity Marks Clinical MDS Progression and Accelerates Leukemic Transformation in Vivo. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  114. Bejar R, Papaemmanuil E, Haferlach T, Garcia-Manero G, **Maciejewski JP**, Sekeres MA, Walter MJ, Graubert TA, Cazzola M, Malcovati L, Campbell PJ, Ogawa S, MD, PhD10, Boultonwood J, Bowen D, Tauro S, Groves MJ, Fontenay M, Shih L-Y, Tüchler H, Stevenson KE, Neuberg D, Greenberg PL, Ebert BL (2014). TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  115. Hönes JM, Botezatu L, Michell LC, Thiede C, van der Reijden B, Heuser M, Makishima H, **Maciejewski JP**, Radivoyevitch T, Ehninger G, Dührsen U, Moroy T, Khandanpour C (2014). Dose Dependent Role of Gfi1 in Human MDS and AML and Its Suitability as a Novel Target. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  116. Advani AS, Elson P, Kalaycio ME, Mukherjee S, Gerds AT, Hamilton BK, Hobson S, Smith A, Rush ML, Bogati S, Biggins M, Hsi ED, Duong HK, Copelan EA, Reu FJ, Sauntharajah Y, Nazha A, Makishima H, Przychodzen B, Dienes B, **Maciejewski JP**, Carew JS, Carraway HE, Sekeres MA (2014). Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial. 56<sup>th</sup> American Society of Hematology Annual Meeting.
  117. Fu S, Kelly KR, Espitia CM, Han Y, Carraway HE, Advani AS, **Maciejewski JP**, Sekeres MA, Steffan NT, Carew JS (2014). The Novel Plk Inhibitor Volasertib Overcomes Cytarabine Resistance in Acute Myeloid Leukemia. 56<sup>th</sup> American Society of Hematology Annual Meeting.

118. Nazha A, Seastone DJ, Pophali PA, Radivoyevitch T, Carraway HE, Advani AS, Kalaycio ME, Rupp G, Colaluca K, Przychodzen BP, Makishima H, **Maciejewski JP**, Sekeres MA (2014). Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype. 56<sup>th</sup> American Society of Hematology Annual Meeting.
119. Seastone DJ, Nazha A, Pophali PA, Ornstein MC, Carraway HE, Advani AS, Gerds AT, Kalaycio ME, **Maciejewski JP**, Sekeres MA (2014). Assessing the Value of Echocardiograms for Patients with Acute Myeloid Leukemia (AML) Receiving Anthracyclines. 56<sup>th</sup> American Society of Hematology Annual Meeting.
120. Thota S, Makishima H, Przychodzen BP, Viny AD, Patel BJ, Radivoyevitch T, Sekeres MA, Carraway HE, Haferlach T, Ogawa S, **Maciejewski JP** (2014). The Impact of Clonal Architecture of IDH1 and IDH2 Mutant Cases on the Biology of Myeloid Malignancies. 56<sup>th</sup> American Society of Hematology Annual Meeting.
121. Cheng C, Siebenaller C, Elson P, Advani AS, Carraway HE, Colaluca K, Hamilton BK, Hobson S, Kalaycio ME, **Maciejewski JP**, Mukherjee S, Rupp G, Zimmerman C, Sekeres MA, Gerds AT (2014). Comparison of Very Low-Dose Decitabine to Standard-Dose Hypomethylating Agents in Myelodysplastic Syndromes (MDS). 56<sup>th</sup> American Society of Hematology Annual Meeting.
122. Zeidan AM, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Zimmerman C, Roboz GJ, Steensma DP, DeZern AE, Jabbour E, Kantarjian HM, Zell K, Wang Q, Gorel SD, Nazha A, **Maciejewski JP**, List AF, Komrokji RS (2014). The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA). 56<sup>th</sup> American Society of Hematology Annual Meeting.
123. Sidana S, Narkhede M, Radivoyevitch T, Ornstein MC, Fincher C, Maggioletto AL, Sauntharajah Y, Advani AS, Gerds AT, Carraway HE, Hamilton BK, Kalaycio ME, **Maciejewski JP**, Sekeres MA, Mukherjee S (2014). Effect of Early Non-Hematologic Treatment Toxicity on Complete Remission (CR) and Time to CR in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy. 56<sup>th</sup> American Society of Hematology Annual Meeting.
124. Radivoyevitch T, Sachs RK, Gale RP, Sekeres MA, **Maciejewski JP**, Kalaycio ME, Mukherjee S (2014). Estimating Therapy-Related Myeloid Neoplasm Risks in the US. 56<sup>th</sup> American Society of Hematology Annual Meeting.
125. Gerds AT, Dennison B, Latsko J, Houk A, Chisolm S, Huber JM, Stone RM, **Maciejewski JP**, Komrokji RS, Garcia-Manero G, Steensma DP, Sekeres MA (2014). Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression. 56<sup>th</sup> American Society of Hematology Annual Meeting.
126. Williams DM, McDevitt MA, Stein BL, Rogers O, Streiff MB, Neal D, Lanzkron S, Resar LMS, O'Keefe C, **Maciejewski JP**, Spivak JL, Moliterno AR (2014). Essential Thrombocytosis: Redefinition in the Genomic Era. 56<sup>th</sup> American Society of Hematology Annual Meeting.
127. Przychodzen BP, Makishima H, Dienes B, Radivoyevitch T, Carraway HE, Thota S, Patel BJ, Sekeres MA, **Maciejewski JP** (2014). Hereditary Mutations Are Present As Pathogenic or Predisposition Factors in Otherwise Typical Adult MDS. 56<sup>th</sup> American Society of Hematology Annual Meeting.
128. Michell LC, Botezatu L, Hönes JM, Marneth A, Grapton D, Vadnais C, Germing U, Platzbecker U, Schroeder T, Haas R, van der Reijden BA, Ehninger G, **Maciejewski JP**, Radivoyevitch T, Görgens A, Giebell B, Fleckhaus J, Makishima H, Moroy T, Dührsen U, Khandanpour C (2014). Gfi136N as a Novel Marker and Therapeutic Target of MDS and AML. 56<sup>th</sup> American Society of Hematology Annual Meeting.
129. Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, MD5, Steensma DP, DeZern AE, Zimmerman C, Jabbour E, Greenberg MD, Lee S, List AF, Kantarjian HM, **Maciejewski JP**, MD, Komrokji RS (2014). Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA). 56<sup>th</sup> American Society of Hematology Annual Meeting.
130. Nazha A, Radivoyevitch T, Seastone DJ, Dienes B, Przychodzen BP, Carew JS, Mukherjee S, Carraway HE, Advani AS, Kalaycio ME, Hobson S, Rupp G, Colaluca K, Gerds AT, **Maciejewski JP**, Sekeres MA (2014). Differences in Genomic Patterns and Clinical Outcomes Between African-American and White Patients with Myelodysplastic Syndromes (MDS). 56<sup>th</sup> American Society of Hematology Annual Meeting.

131. Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Zimmerman, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Jabbour E, Lee S, Greenberg MD, List AF, Kantarjian HM, **Maciejewski JP**, Sekeres MA (2014). The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. 56<sup>th</sup> American Society of Hematology Annual Meeting.
132. Hurtado AM, Hamed C, Przychodzen BP, Anton AI, Garcia-Malo MD, Soler G, De Arriba F, Ortuño F, Montoya RT, **Maciejewski JP**, Vicente V, Jerez A (2014). Anticipating High-Risk Chromosome Clonal Evolution in Chronic Lymphocytic Leukemia: A Next Generation Sequencing and Longitudinal FISH Combined Study. 56<sup>th</sup> American Society of Hematology Annual Meeting.
133. Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu S, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley S, Javidi-Sharifi N, **Maciejewski JP**, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA (2014). GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable by Combined PI3K/mTOR Inhibition. 56<sup>th</sup> American Society of Hematology Annual Meeting.
134. Tohme R, Le Moigne R, Przychodzen BP, Han Y, Rolfe M, Carraway HE, Djakovic S, Anderson D, Wustrow D, Zhou H, Wong S, Kelly KR, Sauntharajah Y, Advani AS, **Maciejewski JP**, Sekeres MA, Nawrocki ST, Carew JS (2014). Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy. 56<sup>th</sup> American Society of Hematology Annual Meeting.
135. Bowler TG, Bartenstein M, MD2, Kerry A, Morrone KA, Rohanizadegan M, Kessel RM, Hooda L, Datt I, Giricz O, Bhagat TD, Przychodzen BP, Parmar S, Gill JB, Yu Y, **Maciejewski JP**, Steidl U, Verma A (2014). Exome Sequencing of Familial MDS Reveals Novel Mutations and High Rates of False Positive Mutations in MLL3 Due to Pseudogene Effects. 56<sup>th</sup> American Society of Hematology Annual Meeting.
136. Nazha A, Seastone DJ, Radivoyevitch T, Dienes B, Przychodzen BP, Hobson S, Mukherjee S, Carraway HE, Carew JS, Advani AS, Gerds AT, Makishima H, Sekeres MA, **Maciejewski JP** (2014). Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS). 56<sup>th</sup> American Society of Hematology Annual Meeting.
137. Shih AH, Rapaport F, Chung SS, Dolezal EK, Hobson S, Amato MK, Park CY, MD, Sekeres MA, van den Brink MRM, Nimer S, Levine RL, **Maciejewski JP**, Klimek VM (2014). Mutation Profiling of Therapy-Related Myeloid Neoplasms Using Next-Generation Sequencing Demonstrates Distinct Profiles from De Novo Disease. 56<sup>th</sup> American Society of Hematology Annual Meeting.
138. Palomo L, Xicoy B, Garcia O, Mallo M, Adema V, Marce S, Arnan M, Pomares H, Larrayoz MJ, Calasanz MJ, Ardanaz MT, **Maciejewski JP**, Huang D, Shih L, Ogawa S, Sanada M, Lin T, López-Pavia M, Cervera J, Such E, Coll R, Arenillas L, Grau J, Jiménez MJ, Milla F, Feliu E, Sole F, Zamor L (2014). Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases. 56<sup>th</sup> American Society of Hematology Annual Meeting.
139. Negoro E, Hosono N, Shen W, Yoshizato T, Patel BJ, Hirsch C, Przychodzen B, Clemente MJ, Mahfouz RZ, Wodnar-Filipowicz A, Makishima H, Ogawa S, Sekeres MA, **Maciejewski JP** (2015). Myelodysplastic Syndrome (MDS)-Determining Clonal Events at Presentation of Aplastic Anemia (AA). 57th American Society of Hematology Annual Meeting.
140. Negoro E, Polprasert C, Radivoyevitch T, Adema V, Hosono N, Makishima H, Przychodzen B, Sekeres MA, Santini V, List AF, McGaw K, Sole F, **Maciejewski JP** (2015). Molecular Predictors of Response in Patients with Myeloid Neoplasms Treated with Lenalidomide. 57th American Society of Hematology Annual Meeting.
141. Patel BJ, Przychodzen B, Clemente MJ, Hirsch C, Radivoyevitch T, Thota S, LaFramboise T, Sakaguchi H, Kojima S, Carraway HE, Sekeres MA, Ogawa S, Makishima H, **Maciejewski JP** (2015). Determinants of Phenotypic Commitment and Clonal Progression--Conclusions from the Study of Clonal Architecture in CMML. 57th American Society of Hematology Annual Meeting.
142. Patel BJ, Przychodzen B, Clemente MJ, Hirsch C, Radivoyevitch T, Thota S, Nazha A, Carraway HE, Sekeres MA, **Maciejewski JP** (2015). Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic

Anemia. 57th American Society of Hematology Annual Meeting.

143. Sanikommu SR, Clemente MJ, Chomczynski P, Thota S, Patel BJ, Nazha A, Przychodzen B, **Maciejewski JP** (2015). Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia. 57th American Society of Hematology Annual Meeting.
144. Ademà V, Palomo L, Przychodzen BP, Diez-campelo M, Hosono N, Mallo M, Xicoy B, Luño E, Patel BJ, Hirsch CM, Zamora L, LaFramboise T, Arenillas L, Perez-Ladaga A, Pedro C, Clemente MJ, Bargay J, Montoro J, Caballero JC, Merchan B, Noriega V, Marcos-Betes V, Del Cañizo C, MD, Lopez R, Raya JM, Sanchez-Garcia J, Rios E, Arnán M, Florensa L, de Paz R, Lemes A, Gomez-Marzo P, Haro N, Fuster-Tormo F, Bayes M, Gut I, Bejar R, Sekeres MA, **Maciejewski JP**, Sole F (2015). The Complete Mutatome and Clonal Architecture of Del(5q). 57th American Society of Hematology Annual Meeting.
145. Okoye-Okafor UC, Bartholdy B, Cartier J, Gao E, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall K, Reif A, Schmidt S, Qi H, Zhao H, Joberty G, Faeth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Narayanagari S, Antony-Debre I, Mitchell K, Carvajal L, Wang HR, Barreyro L, Kao Y, Christopheit M, Paietta E, Makishima H, Will B, Concha N, Adams N, Schwartz B, McCabe MT, **Maciejewski JP**, Verma A, Ulrich Steidl (2015). New Allosteric Inhibitors of Mutant IDH1 in Acute Myeloid Leukemia. 57th American Society of Hematology Annual Meeting.
146. Pastor Loyola VB, Hirabayashi S, Pohl S, Kozyra EJ, Catala A, De Moerloose B, Dworzak M, Hasle H, Masetti R, Schmugge M, Smith O, Starý J, Ussowicz M, van den Heuvel-Eibrink MM, Mejstrikova E, Salzer U, Lübbert M, Heudobler D, Betts D, Cervera J, Göhring G, Haas OA, Haus O, Michalova K, Pasquali F, Tchinda J, van Roy N, Schlegelberger B, Beverloo HB, Noellke P, Yoshimi A, Locatelli F, Strahm B, **Maciejewski JP**, Rehli M, Niemeyer CM, Wlodarski MW (2015). Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency. 57<sup>th</sup> American Society of Hematology Annual Meeting.
147. Takeda J, Yoshida K, Makishima H, Yoshizato T, Shiozawa Y, Shiraishi Y, Okuno Y, Kon A, Nagata Y, Kataoka K, Kenichi C, Tanaka H, Sanada M, Sakata-Yanagimoto M, Obara N, Nakamaki T, Ishiyama K, Haigaishi A, Chiba S, Mori H, Asou N, Kiyoi H, Hirase C, Imai K, Dobashi N, Kiguchi T, Miyazaki Y, Naoe T, Miyano S, Usuki K, Miyawaki S, Kamatani Y, Momozawa Y, Kubo M, Polprasert C, **Maciejewski JP**, Ogawa S (2015). Genetic Predispositions to Myeloid Neoplasms Caused By Germline *DDX41* Mutations. 57<sup>th</sup> American Society of Hematology Annual Meeting.
148. Bejar R, Papaemmanuil E, Haferlach T, Garcia-Manero G, **Maciejewski JP**, Sekeres MA, Walter MJ, Graubert TA, Cazzola M, Malcovati L, Ogawa S, Fenaux P, Hellstrom-Lindberg E, Kern W, Boulwood J, Pellagatti A, Bowen D, Tauro S, Groves MJ, Vyas P, Quek L, Nazha A, Thol F, Heuser M, Shih L, Padron E, Sallman D, Komrokji RS, List AF, Santini V, Fontenay M, Campbell PJ, Tüchler H, Stevenson K, Neuberg DS, Greenberg P, Ebert BL (2015). Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. 57<sup>th</sup> American Society of Hematology Annual Meeting.
149. Makishima H, Yoshida K, LaFramboise T, Yoshizato T, Ruffalo M, Sekeres MA, Przychodzen B, Suzuki H, Sanada M, Nagata Y, Okuno Y, Sato Y, Sato-Otsubo A, Clemente MJ, Hosono N, Shiraishi Y, Chiba K, Tanaka H, Shiozawa Y, Gomez-Segui I, Husseinzadeh H, Thota S, Guinta K, Dienes B, Nakamaki T, Miyawaki S, Sauntharajah Y, Chiba S, Miyano S, Shih L, Ogawa S, **Maciejewski JP** (2015). Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing. 57<sup>th</sup> American Society of Hematology Annual Meeting.
150. Kozyra EJ, Hirabayashi S, Pastor Loyola VB, Przychodzen B, Karow A, Catala A, De Moerloose B, Dworzak M, Hasle H, Masetti R, Schmugge M, Smith O, Starý J, Ussowicz M, van den Heuvel-Eibrink MM, Campr V, Devito R, Paepe P, Hernandez-Marti M, Kerndrup G, Leguit R, Maldyk J, OxSullivan M, Simonitsch-Klupp I, Baumann I, Locatelli F, **Maciejewski JP**, Strahm B, Niemeyer CM, Wlodarski, MW (2015). Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes. 57<sup>th</sup> American Society of Hematology Annual Meeting.
151. Advani AS, Tse W, Jia X, Elson P, Cooper B, Ali-Osman F, Park J, Rao AV, Rizzieri DA, Wang ES, Cotta CV, Kalaycio M, Sobecks RM, Roupail B, **Maciejewski JP**, Fensterl J, Bailey L, Carew JS, Foster B, Rush ML, Adams D, Griffiths EA, Sekeres MA (2015). Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy

- for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML). 57<sup>th</sup> American Society of Hematology Annual Meeting.
152. Komrokji RS, DeZern AE, Zell K, Al Ali NH, Padron E, Estling C, Zimmerman C, Hand W, Brown F, Rizzo N, Barnard J, Roboz GJ, Carraway HE, **Maciejewski JP**, List AF, Garcia-Manero G, Steensma DP, Sekeres MA (2015). Response to Treatment among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC). 57<sup>th</sup> American Society of Hematology Annual Meeting.
  153. Sallman D, Garcia-Manero G, Jabbour E, Sekeres MA, DeZern AE, Steensma DP, Roboz GJ, Barnard J, Al Ali NH, Zimmerman C, Pierce S, Batista D, Lancet JE, Padron E, **Maciejewski JP**, List AF, Kantarjian HM, Komrokji RS (2015). Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities. 57<sup>th</sup> American Society of Hematology Annual Meeting.
  154. Advani AS, Elson P, Visconte V, Carew JS, Fensterl J, Przychodzen B, Sekeres MA, Hirsch CM, Nielsen A, Desamito J, Carraway HE, Gerds AT, Hamilton BK, Mukherjee S, Sobecks RM, Kalaycio M, Sauntharajah Y, **Maciejewski JP** (2015). Prognostic Impact of Molecular Mutations in AML at First Relapse. 57<sup>th</sup> American Society of Hematology Annual Meeting.
  155. Nawrocki ST, Han Y, Le Moigne R, Visconte V, Przychodzen B, Rolfe M, Djakovic S, Anderson D, Wustrow D, Zhou H, Wong S, Advani A, Carraway HE, **Maciejewski JP**, Sekeres MA, Kelly KR, Carew JS (2015). Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML. 57<sup>th</sup> American Society of Hematology Annual Meeting.
  156. Fang J, Lyndsey Bolanos L, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Greis K, Stoilov P, Filippi M, **Maciejewski JP**, Garcia-Manero G, Weirauch M, Salomonis N, Geiger H, Zheng Y, Starczynowski D, PhD (2015). Ubiquitin Editing of a Spliceosome Auxiliary Factor By TRAF6 Links Chronic TLR Signaling with Hematopoietic Defects and Myelodysplasia. 57<sup>th</sup> American Society of Hematology Annual Meeting.
  157. Hurtado AM, Luengo-Gil G, Palomo L, Lumbreras E, Caparrós E, Chen-Liang TH, Przychodzen B, Amigo ML, Díez-Campelo M, Zamora L, Ortuño FJ, Montoya RT, **Maciejewski JP**, Del Cañizo C, Sole F, Francisca American Society of Hematology Annual Meeting.
  158. Nazha A, Przychodzen B, Makishima H, Carraway HE, Patel BJ, Hirsch CM, Clemente M, Sanikommu SR, Gerds AT, Carew JS, Miyano S, Kalaycio M, Ogawa S, **Maciejewski JP**, Sekeres (2015). Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. 57<sup>th</sup> American Society of Hematology Annual Meeting.
  159. Sekeres MA, Zell K, Barnard J, DeZern AE, Steensma DP, Zimmerman C, Estling C, Hand W, Roboz GJ, Rizzo N, Al Ali NH, List AF, Garcia-Manero G, **Maciejewski JP**, Komrokji RS, MD (2015). Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs). 57<sup>th</sup> American Society of Hematology Annual Meeting.
  160. Nazha A, Meggendorfer M, Nadarajah N, Kneen KE, Radivoyevitch T, Przychodzen B, Makishima H, Patel BJ, Sanikommu SR, Hobson S, Mukherji M, Sekeres MA, Haferlach T, **Maciejewski JP** (2015). *TET 2* Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition. 57<sup>th</sup> American Society of Hematology Annual Meeting.
  161. Nazha A, Zarzour A, Radivoyevitch T, Carraway HE, Carew JS, Hirsch CM, Kneen KE, Przychodzen B, Patel BJ, Clemente M, Sanikommu SR, Kalaycio M, **Maciejewski JP**, Sekeres MA (2015). The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML). 57<sup>th</sup> American Society of Hematology Annual Meeting.
  162. Przychodzen B, Gu X, You D, Hirsch CM, Clemente MJ, Viny AD, Levine RL, Haferlach T, Maggendorfer M, Sekeres MA, Carraway HE, Nazha A, Enane F, **Maciejewski JP** (2015). PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML. 57<sup>th</sup> American Society of Hematology Annual Meeting.
  163. Viny AD, Ott CJ, Spitzer B, Rivas MA, Meydan C, Papalexi E, Yelin D, Shank K, Reyes J, Chiu A, Thota S, **Maciejewski JP**, Melnick A, Bradner JE, Levine RL (2015). Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. 57<sup>th</sup> American Society of Hematology Annual Meeting.

164. Nazha A, Narkhede MS, Radivoyevitch T, Kalaycio M, Patel BJ, Gerds AT, Mukherjee S, Clemente M, Hirsch CM, Advani AS, Przychodzen B, Carraway HE, **Maciejewski JP**, Sekeres MA (2015). The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS). 57th American Society of Hematology Annual Meeting.
165. Hamilton BK, Majhail NS, Hirsch CM, Przychodzen B, Rybicki LA, De Lima M, Kalaycio M, Bolwell BJ, Gerds AT, Sobecks R, Hanna R, Sekeres MA, **Maciejewski JP** (2015). Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of *TET2* Mutations. 57th American Society of Hematology Annual Meeting.
166. Ebrahim Q, Mahfouz RZ, Durkin L, Sekeres MA, Advani AS, Carraway HE, Mukherjee S, Hamilton BK, Gerds AT, Sobecks R, Reu FJ, Hsi ED, **Maciejewski JP**, Sauntharajah Y (2015). Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response. 57th American Society of Hematology Annual Meeting.
167. Visconte V, Nawrocki ST, Kelly KR, Han Y, Possemato A, Beausoleil S, Nazha A, **Maciejewski JP**, Carraway HE, Advani AS, Sekeres MA, Carew JS (2015). Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy. 57th American Society of Hematology Annual Meeting.
168. Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Mufti GJ, **Maciejewski JP**, Wei S, Fenaux P, Santini V, List AF (2015). The Proinflammatory Protein S100A9 Suppresses Erythropoietin Elaboration in Patients with Myelodysplastic Syndromes. 57th American Society of Hematology Annual Meeting.
169. Pleyer C, Afzal A, Shomali W, Elson P, Xuefei J, Bakdash S, Advani AS, Gerds AT, Carraway HE, Kalaycio M, **Maciejewski JP**, Sekeres MA, Mukherjee S (2015). Impact of Red Blood Cell and Platelet Transfusions in Acute Myeloid Leukemia (AML) Patients Undergoing Remission Induction Chemotherapy. 57th American Society of Hematology Annual Meeting.
170. Visconte V, Kelly KR, Nawrocki ST, Han Y, Carraway HE, Advani AS, **Maciejewski JP**, Rogers HJ, Sekeres MA, Carew JS (2015). Elevated Basal Autophagy in *SF3B1* Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications. 57th American Society of Hematology Annual Meeting.
171. Pleyer C, Sidana S, Radivoyevitch T, Molenaar R, Godley A, Offerman E, Advani AS, Gerds AT, Carraway HE, Kalaycio M, **Maciejewski JP**, Sekeres MA, Mukherjee S (2015). Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes. 57th American Society of Hematology Annual Meeting.
172. Molenaar R, Patel BJ, Khurshed M, Przychodzen B, Sanikommu SR, Carraway HE, Radivoyevitch T, Makishima H, van Noorden CJ, **Maciejewski JP** (2015). Ex Vivo Experiments Show That IDH1/2-Mutant Inhibitors Can be Safely Used as Adjuvants to Regular Chemotherapy in *IDH1/2*-Mutated Acute Myeloid Leukemia. 57th American Society of Hematology Annual Meeting.
173. Sidana S, Elson P, Gerds AT, Carraway HE, Advani AS, Sauntharajah Y, **Maciejewski JP**, Kalaycio M, Sekeres MA, Mukherjee S (2015). Real World Outcomes of Less Well-Characterized Acute Leukemias: A Population-Based Survival Analysis Using SEER Registry (1973-2012). 57th American Society of Hematology Annual Meeting.
174. Molenaar R, Sanikommu SR, Patel BJ, Przychodzen B, van Noorden CJ, Radivoyevitch T, Makishima H, Carraway HE, **Maciejewski JP** (2015). Whole-Exome Sequencing Identifies Germline *IDH2* and *IDH3* mutations That Predispose to Myeloid Neoplasms. 57th American Society of Hematology Annual Meeting.
175. Sidana S, Elson P, Gerds AT, Carraway HE, Advani AS, Sauntharajah Y, **Maciejewski JP**, Kalaycio M, Sekeres MA, Mukherjee S (2015). Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis. 57th American Society of Hematology Annual Meeting.
176. Visconte V, Nawrocki ST, Przychodzen B, Kelly KR, Yin M, Parker Y, Clemente M, Barnard J, Advani AS, Carraway HE, Sekeres MA, Lindner DJ, Rogers HJ, **Maciejewski JP**, Carew JS (2016). Targeting Autophagy in Myelodysplastic Syndromes. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
177. Visconte V, Przychodzen B, Nawrocki ST, Thota S, Kelly KR, Patel BJ, Hirsch C, Carraway HE, Parker Y, Lindner D,

- Sekeres MA, Rogers HJ, **Maciejewski JP**, Carew JS (2016). Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
178. Coppe A, Andersson E, Binatti A, Gasparini V, Bortoluzzi S, Clemente M, Herling M, **Maciejewski JP**, Mustjoki S, Bortoluzzi S (2016). Class-Specific Recurrence of Mutations and Identification of Functional Modules Provides New Clues on the Pathogenesis of Large Granular Lymphocyte Leukemia. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  179. Clemente MJ, Przychodzen B, Hirsch C, **Maciejewski JP** (2016). Clonal Hierarchy of PIGA Mutant Cells Assessed by Next Generation Sequencing is More Complex than Previously Recognized in Paroxysmal Nocturnal Hemoglobinuria. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  180. Nagata Y, Makishima H, Radivoyevitch T, Hirsch CM, Przychodzen BP, Kuzmanovic T, Li S, Yoshida K, Yoshizato T, Adema V, Negoro E, Clemente MJ, Hosono N, Shiraishi Y, Chiba K, Tanaka H, Mukherjee S, Nazha A, Sole F, Carraway HE, Miyano S, LaFramboise T, Sekeres MA, Ogawa S, **Maciejewski JP** (2016). Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage by Combining Germline and Somatic Mutations. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  181. Nagata Y, Radivoyevitch T, Makishima H, Hirsch CM, Przychodzen BP, Kuzmanovic T, Negoro E, Clemente MJ, Mukherjee S, Carraway HE, Sekeres MA, **Maciejewski JP** (2016). UTX Mutations in Myeloid Neoplasms. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  182. Aly M, Hosono N, Przychodzen B, Makishima H, Nagata Y, Hirsch CM, Sekeres MA, **Maciejewski JP** (2016). Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  183. Patel B, Przychodzen BP, Clemente MJ, Hirsch CM, Saygin C, Versalle M, Thota S, Nazha A, Souaid R, Visconte V, Bat T, Balasubramanian SK, Radivoyevitch T, Carraway HE, Sekeres MA, **Maciejewski JP** (2016). Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  184. Patel B, Saygin C, Przychodzen BP, Hirsch CM, Clemente MJ, Hamilton BK, Advani AS, Nazha A, Ondrejka SL, Kalaycio M, Sekeres MA, Carraway HE, **Maciejewski JP** (2016). Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  185. Adema V, Hirsch CM, Przychodzen BP, Nazha A, Kuzmanovic T, Negoro E, You D, Makishima H, Clemente MJ, Carraway HE, Sekeres MA, Visconte V, **Maciejewski JP** (2016). U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  186. Adema V, Hirsch CM, Przychodzen BP, Pellagatti A, Boultonwood J, Nazha A, Carraway HE, Sole F, Sekeres MA, Visconte V, **Maciejewski JP** (2016). Molecular and Clinical Characterization of Patients with Myeloid Neoplasms Carrying the 12p Deletion. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  187. Nielson A, Al-Harbi S, Hirsch C, Przychodzen B, Sekeres M, Sauntharajah Y, Carraway H, **Maciejewski JP** (2016). Germline Variants of RUNX-1 in Myeloid Malignancy. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  188. Mitsuhashi M, Makishima H, **Maciejewski JP** (2016). Quantification of Erythroblast- and Myelocyte-Derived mRNAs in Plasma Exosomes as an Indicator of Bone Marrow Status in Patients with Various Types of Anemias and Myeloproliferative Disorders. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  189. Hirsch CM, Nazha A, Kneen K, Meggendorfer M, Przychodzen BP, Nadarajah N, Carraway HE, Sekeres MA, Haferlach T, Radivoyevitch T, **Maciejewski JP** (2016). Phenotype/Genotype Associations in TET2-Driven Myeloid Neoplasms. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  190. Hirsch CM, Nazha A, Kneen K, Meggendorfer M, Przychodzen BP, Nadarajah N, Carraway HE, Sekeres MA, Haferlach T, LaFramboise T, Radivoyevitch T, **Maciejewski JP** (2016). Pathogenic Relevance of Germ Line TET2 Alterations. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  191. Alharbi S, Nielsen AD, Hasipek M, Przychodzen BP, Phillips JG, **Maciejewski JP**, Jha B (2016). The GLI-Code As a

- Potential Therapeutic Target in Myeloid Neoplasms. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
192. Chomczynski PW, Sanikommu SR, Rajala HLM, Nielsen AD, Hirsch CM, Lichtin AE, Sekeres MA, Carraway HE, Mustjoki S, Clemente MJ, **Maciejewski JP** (2016). Next-Generation Sequencing Analysis of Clonal Hierarchy and Dynamics in T-Large Granular Lymphocyte Leukemia Suggests Emergence of STAT3 Clones within Pre-Existing Dominant T-cell Repertoire Responses Otherwise Silenced in Normal Individuals. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  193. Negoro E, Clemente M, Hosono N, Nazha A, Shen W, Nagata Y, Hirsch CM, Przychodzen BP, Mahfouz RZ, Kuzmanovic T, Makishima H, Sekeres MA, **Maciejewski JP** (2016). Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndromes. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  194. Balasubramanian SK, Ali M, Bat T, Patel B, Przychodzen BP, Hirsch CM, Nazha A, Carraway HE, Sekeres MA, **Maciejewski JP** (2016). Distinct Clinical and Biological Implications of Various DNMT3A Mutations in Myeloid Neoplasms. Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  195. Przychodzen BP, You D, Makishima H, Hirsch C, Clemente M, Gu X, Nazha A, Sekeres MA, Maciejewski JP (2016). PHF6 Somatic Mutations and Their Functional Role in the Pathophysiology of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Submitted to the 58<sup>th</sup> American Society of Hematology Annual Meeting.
  196. Vera Adema, Cassandra M. Hirsch, Bartłomiej P. Przychodzen, Yasunobu Nagata, Elise Lemelle, Aziz Nazha, Hetty Carraway, Mikkael A. Sekeres, Valeria Visconte, Richard A Padgett, **Jaroslaw P. Maciejewski** (2017) Somatic PRPF8 Mutations in Myeloid Neoplasia. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  197. Vera Adema, Suresh K. Balasubramanian, Cassandra M. Hirsch, Bartłomiej P. Przychodzen, James G. Phillips, Daniel Lindner, Thomas Radivoyevitch, Sudipto Mukherjee, Aziz Nazha, Hetty Carraway, Francesec Sole, Mikkael A. Sekeres, Valeria Visconte, **Jaroslaw P. Maciejewski** (2017) Novel Therapeutic Targets for DNMT3A Mutant Myeloid Neoplasms. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  198. Mai Aly, Zubaidah M. Ramdzan, Yasunobu Nagata, Suresh K. Balasubramanian, Naoko Hosono, Hideki Makishima, Valeria Visconte, Bartłomiej P. Przychodzen, Cassandra M. Hirsch, Mikkael A. Sekeres, Alain Nepveu, **Jaroslaw P. Maciejewski** (2017) Functional and Biological Implications of CUX1 Mutations and Deletions in Myeloid Neoplasms. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  199. Abuhadra, Karam Al-Issa, Sudipto Mukherjee, Cassansra M. Hirsch, Aaron T. gerds, Babal K Jha, Nour Vera Adema, Hassan Awada, Mohammed Fahad B. Asad, Abhinav Goyal, Anjali S. Advani, Yasunobu Nagata, Bartłomiej P. Przychodzen, Hetty E. Carraway, Mikkael A. Sekers, Aziz Nazha **Jaroslaw P. Maciejewski** (2017) BCOR Mutations in Myelodysplastic Syndromes (MDS): Mutation Characteristics Impact Clincial Outcomes. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  200. Cassandra M. Hirsch, Aziz Nazha, Kneen Kasy, Manja egenorfer, Bartłomiej P. Przychodzen, Niroshan Nadarajah, Vera Adema, Yasunobu Nagata, Valeria Visconte, Hetty E. Carraway, Mikkael A. Sekeres, Ryszard Olinski, Sudipto Mukherjee, Babal K jha, Thomas Laframboise, Tomas Radivoyevitch, Torsten Haferlach, **Jaroslaw P. Maciejewski** (2017) Clonal Architecture of TET2 Mutations Influences the Clinical Phenotype of Patients with Myeloid Neoplasms. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  201. Valeria Visconte, Vera Adema, Bartłomiej P. Przychodzen, Allison Now, Rachel Toth, Yasmine Hirbawi, Cassandra M. Hirsch, Jack Khouri, Elise LeMelle, Suresh K. Balasubramanian, Hetty E. Carraway, Daniel Lindner, Anjali S. Advani, Heesun J Rodgers, James G. Phillips, Tomas Radivoyevitch, Kevin R Kelly, Steffan T. Nawrocki, Mikkael A. Sekers, **Jaroslaw P. Maciejewski** (2017) Activation of Autophagy in Models of SF3B1 Mutant MDS. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  202. Aziz Nazha, Mrinal M. Patnail, Rami S. Komrokji, Karam AL-Issa, Naval Daver, Guillermo Garcia-Manero, Alan F, List, Michael R. Savona, Raphael Itzykson, Pierre Fenaux, Valeria Santini, Ayalew Tefferi, Mikkael A. Sekeres, Eric Padron, **Jaroslaw P. Maciejewski** (2017) Model Heterogeneity in Predicting Outcomes in Patients with Chronic Myelomonocytic Leukemia (CMML): An Overestimation of Survival in Lower-Risk Group. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.



203. Yazan F. Madanat, Mikkael A. Sekers, Karam Al-Issa, Cassandra M. Hirsch, Sudipto Mukherjee, Aaron T. Gerds, Nour Abuhadra, babal K. Jha, Vera Adema, Anjali S. Advani, Yasunobu Nagata, Teodore Kuzmanovic, Bartlomiej P. Przychodzen, Hetty E. Carraway, Aziz Nazha, **Jaroslaw P. Maciejewski** (2017) Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS). Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
204. Reem Elagooz, Mai Aly, Cassandra M. Hirsch. Bartlomiej P. Przychodzen, Teodora Kuzmanovic, Tomas Radivoyevotch, Valeria Visconte, Sudipto Mukherjee, Hetty E. Carraway, Mikkael A. Sekeres. Aziz Nazha, Yasinobi Nagat, **Jaroslaw P. Maciejewski** (2017) PPM1D Mutations and up Modulation Phenocopy TP53 Lesions in Myeloid Neoplasms. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
205. Aziz Nazha, Betty K. Hamilton, Mikkael A. sekere, Sudipto Mukherjee, Aaron T. Gerds, Rabi Hanna. Cassansdra M. Hirsch, Teodora Kuzmanovic, Karam Al-Issa, Bartlomiej P. Przychodzen, Ronald Sobecks, Matt Kalaycio, Navneet S. Majhail, **Jaroslaw P. Maciejewski** (2017) Mutational Burden before and after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML) Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
206. Remco J Molenaar, Tomas Radivoyevotch, Aziz Nazha, Anjali S. Advani, Aaron T. Gerds. Navneet S. Majhail, Mikkael A. Sekeres, Matt Kalaycio, Sudipto Mukherjee. **Jaroslaw P. Maciejewski** (2017) Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
207. Jack Khouri, Vera Adema, Ying Ni, Heesun J. Rogers, Bartlomiej P. Przychodzen, Cassandra M. Hirsch. Elise LeMelle, Teodora Kuzmanovic, Anjali S. Advani, Aaron T. Gerds, Sudipto Mukherjee, Aziz Nazha, Yogenthiran Sauntharajah, Yazan F. Madanat, Bhumiika J. Patel, Francesc Sole, Steffan T. Nawrocki, Jennifer Carew, Matt Kalaycio, Mikkael A. Sekeres. Valeria Visconte, Hetty E. Carraway, **Jaroslaw P. Maciejewski** (2017) Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
208. Lillian Iglesias, Sudipto Mukherjee, Aziz Nazha, Anjali S. Advani, Aaron T. Gerds. Hetty E. Carraway, Mett Kalaycio, Navneet S. Majhail, Mikkael A. Sekeres, **Jaroslaw P. Maciejewski** (2017) No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs). Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
209. Karam Al-Issa, Yazan F. Madant, Sudipto Mukherjee. Cassandra M. Hirsch, aaron T. Gerd, Nour Abuhadra, Ahed Makhoul, Hassan Awada, Mohammad Fahad B. Asad, Abhinav Goyal , Anjali S. Advani, Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Hetty E. carraway, Mikkael A. Sekeres, Aziz Nazha, **Jaroslaw P. Maciejewski** (2017) Model Heterogeneity in Prediciting Outcomes of Patients with Myelodysplastic Syndromes (MDS) Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
210. Abinav Goyal, Mohammad Fahad B. Asad, Hassan Awada, Mai Aly, Cassandra M. Hirsch. Bartlomiej P. Przychodzen, Tomas Radivoyevitch, Aziz Nazha, Sudipto Mukerjee, Mikkaek A. Sekers, Yasunobu Nagata, **Jaroslaw P. Maciejewski** (2017) How Somatic Mutations Carve Morphologic Imprint in MDS? Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting
211. Yazeed Sawalha, Paul Elson, Yazan F. Madanat, Nicole Droz, Apostolos Kontzias, Teodora Kuzmanovic, Cassandra M. Hirsch, Christopher Goebel, John Desamito, Benjamin Tomlinson, Aziz Nazha, Ronald Sobecks, Betty K. Hamilton, Sudipto Mukherjee, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, **Jaroslaw P. Maciejewski**, Mikkael A. Sekeres and Anjali S. Advani (2017) Characteristics, Mutation Profiles and Outcomes of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease. Submitted to the 59<sup>th</sup>
212. Metis Hasipek, Sayer Al-Harbi, James G Phillips, Bartlomiej P. Przychodzen, Alek Nielsen, Yihong Guan, Dale Grabowski, Phillip J Maciejewski, Aziz Nazha, Hetty E. Carraway, **Jaroslaw P. Maciejewski** and Babal K Jha (2017) Therapeutic Targeting of GLI1 in Acute Myeloid Leukemia. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
213. Caner Saygin, Cassandra M. Hirsch, Bartlomiej Przychodzen, Mikkael A. Sekeres, Betty K. Hamilton, Matt Kalaycio, Hetty E. Carraway, Aaron T. Gerds, Sudipto Mukherjee, Aziz Nazha, Ronald Sobecks, Christopher Goebel, Donna M.

- Abounader, Jaroslaw P. Maciejewski, Anjali S. Advani (2017) Mutations in DNMT3A, U2AF1, and EZH2 Identify Intermediate-Risk Acute Myeloid Leukemia Patients with Poor Outcome after CR1. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
214. Cassandra M. Hirsch, Michael J. Clemente, Valeria Visconte, Taha Bat, Bartłomiej P. Przychodzen, Tomas Radivoyevitch, Vera Adema, Yasunobu Nagata, Hetty E. Carraway, Mikkael A. Sekeres, Babal K Jha, Sudipto Mukherjee, Thomas Laframboise, **Jaroslaw P. Maciejewski** (2017) Surveillance of the Immune Repertoire of Aplastic Anemia Patients Using Deep Sequencing. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  215. Bhumika J. Patel, Sagar S. Patel, Tomas Radivoyevitch, Swapna Thota, Teodora Kuzmanovic, Bartłomiej P. Przychodzen, Cassandra M. Hirsch, Donna M. Abounader, Aziz Nazha, Sudipto Mukherjee, Aaron T. Gerds, Anjali S. Advani, Brian J. Bolwell, Matt Kalaycio, Mikkael A. Sekeres, Ronald Sobecks, Hetty E. Carraway, Navneet S. Majhail, Betty K. Hamilton, **Jaroslaw P. Maciejewski** (2017) Evolution in Myeloid Neoplasms Clonal Architecture Post Allogeneic Hematopoietic Cell Transplantation. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  216. Yasunobu Nagata, Bartłomiej P. Przychodzen, Cassandra M. Hirsch, Hideki Makishima, Victor Pastor Loyola, Babal K Jha, Teodora Kuzmanovic, Tomas Radivoyevitch, Vera Adema, Kenichi Yoshida, Samuel Li, Francesc Sole, Thomas Laframboise, Rabi Hanna, Mikkael A. Sekeres, Seishi Ogawa, Marcin W. Wlodarski, Jorg Cammenga and **Jaroslaw P. Maciejewski** (2017) Germline SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  217. Teodora Kuzmanovic, Tomas Radivoyevitch, Srinivasa Reddy Sanikommu, Bhumika J. Patel, Yasunobu Nagata, Cassandra M. Hirsch, Bartłomiej P. Przychodzen, Sudipto Mukherjee, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Hetty E. Carraway, Mikkael A. Sekeres and **Jaroslaw P. Maciejewski** (2017) Chemotherapy and Radiation Results in Distinct Patterns of Somatic Mutations in Subsequent Myeloid Disease. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  218. Ana M Hurtado, Ginés Luengo-Gil, Tzu Hua Chen-Liang, Fabio Amaral, Laura Palomo, Eva Lumbreras, Bartłomiej Przychodzen, Eva Caparrós, Maria Luz Amigo, Maria Díez-Campelo, Lurdes Zamora, Eduardo José Salido, **Jaroslaw P. Maciejewski**, Francisco José Ortuño, Vicente Vicente, Consuelo Del Cañizo, Francesc Sole, Francisca Ferrer Marin, Daniel Wiseman and Andres Jerez (2017) Transcriptome of DNA Repair Genes in CMML: Rationale for Targeting ERCC1 and CDKN1A As a Synthetic Lethality Approach. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  219. Yi Hu, Jing Fang, Hua Fang, Chen Li, Shuang Liu, Sarah L. Ondrejka, Zihua Gong, **Jaroslaw P. Maciejewski**, Frederic J. Reu, Qing Yi and Jianjun Zhao. (2017) Targeting the MALAT1/PARP1/LIG3 Complex Induces DNA Damage and Apoptosis in Multiple Myeloma Mouse Models. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  220. Edward F Greenberg, Cassandra M. Hirsch, Feng Pan, Babal K Jha, Yihong Guan, Valeria Visconte, Dewen You, Guangbo Qu, Amy Graham, Bartłomiej P. Przychodzen, Thomas Laframboise, Hideki Makishima, Daniel Gackowski, Ryszard Ólinski, Yu-Wei Cheng, Mikkael A. Sekeres, Mingjiang Xu and **Jaroslaw P. Maciejewski** (2017) TET2 and MSH6: A Novel Role for MMR in the Pathogenesis of Myeloid Malignancies. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  221. Aziz Nazha, Sudipto Mukherjee, Karam Al-Issa, Ahed Makhoul, Vera Adema, Cassandra M. Hirsch, Anjali S. Advani, Aaron T. Gerds, Matt Kalaycio, Hetty E. Carraway, **Jaroslaw P. Maciejewski** and Mikkael A. Sekeres. (2017) A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML). Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  222. Aziz Nazha, Mikkael A. Sekeres, Karam Al-Issa, Ahed Makhoul, Vera Adema, Cassandra M. Hirsch, Anjali S. Advani, Bartłomiej P. Przychodzen, Teodora Kuzmanovic, Babal K Jha, Aaron T. Gerds, Hetty E. Carraway, Sudipto Mukherjee, Matt Kalaycio and **Jaroslaw P. Maciejewski** (2017) Patterns of Genomic Associations Can Define Acute Myeloid Leukemia (AML) Phenotype. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.
  223. Elise LeMelle, Cassandra M. Hirsch, Michael Clemente, Srinivasa Reddy Sanikommu, Vera Adema, Hassan Awada, Bartłomiej P. Przychodzen, Hetty E. Carraway, Alan Lichtin, Mikkael A. Sekeres, Sudipto Mukherjee, Valeria Visconte and **Jaroslaw P. Maciejewski** (2017) High Frequency of Subclonal Myeloid Mutations Can be found in Large Granular Lymphocyte Leukemia. Submitted to the 59<sup>th</sup> American Society of Hematology Annual Meeting.

224. Edward F Greenberg, Cassandra M. Hirsch, Shi Chen, Xiaochen Liiu, Babal K Jha, Valeria Visconte, Dewen You, Bartłomiej P. Przychodzen, Thomas Laframboise, Hideki Makishima, Aziz Nazha, Mingjiang Xu, Daniel Gackowski, Mridul Mukherji, Mikkael A. Sekeres, Ryszard Ólinski and **Jaroslaw P. Maciejewski** (2017) Modulation of TET2 Activity with Ascorbic Acid in Myeloid Neoplasia: Diagnostic and Therapeutic Implications. Submitted to the 59th American Society of Hematology Annual Meeting
225. Sofie Lundgren, Mikko Keränen, Kari Nousiainen, Samuli Eldfors, Sari Hannula, Tiina Hannunen, Pekka Ellonen, Gunilla Walldin, Michael Clemente, Freja Ebeling, Hanna Rajala, **Jaroslaw P. Maciejewski**, Harri Lähdesmäki, Eva Hellstrom-Lindberg and Satu Mustjoki (2017) Acquired Somatic Mutations in T Cells in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndromes. Submitted to the 59th American Society of Hematology Annual Meeting
226. Michael J. Clemente, Bartłomiej Przychodzen, Cassandra M. Hirsch, Bhumika J. Patel, Taha Bat, Yasunobu Nagata, Marcin W. Wlodarski, Hideki Makishima and **Jaroslaw P. Maciejewski** (2017) Paroxysmal Nocturnal Hemoglobinuria. Results from Initial Clonal PIG-a Mosaicism. Submitted to the 59th American Society of Hematology Annual Meeting
227. Xiaorong Gu, Quteba Ebrahim, Reda Z. Mahfouz, Metis Hasipek, Francis Enane, Tomas Radivoyevitch, Nicolas Rapin, Bartłomiej P. Przychodzen, Ramesh Balusu, Claudiu V Cotta, David Wald, Zhenbo Hu, Yosef Landesman, Maria Paola Martelli, Brunangelo Falini, Hetty E. Carraway, **Jaroslaw P. Maciejewski**, Babal K Jha and Yogenthiran Sauntharajah (2017) The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy. Submitted to the 59th American Society of Hematology Annual Meeting
228. Yasunobu Nagata, Hideki Makishima, Cassandra M. Hirsch, Mai Aly, Abhinav Goyal, Hassan Awada, Mohammad Fahad B Asad, Teodora Kuzmanovic, Bartłomiej P. Przychodzen, Hiromichi Suzuki, Tetsuichi Yoshizato, Kenichi Yoshida, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Satoru Miyano, Sudipto Mukherjee, Tomas Radivoyevitch, Thomas Laframboise, Aziz Nazha, Mikkael A. Sekeres, Torsten Haferlach, Seishi Ogawa and **Jaroslaw P. Maciejewski** (2017). Non-Random Interactions between Founder and Subclonal Mutations Shape the Clinical and Morphological Features of MDS. Submitted to the 59th American Society of Hematology Annual Meeting
229. Remco J Molenaar, Tomas Radivoyevitch, Yasunobu Nagata, Bartłomiej P. Przychodzen, Hideki Makishima, Hetty E. Carraway, Sudipto Mukherjee, Mikkael A. Sekeres, Cornelis van Noorden and **Jaroslaw P. Maciejewski** (2017) IDH1/2-Mutated Acute Myeloid Leukemia Has Impaired DNA Damage Response and Is Sensitive to Monotherapy with the PARP Inhibitor Olaparib. Submitted to the 59th American Society of Hematology Annual Meeting
230. Mohammad Fahad B Asad, Abhinav Goyal, Hassan Awada, Mai Aly, Cassandra Hirsch, Michael J. Clemente, Aziz Nazha, Hetty E. Carraway, Sudipto Mukherjee, Yasunobu Nagata and **Jaroslaw P. Maciejewski** (2017) Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria. Submitted to the 59th American Society of Hematology Annual Meeting
231. Yazan F. Madanat, Tomas Radivoyevitch, Aziz Nazha, Yazeed Sawalha, Karam Al-Issa, Nour Abuhadra, Teodora Kuzmanovic, Bartłomiej Przychodzen, Cassandra M. Hirsch, Bhumika J. Patel, David Seastone, Yogenthiran Sauntharajah, Sudipto Mukherjee, Anjali S. Advani, Hetty E. Carraway, Aaron T. Gerds, **Jaroslaw P. Maciejewski** and Mikkael A. Sekeres (2017) Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS) Submitted to the 59th American Society of Hematology Annual Meeting
232. Remco J Molenaar, Tomas Radivoyevitch, Mikkael A. Sekeres, Sudipto Mukherjee and **Jaroslaw P. Maciejewski** (2017) High Rates of Atherosclerotic Disease-Related Mortality in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Patients Associated with TET2-Mutations. Submitted to the 59th American Society of Hematology Annual Meeting
233. Raffi Tchekmedyian, Aziz Nazha, Anjali S. Advani, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, **Jaroslaw P. Maciejewski**, Navneet S. Majhail, Mikkael A. Sekeres and Sudipto Mukherjee (2017) Survival Among Acute Lymphocytic Leukemia Patients Conditional on Years Already Survived and Relative to the General Population in the United States. Submitted to the 59th American Society of Hematology Annual Meeting
234. Remco J Molenaar, Tomas Radivoyevitch, Mikkael A. Sekeres, Sudipto Mukherjee and **Jaroslaw P. Maciejewski** (2017) High Rates of Atherosclerotic Disease-Related Mortality in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Patients Associated with TET2-Mutations. Submitted to the 59th American Society of Hematology Annual Meeting

## Meeting

235. Anjali S. Advani, Brenda W. Cooper, Valeria Visconte, Paul Elson, E. Ricky Chan, Jennifer Carew, Sudipto Mukherjee, Aaron T. Gerds, Hetty E. Carraway, Aziz Nazha, Betty K. Hamilton, Ronald Sobecks, Paolo Caimi, Benjamin Tomlinson, Ehsan Malek, Jane A. Little, Jaime Fensterl, Allison Unger, Cassie Zimmerman, Christopher Goebel, Nita Hoxha, Caitlin Siebenaller, Jenna Thomas, Mary Lynn Rush, Samjhana Bogati, Eric Parsons, Rachael Diligente, Donna Kane, Alek Nielsen, Cassandra M. Hirsch, Simone Edelheit, Alexander Miron, John Pink, **Jaroslaw P. Maciejewski**, Matt Kalaycio, Marcos DeLima and Mikkael A. Sekeres (2017) A Phase I Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results. Submitted to the 59th American Society of Hematology Annual Meeting
236. Aziz Nazha, Rami S. Komrokji, John Barnard, Karam Al-Issa, Eric Padron, Yazan F. Madanat, Teodora Kuzmanovic, Nour Abuhadra, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, Alan F. List, **Jaroslaw P. Maciejewski** and Mikkael A. Sekeres (2017) A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS) Submitted to the 59th American Society of Hematology Annual Meeting
237. Aziz Nazha, Mikkael A. Sekeres, Rafael Bejar, Rami S. Komrokji, John Barnard, Karam Al-Issa, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, Benjamin L. Ebert and **Jaroslaw P. Maciejewski** (2017) Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Submitted to the 59th American Society of Hematology Annual Meeting.
238. Zubaidah M Ramdzan', Yasunobu Nagata, Suresh K. Balasubramanian, Naoko Hosono, Hideki Makishima, Valeria Visconte, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Mikkael A. Sekeres, Alain Nepveu" and **Jaroslaw Maciejewski** (2017) Functional and Biological Implications of CUX1 Mutations and Deletions in Myeloid Neoplasms. Submitted to the 59th American Society of Hematology Annual Meeting
239. Eiju Negoro, Yasunobu Nagata, Michael J. Clemente, Naoko Hosono, Wenyi Shen, Aziz Nazha, Tetsuichi Yoshizato, Cassandra Hirsch, Bartlomiej Przychodzen, Reda Z. Mahfouz, Teodora Kuzmanovic, Mikkael A. Sekeres, Hideki Makishima, Seishi Ogawa and **Jaroslaw P. Maciejewski** (2017) Origins of myelodysplastic syndromes after aplastic anemia. Submitted to the 59th American Society of Hematology Annual Meeting
240. Tetsuichi Yoshizato, Yasuhito Nannya, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Hiromichi Suzuki, Yasunobu Nagata, Yusuke Sato, Nobuyuki Kakiuchi, Keitaro Matsuo, Makoto, Keisuke Kataoka, Kenichi Chiba, Hiroko Tanaka, Hiroo Ueno, Masahiro M. Nakagawa, Bartlomiej Przychodzen, Claudia Haferlach, Wolfgang Kern, Kosuke Aoki, Hidehiro Itonaga, Yoshinobu Kanda, Mikkael A. Sekeres, **Jaroslaw P. Maciejewski**, Haferlach, Yasushi Miyazaki, Keizo Horibe, Masashi Sanada, Satoru Miyano, Hideki Makishima and Seishi Ogawa (2017) Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell Submitted to the 59th American Society of Hematology Annual Meeting
241. Swapna Thota, Bhumika J. Patel, Hetty E. Carraway, Elizabeth A. Griffiths, Amanda Przespolewski, James E. Thompson, Teodora Kuzmanovic, Aziz Nazha, Shimoli Vipul Barot, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Sudipto Mukherjee, Meghan Scully, Aaron T. Gerds, Anjali S. Advani, Mikkael A. Sekeres, Manja Meggendorfer, Eunice S. Wang and **Jaroslaw P. Maciejewski**, Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy Blood 2018 132:1389; doi: <https://doi.org/10.1182/blood-2018-99-119306>. Submitted to the 60<sup>th</sup> American Society of Hematology Annual Meeting.
242. Deepak Singhal, Christopher N. Hahn, Cassandra M. Hirsch, Amilia Wee, Monika M Kutyna, Milena Babic, Rakchha Chhetri, Smita Hiwase, Wendy Parker, Jinghua Feng, Andreas Schreiber, Joel Goeghegan, Peer Arts, Nimit Singhal, Karin Kassahn, Susan Branford, Anna L. Brown, Ian D Lewis, Richard D'Andrea, Hamish S. Scott, **Jaroslaw P. Maciejewski** and Devendra K Hiwase, Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes, Blood 2018 132:1802; doi: <https://doi.org/10.1182/blood-2018-99-117815>. Submitted to the 60th American Society of Hematology Annual Meeting.
243. Valeria Visconte, Bartlomiej P. Przychodzen, Vera Adema, Cassandra M. Hirsch, Allison Noe, Rachel Toth, Christina Snider, Hassan Awada, Amy C Graham, Yvonne Parker, Yuriy Fedorov, Drew Adams, Hetty E. Carraway,

- Anjali S. Advani, Tomas Radivoyevitch, Heesun J. Rogers, Kevin R Kelly, Steffan T. Nawrocki, Jennifer S. Carew, Daniel Lindner, Richard A Padgett, Mikkael A. Sekeres, James G Phillips and **Jaroslaw P. Maciejewski**, of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies *Blood* 2018 132:211; doi.org/10.1182/blood-2018-99-116411. Submitted to the 60<sup>th</sup> American Society of Hematology Annual Meeting
244. Aziz Nazha, Rami S. Komrokji, Manja Meggendorfer, Sudipto Mukherjee, Najla Al Ali, Wencke Walter, Stephan Hutter, Eric Padron, Yazan F. Madanat, David A Sallman, Teodora Kuzmanovic, Cassandra M. Hirsch, Vera Adema, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, Alan F. List, Claudia Haferlach, **Jaroslaw P. Maciejewski**, Torsten Haferlach and Mikkael A. Sekeres. A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes *Blood* 2018 132:793; doi://doi.org/10.1182/blood-2018-99-114774. Submitted to the 60<sup>th</sup> American Society of Hematology Annual Meeting
245. Yasunobu Nagata, Hideki Makishima, Tetsuichi Yoshizato, Hiromichi Suzuki, Cassandra M. Hirsch, Abhinav HGoyal, Hassan Awada, Mohammad Fahad B. Asad, Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Kenichi Yoshida, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Satoru Miyano, Sudipto Mukherjee, Tomas Radivoyevitch, Thomas Laframboise, Aziz Nazha, Mikkael A. Sekeres, Torsten Haferlach, Seishi Ogawa and **Jaroslaw P. Maciejewski**, Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS) *Blood* 2018 132:104; doi: Submitted to the 60<sup>th</sup> American Society of Hematology Annual Meeting
246. Kathy L McGraw, Chia-Ho Cheng, Y. Ann Chen, Hsin-An Hou, Guilio Genovese, Thomas Cluzeau, Andrea, Przychodzen, Mar Mallo, Arenillas Leonor, Azim M. Mohamedali, Lionel Ades, David A Sallman, Eric Padron, Lubomir Sokol, Chimene Moreilhon, Sophie Raynaud, Bjorn Nilsson, Hwei-Fang Tien, Jacqueline Boulwood, Benjamin L. Ebert, Francesc Sole, Pierre Fenaux, Ghulam Mufti, **Jaroslaw P. Maciejewski**, Peter Kanetsky and Alan F. List, SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition *Blood* 2018 132:107; doi: //doi.org/10.1182/blood-2018-99-118747. Submitted to the 60<sup>th</sup> American Society of Hematology Annual Meeting
247. Prithviraj Bose, Aziz Nazha, Rami S. Komrokji, Keyur P. Patel, Sherry A. Pierce, Najla Al-Ali, Andrew Sochacki, Aaron Shaver, Wencai Ma, Xiaoping Su, Naval G. Daver, Courtney D. DiNardo, Guillermo Garcia-Manero, Sanam Loghavi, Carlos Bueso-Ramos, Hagop M. Kantarjian, Mikkael A. Sekeres, Michael R. Savona, **Jaroslaw P. Maciejewski** and Srdan Verstovsek Mutational landscape of myelodysplastic/myeloproliferative neoplasm—unclassifiable *Blood* 2018 132:2100-2103; doi: https://doi.org/10.1182/blood-2018-05-848473. Submitted to the 60<sup>th</sup> American Society of Hematology Annual Meeting.
248. Yasunobu Nagata, Satoshi Narumi, Yihong Guan, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Hideki Makishima, Hirohito Shima, Victor Pastor Loyola, Teodora Kuzmanovic, Tomas Radivoyevitch, Vera Adema, Hassan Awada, Kenichi Yoshida, Francesc Sole, Babal K. Jha, Rabi Hanna, Thomas Laframboise, Seishi Ogawa, Mikkael A. Sekeres, Marcin W. Wlodarski, Jorg Cammenga and **Jaroslaw P. Maciejewski**, Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS) *Blood* 2018 132:4351; doi: https://doi.org/10.1182/blood-2018-99-119896 . Submitted to the 60<sup>th</sup> American Society of Hematology Annual Meeting.
249. Teodora Kuzmanovic, Bhumika J. Patel, Srinivasa Reddy Sanikommu, Yasunobu Nagata, Hassan Awada, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Remco J Molenaar, Babal K. Jha, Sudipto Mukherjee, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Hetty E. Carraway, Mikkael A. Sekeres, **Jaroslaw P. Maciejewski** and Tomas Radivoyevitch, Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential *Blood* 2018 132:3084; doi: https://doi.org/10.1182/blood-2018-99-119950. Submitted to the 60<sup>th</sup> American Society of Hematology Annual Meeting.
250. Yasunobu Nagata, Satoshi Narumi, Yihong Guan, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Hideki Makishima, Hirohito Shima, Mai Aly, Victor Pastor, Teodora Kuzmanovic, Tomas Radivoyevitch, Vera Adema, Hassan Awada, Kenichi Yoshida, Samuel Li, Francesc Sole, Rabi Hanna, Babal K. Jha, Thomas LaFramboise, Seishi Ogawa, Mikkael A. Sekeres, Marcin W. Wlodarski, Jörg Cammenga and **Jaroslaw P. Maciejewski**, Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. *Blood* 2018 132:2309-2313; doi:

<https://doi.org/10.1182/blood-2017-05-787390> . Submitted to the 60th American Society of Hematology Annual Meeting.

251. Yihong Guan, Edward F Greenberg, Metis Hasipek, Cassandra M. Hirsch, Amy C Graham, Tomas Radivoyevitch, Shi Chen, Xiaochen Liu, Valeria Visconte, Dewen You, Eiju Negoro, Bartłomiej P. Przychodzen, Hideki Makishima, Aziz Nazha, Daniel Gackowski, Ewelina Zarakowska, Mridul Mukherji, Mikkael A. Sekeres, Mingjiang Xu, Ryszard Ólinski, **Jarosław P. Maciejewski** and Babal K. Jha, Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation Blood 2018 132:4346; doi: <https://doi.org/10.1182/blood-2018-99-119712> Submitted to the 60th American Society of Hematology Annual Meeting.
252. Bhumika J. Patel, Shimoli Vipul Barot, Bartłomiej P. Przychodzen, Teodora Kuzmanovic, Michael Clemente, Cassandra M. Hirsch, Valeria Visconte, Roy Souaid, Marissa Versalle, Sarah S Lee, Tomas Radivoyevitch, Metis Haspiek, Swapna Thota, Aziz Nazha, Matt Kalaycio, Anjali S. Advani, Hetty E. Carraway, Mikkael A. Sekeres and **Jarosław P. Maciejewski** Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia Blood 2018 132:3869; doi: <https://doi.org/10.1182/blood-2018-99-120330> Submitted to the 60<sup>th</sup> American Society of Hematology Annual Meeting.
253. Sagar S. Patel, Betty K. Hamilton, Lisa Rybicki, Dawn Thomas, Arden Emrick, Aziz Nazha, Sudipto Mukherjee, Anjali S. Advani, Hetty E. Carraway, Brad Pohlman, Brian J. Bolwell, Robert M. Dean, Aaron T. Gerds, Rabi Hanna, Matt Kalaycio, Aiwen Zhang, Mikkael A. Sekeres, **Jarosław P. Maciejewski**, Navneet S. Majhail, Medhat Askar and Ronald Sobecks Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Blood 2018 132:4603; doi: <https://doi.org/10.1182/blood-2018-99-111890> Submitted to the 60th American Society of Hematology Annual Meeting.
254. Hassan Awada, Yasunobu Nagata, Abhinav Goyal, Mohammad Fahad B. Asad, Bhumika J. Patel, Cassandra M. Hirsch, Teodora Kuzmanovic, Vera Adema, Mai Aly, Bartłomiej P. Przychodzen, Yihong Guan, Wenyi Shen, Louis Williams, Aziz Nazha, Mohamed Abazeed, Mikkael A. Sekeres, Tomas Radivoyevitch, Torsten Haferlach, Babal K. Jha, Valeria Visconte and **Jarosław P. Maciejewski** Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes Blood 2018 132:1805; doi: <https://doi.org/10.1182/blood-2018-99-115154>. Submitted to the 60th American Society of Hematology Annual Meeting.
255. Kiyomi Morita, Feng Wang, Hideki Makishima, Yuanqing Yan, Tetsuichi Yoshizato, Kenichi Yoshida, Bartłomiej P. Przychodzen, Keyur Patel, Carlos E. Bueso-Ramos, Curtis Gumbs, Latasha Little, Samantha Tippen, Jianhua Zhang, Xingzhi Song, Tapan M. Kadia, Naval G. Daver, Naveen Pemmaraju, Courtney D. DiNardo, Farhad Ravandi, Srdan Verstovsek, Elias J. Jabbour, Jorge E. Cortes, Hagop M. Kantarjian, Guillermo Garcia-Manero, **Jarosław P. Maciejewski**, Seishi Ogawa, P Andrew Futreal and Koichi Takahashi Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data Blood 2018 132:1801; doi: <https://doi.org/10.1182/blood-2018-99-116685> Submitted to the 60th American Society of Hematology Annual Meeting.
256. Deepak Singhal, Christopher N. Hahn, Cassandra M. Hirsch, Amilia Wee, Monika M Kutyna, Milena Babic, Rakchha Chhetri, Smita Hiwase, Wendy Parker, Jinghua Feng, Andreas Schreiber, Joel Goeghegan, Peer Arts, Nimit Singhal, Karin Kassahn, Susan Branford, Anna L. Brown, Ian D Lewis, Richard D'Andrea, Hamish S. Scott, **Jarosław P. Maciejewski** and Devendra K Hiwase Genetic Predisposition to Therapy-Related Myeloid Neoplasm by Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes Blood 2018 132:1802; doi: <https://doi.org/10.1182/blood-2018-99-117815> Submitted to the 60th American Society of Hematology Annual Meeting.
257. Sagar S. Patel, Betty K. Hamilton, Lisa Rybicki, Dawn Thomas, Arden Emrick, Aziz Nazha, Sudipto Mukherjee, Anjali S. Advani, Hetty E. Carraway, Brad Pohlman, Brian J. Bolwell, Robert M. Dean, Aaron T. Gerds, Rabi Hanna, Matt Kalaycio, Aiwen Zhang, Mikkael A. Sekeres, **Jarosław P. Maciejewski**, Navneet S. Majhail, Medhat Askar Ronald Sobecks Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia Blood 2018 132:2075; doi: [://doi.org/10.1182/blood-2018-99-112745](https://doi.org/10.1182/blood-2018-99-112745) Submitted to the 60th American Society of Hematology Annual Meeting.
258. Vera Adema, Cassandra M. Hirsch, Bartłomiej Przychodzen, Yasunobu Nagata, Tomas Radivoyevitch, Thomas Laframboise, Amy C Graham, Louis Williams, Hassan Awada, Aziz Nazha, Hetty E. Carraway, Valeria Santini,

- Hrishikesh M Mehta, Francesc Sole, Mikkael A. Sekeres, Valeria Visconte, Rabi Hanna, Seth J. Corey and **P. Maciejewski** Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations *Blood* 2018 132:4389; doi: <https://doi.org/10.1182/blood-2018-99-116554> Submitted to the 60th American Society of Hematology Annual Meeting.
259. Sudipto Mukherjee, David P. Steensma, Rami S. Komrokji, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, Aziz Nazha, **Jaroslaw P. Maciejewski**, Mikkael A. Sekeres, Brian P. Hobbs and Xuefei Jia, Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers? *Blood* 2018 132:3096; doi: <https://doi.org/10.1182/blood-2018-99-117174>. Submitted to the American Society of Hematology Annual Meeting.
  260. Yihong Guan, Anand D. Tiwari, Metis Hasipek, Dale Grabowski, Yvonne Parker, Cassandra M. Hirsch, Amy C Graham, Yasunobu Nagata, Bartlomiej P. Przychodzen, Aziz Nazha, Daniel Lindner, Tomas Radivoyevitch, James G Phillips, **Jaroslaw P. Maciejewski** and Babal K. Jha Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases *Blood* 2018 132:4345; doi: <https://doi.org/10.1182/blood-2018-99-117186> Submitted to the 60th American Society of Hematology Annual Meeting.
  261. Louis Williams, Teodora Kuzmanovic, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Yogenthiran Sauntharajah, Hassan Awada, Vera Adema, Amy C Graham, Tomas Radivoyevitch, Hetty E. Carraway, Aziz Nazha, Mikkael A. Sekeres and **Jaroslaw P. Maciejewski** BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden *Blood* 2018 132:4352; doi: <https://doi.org/10.1182/blood-2018-99-116802> Submitted to the 60th American Society of Hematology Annual Meeting.
  262. Aziz Nazha, Manja Meggendorfer, Sudipto Mukherjee, Wencke Walter, Stephan Hutter, Ahed Makhoul, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Hetty E. Carraway, Yasunobu Nagata, Yihong Guan, Teodora Kuzmanovic, Metis Hasipek, Babal K. Jha, **Jaroslaw P. Maciejewski**, Claudia Haferlach, Mikkael A. Sekeres and Torsten Haferlach Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype *Blood* 2018 132:2809; doi: <https://doi.org/10.1182/blood-2018-99-114782> Submitted to the 60th American Society of Hematology Annual Meeting.
  263. Yasunobu Nagata, Hideki Makishima, Cassandra M. Hirsch, Hassan Awada, Abhinav Goyal, Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Tetsuichi Yoshizato, Kenichi Yoshida, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Satoru Miyano, Sudipto Mukherjee, Tomas Radivoyevitch, Thomas Laframboise, Aziz Nazha, Mikkael A. Sekeres, Torsten Haferlach, Seishi Ogawa and **Jaroslaw P. Maciejewski** , Distinct Features of Chip-Derived and De Novo MDS *Blood* 2018 132:2572; doi: <https://doi.org/10.1182/blood-2018-99-117763> Submitted to the 60th American Society of Hematology Annual Meeting.
  264. Robert A. Brodsky, Regis Peffault De Latour, Scott T. Rottinghaus, Alexander Röth, Antonio M. Risitano, Ilene C. Weitz, Peter Hillmen, **Jaroslaw P. Maciejewski**, Jeffrey Szer, Jong-Wook Lee, Austin G. Kulasekararaj, Lori Volles, Andrew I. Damokosh, Stephan Ortiz, Lori Shafner, Anita Hill and Hubert Schrezenmeier A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria *Blood* 2018 132:2330; doi: [99-110874](https://doi.org/10.1182/blood-2018-99-110874) Submitted to the 60th American Society of Hematology Annual Meeting.
  265. Bhumika J. Patel, Shimoli Vipul Barot, Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Hassan Awada, Metis Hasipek, Swapna Thota, Tomas Radivoyevitch, Anjali S. Advani, Matt Kalaycio, Mikkael A. Sekeres, Hetty E. Carraway and **Jaroslaw P. Maciejewski**, Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia *Blood* 2018 132:2590; doi: <https://doi.org/10.1182/blood-2018-99-119852> Submitted to the 60th American Society of Hematology Annual Meeting.
  266. Sophia Colombari Figueroa, Bhumika J. Patel, Shimoli Vipul Barot, Teodora Kuzmanovic, Aziz Nazha, Eric D. Hsi, James R. Cook, Sudipto Mukherjee, Aaron T. Gerds, Mikkael A. Sekeres, Matt Kalaycio, Anjali S. Advani, **Jaroslaw P. Maciejewski** and Hetty E. Carraway TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer *Blood* 2018 132:2270; doi: <https://doi.org/10.1182/blood-2018-99-115562>. Submitted to the 60th American Society of Hematology Annual Meeting.

267. Abhinav Goyal, Inom Mirzaev, Mohammad Fahad B. Asad, Hassan Awada, Cassandra M. Hirsch, Hideki Makishima, Kenichi Yoshida, Bartłomiej P. Przychodzen, Aziz Nazha, Sudipto Mukherjee, Mikkael A. Sekeres, Seishi Ogawa, Tomas Radivoyevitch, Jacob Scott, **Jaroslaw P. Maciejewski** and Yasunobu Nagata Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS) Blood 2018 132:1824; Submitted to the 60th American Society of Hematology Annual Meeting.
268. Cassandra M. Hirsch, Wenyi Shen, Bartłomiej P. Przychodzen, Yasunobu Nagata, Vera Adema, Teodora Kuzmanovic, Louis Williams, Aziz Nazha, Valeria Visconte, Hetty E. Carraway, Mikkael A. Sekeres and **Jaroslaw P. Maciejewski**, Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS Blood 2018 132:3074; doi: <https://doi.org/10.1182/blood-2018-99-116535>. Submitted to the 60th American Society of Hematology Annual Meeting.
269. Wenyi Shen, Cassandra M. Hirsch, Bartłomiej P. Przychodzen, Hideki Makishima, Louis Williams, Sudipto Mukherjee, Hetty E. Carraway, Mikkael A. Sekeres and **Jaroslaw P. Maciejewski**, Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) Blood 2018 132:2583; doi: <https://doi.org/10.1182/blood-2018-99-115228> Submitted to the 60th American Society of Hematology Annual Meeting
270. Raffi Tchekmedyian, Tomas Radivoyevitch, Aaron T. Gerds, Aziz Nazha, Hetty E. Carraway, Anjali S. Advani, **Jaroslaw P. Maciejewski**, Matt Kalaycio, Navneet S. Majhail, Mikkael A. Sekeres and Sudipto Mukherjee Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States Blood 2018 132:2298; doi: <https://doi.org/10.1182/blood-2018-99-119535> Submitted to the 60th American Society of Hematology Annual Meeting
271. Cassandra M. Hirsch, Michael Clemente, Peter Chomczynski, Bartłomiej P. Przychodzen, Yasunobu Nagata, Vera Adema, Louis Williams, Valeria Visconte, Alan Lichtin, MD, Satu Mustjoki, Mikkael A. Sekeres and **Jaroslaw P. Maciejewski** Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance Blood 2018 132:516; doi: <https://doi.org/10.1182/blood-2018-99-116307>. Submitted to the 60th American Society of Hematology Annual Meeting
272. Rachel Hu, Aziz Nazha, Xuefei Jia, Brian P. Hobbs, Hetty E. Carraway, Sudipto Mukherjee, Aaron T. Gerds, Anjali S. Advani, Yasunobu Nagata, Cassandra M. Hirsch, Bartłomiej P. Przychodzen, Babal K. Jha, **Jaroslaw P. Maciejewski** and Mikkael A. Sekeres Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia Blood 2018 132:1527; doi: <https://doi.org/10.1182/blood-2018-99-114273> Submitted to the 60th American Society of Hematology Annual Meeting.
273. Yazan F. Madanat, Mikkael A. Sekeres, Sudipto Mukherjee, Cassandra M. Hirsch, Yihong Guan, Yasunobu Nagata, Vera Adema, Metis Hasipek, Aaron T. Gerds, Hetty E. Carraway, Anjali S. Advani, Bartłomiej P. Przychodzen, Valeria Santini, **Jaroslaw P. Maciejewski**, Babal K. Jha and Aziz Nazha Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes Blood 2018 132:1797; doi: <https://doi.org/10.1182/blood-2018-99-114681> Submitted to the 60th American Society of Hematology Annual Meeting
274. Teodora Kuzmanovic, Bhumika J. Patel, Yasunobu Nagata, Hassan Awada, Cassandra M. Hirsch, Bartłomiej P. Przychodzen, Srinivasa Reddy Sanikommu, Louis Williams, Sudipto Mukherjee, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Tomas Radivoyevitch, Hetty E. Carraway, Mikkael A. Sekeres and **Jaroslaw P. Maciejewski** Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML Blood 2018 132:4353; doi: <https://doi.org/10.1182/blood-2018-99-120059> Submitted to the 60th American Society of Hematology Annual Meeting
275. Sudipto Mukherjee, Tomas Radivoyevitch, Brian P. Hobbs, Xuefei Jia, Rami S. Komrokji, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, **Jaroslaw P. Maciejewski**, Aziz Nazha and Mikkael A. Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA Blood 2018 132:3095; doi: <https://doi.org/10.1182/blood-2018-99-119146> 120059 Submitted to the 60th American Society of Hematology Annual Meeting



276. Courtney Hershberger, James Hiznay, Rosemary Dietrich, Xiaorong Gu, Cassandra M. Hirsch, Amy Graham, Bartłomiej P. Przychodzen, Valeria Visconte, Vera Adema, Yvonne Parker, Hetty E. Carraway, Tomas Radivoyevitch, Mikkael A. Sekeres, Yogenthiran Sauntharajah, **Jaroslaw P. Maciejewski** and Richard A Padgett Blood 2018 132:3073; doi: <https://doi.org/10.1182/blood-2018-99-112838> Submitted to the 60th American Society of Hematology Annual Meeting
277. Sergei Vatolin and **Jaroslaw P. Maciejewski** Novel Small Molecule Stimulants of Hematopoietic Stem Cells and Their Mode of Action Blood 2018 132:1302; doi: <https://doi.org/10.1182/blood-2018-99-114838> Submitted to the 60th American Society of Hematology Annual Meeting
278. Tomas Radivoyevitch, Brian P. Hobbs and **Jaroslaw P. Maciejewski** Poisson Regression Modeling of Chronic Myeloid Leukemia Mortality Trends Blood 2018 132:4274; doi: <https://doi.org/10.1182/blood-2018-99-118143> Submitted to the 60th American Society of Hematology Annual Meeting
279. Phillip J Maciejewski, Yihong Guan, Metis Hasipek, Anand D. Tiwari, Dale Grabowski, James G Phillips, Yogenthiran Sauntharajah, **Jaroslaw P. Maciejewski** and Babal K. Jha Targeting NAD<sup>+</sup> Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure Blood 2018 132:3840; doi: <https://doi.org/10.1182/blood-2018-99-119300> Submitted to the 60th American Society of Hematology Annual Meeting
280. Tomas Radivoyevitch, Brian P. Hobbs, Yasunobu Nagata, Jacob Scott, Asha Kallianpour, Takuya Sakaguchi, **Jaroslaw P. Maciejewski** and Yasushi Miyazaki Chronic Myeloid Leukemia Incidence Based Estimates of Hematopoietic Stem Cell Numbers per Person Blood 2018 132:5441; doi: <https://doi.org/10.1182/blood-2018-99-119583> Submitted to the 60th American Society of Hematology Annual Meeting
281. Amy C Graham, Alexey Efanov, Bartłomiej P. Przychodzen, Cassandra M. Hirsch, Vera Adema, Valeria Visconte and **Jaroslaw P. Maciejewski** Selective Pharmacologic Inhibition of Paroxysmal Nocturnal Hemoglobinuria Clones Blood 2018 132:1303; doi: <https://doi.org/10.1182/blood-2018-99-114973> Submitted to the 60th American Society of Hematology Annual Meeting
282. Metis Hasipek, Dale Grabowski, Yihong Guan, James G Phillips, **Jaroslaw P. Maciejewski**, Hetty E. Carraway and Babal K. Jha Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia Blood 2018 32:4067; doi: <https://doi.org/10.1182/blood-2018-99-118924> Submitted to the 60th American Society of Hematology Annual Meeting
283. Regis Peffault De Latour, **Jaroslaw P. Maciejewski**, Austin G. Kulasekararaj, Loree Larratt, Ronald S. Go, David Dingli, Amanda Wilson, Philippe Gustovic and Aleksandr Kulagin Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry Blood 2018 132:1038; doi: <https://doi.org/10.1182/blood-2018-99-111324> Submitted to the 60th American Society of Hematology Annual Meeting
284. Sofie Lundgren, Jani Huuhtanen, Mikko A Keränen, Cassandra M. Hirsch, Emmi Jokinen, Markus Heinonen, Paula Savola, Tiina Kelkka, Freja Ebeling, **Jaroslaw P. Maciejewski**, Eva Hellström-Lindberg, Harri Lähdesmäki and Satu Mustjoki Next-Generation Sequencing Reveals a T Cell Receptor Signature Characteristic of Patients with Aplastic Anemia Blood 2018 132:537; doi: <https://doi.org/10.1182/blood-2018-99-117811>. Submitted to the 60th American Society of Hematology Annual Meeting
285. Wenyi Shen, Cassandra M. Hirsch, Bartłomiej P. Przychodzen, Reda Z. Mahfouz, Tomas Radivoyevitch, Louis Williams, Mohammad Fahad B. Asad, **Jaroslaw P. Maciejewski** Heterozygous CTC1 Variants in Acquired Bone Marrow Failure Blood 2018 132:3866; doi: <https://doi.org/10.1182/blood-2018-99-115193> Submitted to the 60th American Society of Hematology Annual Meeting
286. Remco J Molenaar, Tomas Radivoyevitch, Aaron T. Gerds, Aziz Nazha, Hetty E. Carraway, Anjali S. Advani, Matt Kalaycio, Navneet S. Majhail, **Jaroslaw P. Maciejewski**, Mikkael A. Sekeres and Sudipto Mukherjee Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy. Blood 2018 132:900; doi: <https://doi.org/10.1182/blood-2018-99-118207> Submitted to the 60th American Society of Hematology Annual Meeting

287. Cassandra M Kerr, Vera Adema, Wencke, Walter, Stephan Hutter, Christina A. Snider, Yasunobu Nagata, Manja Meggendorfer, Claudia Haferlach, Valeria Viconte, Mikkael A. Sekkers, Thomas Laframboise, Torsten Haferlach, and **Jaroslaw P. Maciejewski**, Genetics of Monosomy 7 and Del (7q) in MDS Informs Potential Therapeutic Targets. (2019) Submitted to the 61st American Society of Hematology Annual Meeting
288. Sunisa Kongkiakamon, Yihong Guan, Anand Tiwari, Phillip J Maciejewski, Dale Grabowski, Sergei Vatin, Vera Adema, Cassandra M Kerr, Yasunobu Nagata, Milo Co, Christina Snider, Hassan Awada, Jibrán Durrani, Yvonne Parker, Daniel Lindner, Mikkael A. Sekeres, Valeria Viconte, James G. Phillips, **Jaroslaw P. Maciejewski**, Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function (2019) Submitted to the 61st American Society of Hematology Annual Meeting
289. Christina A. Snider, Kevin Fung, Francesca Gould, Vera Adema, Cassandra M Kerr, Sunisa Kongkiakamon, Hassan Awada, Milo Co, Teodora Kuzmanovic, Bhumika J. Patel, Aaron T. Gerds, Sudipto Mukherjee, Aziz Nazha, Hetty E. Carraway, Tomas Radivoyevitch, Jaroslaw P. Maciejewski, Valeria Visconte, Mikkael A. Sekeres, Anjali S. Advani RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. (2019) Submitted to the 61st American Society of Hematology Annual Meeting
290. Sudipto Mukherjee, Hong Li, Brian P. Hobbs, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Aziz Nazha, Samjhana Bogati, Eric Parsons, Benjamin Pannell, Matt Kalaycio, Yogenthiran Sauntharajah, **Jaroslaw P. Maciejewski**, Mikkael A. Sekeres. A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy (2019) Submitted to the 61st American Society of Hematology Annual Meeting
291. Yasunobu Nagata, Ran Zhao, Hassan Awada, Cassandra M Kerr, Abhinav Goyal, Inom Mirzaev, Sunisa Kongkiakamon, Aziz Nazha, Tomas Radivoyevitch, Jacob Scott, Mikkael A. Sekeres, Brian P. Hobbs, **Jaroslaw P. Maciejewski** How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS (2019) Submitted to the 61st American Society of Hematology Annual Meeting
292. Yihong Guan, Bhumika J. Patel, Metis Hasipek, Dale Grabowski, Hassan Awada, Cassandra M Kerr, Valeria Visconte, Aziz Nazha, Yogenthiran Sauntharajah, Mikkael A. Sekeres, **Jaroslaw P. Maciejewski**, Babal K. Jha Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion (2019) Submitted to the 61st American Society of Hematology Annual Meeting
293. Ashwin Kishtagari, Hassan Awada, Reda Z. Mahfouz, Teodora Kuzmanovic, Jibrán Durrani, Cassandra M Kerr, Bhumika J. Patel, Valeria Visconte, Tomas Radivoyevitch, Alan Lichtin, Hetty E. Carraway, **Jaroslaw Maciejewski** Yogenthiran Sauntharajah Extended Experience with a Very Low Dose; Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity (2019) Submitted to the 61st American Society of Hematology Annual Meeting
294. Johannes B Goll, Coleman Lindsley, William F. Hooper, Rafael Bejar, Jason Walker, Robert Fulton, Gregory A. Abel, Tareq Al Baghdadi, H. Joachim Deeg, Amy E. DeZern, Benjamin Ebert, Pearl Epling-Burnette, James M. Foran, Edward J. Gorak, Steven D. Gore, Rami S. Komrokji, Jane Jijun, **Jaroslaw P. Maciejewski**, Eric Padron, Wael Saber, Daniel T. Starczynowski, Myron Wacławiw, Nancy Di Fronzo, Mikkael A. Sekeres, Ling Zhang, Matthew J. Walter Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study (2019) Submitted to the 61st American Society of Hematology Annual Meeting
295. Hassan Awada, Arda Durmaz, Yasunobu Nagata, Teodora Kuzmanovic, Ashwin Kishtagari, Jibrán Durrani, Cassandra M Kerr, Anjali S. Advani, Hetty E. Carraway, Tomas Radivoyevitch, Manja Meggendorfer, Aziz Nazha, Valeria Visconte, Mikkael A. Sekeres, Torsten Haferlach, **Jaroslaw P. Maciejewski**. Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis (2019) Submitted to the 61st American Society of Hematology Annual Meeting

296. Nathan Radakovich, Mikkael A. Sekeres, Cameron Beau Hilton, Sudipto Mukherjee, Jacob Shreve, Yazan Roupail, Rachel Shirley, Vera Adema, Hassan Awada, Anjali S. Advani, Cassandra M Kerr, Yasunobu Nagata, Yihong Guan, Teodora Kuzmanovic, Metis Hasipek, Babal K. Jha, **Jaroslaw P. Maciejewski**, Aziz Nazha Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI) (2019) Submitted to the 61st American Society of Hematology Annual Meeting
297. Jacob Shreve, Manja Meggendorfer, Hassan Awada, Sudipto Mukherjee, Wencke Walter, Stephan Hutter, Ahed Makhoul, Cameron Beau Hilton, Nathan Radakovich, Yasunobu Nagata, Yazan Roupail, Vera Adema, Cassandra M Kerr, Bhumika J. Patel, Teodora Kuzmanovic, **Jaroslaw P. Maciejewski**, Claudia Haferlach, Mikkael A. Sekeres, Torsten Haferlach, Aziz Nazha A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence (2019) Submitted to the 61st American Society of Hematology Annual Meeting
298. Jibrán Durrani, Hassan Awada, Wenyi Shen, Cassandra M Kerr, Vera Adema, Sunisa Kongkiatkamon Ashwin Kishtagari, Samuel Li, Yasunobu Nagata, Sanghee Hong, Aziz Nazha, Bhumika J. Patel, Yogenthiran Sauntharajah, Hetty E. Carraway, Valeria Visconte, Seth J. Corey, Mikkael A. Sekeres, Thomas Laframboise, **Jaroslaw P. Maciejewski** FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults ) Submitted to the 61st American Society of Hematology Annual Meeting
299. Jibrán Durrani, Hassan Awada, Ashwin Kishtagari, Cassandra M Kerr, Vera Adema, Yasunobu Nagata, Teodora Kuzmanovi, Sanghee Hong, Sunisa Kongkiatkamon, Alan Lichtin, Aziz Nazha, Bhumika J. Patel, Yogenthiran Sauntharajah, Hetty E. Carraway, Valeria Visconte, Mikkael A. Sekeres, **Jaroslaw P. Maciejewski**, Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential (2019) Submitted to the 61st American Society of Hematology Annual Meeting
300. Yasunobu Nagata, MD, Hideki Makishima, Cassandra M Kerr, Bhumika J. Patel, Hassan Awada, Vera Adema, Valeria Visconte, Sudipto Mukherjee, Thomas Laframboise, Aziz Nazha, Tomas Radivoyevitch, Mikkael A. Sekeres, Seishi Ogawa, **Jaroslaw P. Maciejewski** Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features (2019) Submitted to the 61st American Society of Hematology Annual Meeting
301. Vera Adema, Cassandra M Kerr, Sunisa Kongkiatkamon Jibrán Durrani, Hassan Awada, Stephan Hutter, Kevin Fung, Francesca Gould, Christina A. Snider, Anjali S. Advani, Hetty E. Carraway, Kevin R Kelly, Steffan T. Nawrocki, Yogenthiran Sauntharajah, Jennifer S. Carew, Manja Meggendorfer, James G Phillips, Mikkael A. Sekeres, Michael R. Savona, Torsten Haferlach, **Jaroslaw P. Maciejewski**, Valeria Visconte Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q) (2019) Submitted to the 61st American Society of Hematology Annual Meeting
302. Hassan Awada Teodora Kuzmanovic, Ashwin Kishtagari, Jibrán Durrani, Arda Durmaz, Sanghee Hong, Cassandra M Kerr, Vera Adema, Yihong Guan, Sonia Sandhu, Aziz Nazha, Manja Meggendorfer, Torsten Haferlach, Hetty E. Carraway, Mikkael A. Sekeres, Valeria Visconte, **Jaroslaw P. Maciejewski**, Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia (2019) Submitted to the 61st American Society of Hematology Annual Meeting
303. Lisa Pleyer Michael Leisch, Alexandra Kourakli, Eric Padron, **Jaroslaw P. Maciejewski**, Blanca Xicoy, Jennifer Kaivers, Johanna Ungerstedt, Sonja Heibl, Peristera Patiou, Anthony M. Hunter, Elvira Mora Casterá, Klaus Geissler, Maria Dimou, Maria-José Jimenez, David Kiesl, Nora-Athina Viniou, Bhumika J. Patel, Montserrat Arnan Sangerman, Peter Valent, Christoforos Roubakis, Teresa Bernal del Castillo, Athanasios Galanopoulos, Marisa Calabuig, Nicolas Bonadies, Antonio Medina de Almeida, Jaroslav Cermak, Andres Jerez, Julia Montoro, Albert Cortés, Alejandro Avendaño Pita, Bernardo López Andrade, Eva Hellstrom Lindberg, Ulrich Germing, Mikkael A. Sekeres, Alan F. List, Argiris Symeonidis, Guillermo F. Sanz, Richard Greil, Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group (2019) Submitted to the 61st American Society of Hematology

## Annual Meeting

304. Teodora Kuzmanovic, Bhumika J. Patel, Jibran Durrani, Hassan Awada, Cassandra M Kerr, Bartlomiej P. Przychodzen, Samuel Li, Seth J. Corey, Sudipto Mukherjee, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Hetty E. Carraway, Thomas Laframboise, Mikkael A. Sekeres, **Jaroslaw P. Maciejewski**, *ANKRD26* Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia (2019) Submitted to the 61st American Society of Hematology Annual Meeting
305. Sanghee Hong, Lisa Rybicki, Aiwen Zhang, Dawn Thomas, Cassandra M Kerr, Donna Corrigan, Arden Emrick, Hetty E. Carraway, Aziz Nazha, Sudipto Mukherjee, Anjali S. Advani, Matt Kalaycio, Brian J. Bolwell, Rabi Hanna, Aaron T. Gerds, Brad Pohlman, Betty K. Hamilton, Mikkael A. Sekeres, Navneet S. Majhail, **Jaroslaw P. Maciejewski**, Medhat Askar, Ronald Sobecks, Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML) (2019) Submitted to the 61st American Society of Hematology Annual Meeting
306. Vera Adema, Laura Palomo, Cassandra M Kerr, Wencke Walter, Bartlomiej Przychodzen, Stephan Hutter, Thomas Laframboise, María Díez-Campelo, Mar Mallo, Aziz Nazha, Blanca Xicoy, Manja Meggendorfer, Hetty E. Carraway, Claudia Haferlach, Mikkael A. Sekeres, Valeria Visconte, Torsten Haferlach, Francesc Sole, **Jaroslaw P. Maciejewski**, Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications (2019) Submitted to the 61st American Society of Hematology Annual Meeting
307. Valeria Visconte, Vera Adema, Anand D. Tiwari, Cassandra M Kerr, Hassan Awada, Bartlomiej Przychodzen, Allison Noe, Rachel Toth, Christina Snider, Yvonne Parker, Yuriy Fedorov, Drew Adams, Hetty E. Carraway, Anjali S. Advani, Kevin R Kelly, Steffan T. Nawrocki, Jennifer S. Carew, Heesun J. Rogers, Daniel J. Lindner, Mikkael A. Sekeres, James G Phillips, **Jaroslaw P. Maciejewski**, Pharmacologic Normalization of Altered Transcriptome of *SF3B1* Mutant Myeloid Neoplasia (2019) Submitted to the 61<sup>st</sup> American Society of Hematology Annual Meeting
308. Alan F. List, Zhuoxin Sun, Amit Verma, John M. Bennett, Kathy McGraw, **Jaroslaw P. Maciejewski**, Rami S. Komrokji, Timothy R. Wassenaar, Selina M. Luger, Ryan J. Mattison, Puneet S. Cheema, Jessica K. Altman, David F. Claxton, MD, Charles A. Schiffer, Andrew S. Artz, Mark Litzow, Martin S. Tallman, Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health (2019) Submitted to the 61st American Society of Hematology Annual Meeting
309. Vera Adema, Courtney E Hershberger, Wencke Walter, Cassandra M Kerr, Stephan Hutter, Yasunobu Nagata, Hassan Awada, Sunisa Kongkiatkamon, Christina Snider, Milo Co, Manja Meggendorfer, Aziz Nazha, Hetty E. Carraway, Mikkael A. Sekeres, Francesc Sole, Richard A Padgett, Torsten Haferlach, **Jaroslaw P. Maciejewski**, Valeria Visconte, Hotspot *U2AF1* Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors (2019) Submitted to the 61<sup>st</sup> American Society of Hematology Annual Meeting
310. Vera Adema, Cassandra M Kerr, Wencke Walter, Stephan Hutter, Yasunobu Nagata, Hassan Awada, Sunisa Kongkiatkamon, Christina A. Snider, Milo Co, Rainey Magdalena, Arda Durmaz, Manja Meggendorfer, Aziz Nazha, Jacob Scott, MD, Hetty E. Carraway, Mikkael A. Sekeres, Francesc Sole, Torsten Haferlach, Valeria Visconte, **Jaroslaw P. Maciejewski** Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents? (2019) Submitted to the 61<sup>st</sup> American Society of Hematology Annual Meeting
311. Hassan Awada, Reda Z. Mahfouz, MD, PhD, Jibran Durrani, Ashwin Kishtagari, Deepa Jagadeesh, Alan Lichtin, Brian T. Hill, Betty K. Hamilton, Hetty E. Carraway, Navneet S. Majhail, Ronald Sobecks, Valeria Visconte, Matt Kalaycio, Mikkael A. Sekeres, **Jaroslaw P. Maciejewski**, Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation (2019) Submitted

to the 61<sup>st</sup> American Society of Hematology Annual Meeting

312. Reina Takeda, Shuhei Asada, Sung-Joon Park, Akihiko Yokoyama, Akinori Kanai, Valeria Visconte, Courtney Hershberger, Yasutaka Hayashi, Taishi Yonezawa, Moe Tamura, Tomofusa Fukuyama, Akiko Matsumoto, Satoshi Yamasaki, Kenta Nakai, Toshiya Inaba, MD, Tatsuhiro Shibata, Daichi Inoue, Hiroaki Honda, Susumu Goyama, **Jaroslaw P. Maciejewski**, Toshio Kitamura, Homeobox Transcription Factor Hhex Promotes Myeloid Leukemia in Cooperation with Mutant ASXL1 (2019) Submitted to the 61<sup>st</sup> American Society of Hematology Annual Meeting
313. Yihong Guan, Anand D. Tiwari, James G Phillips, Metis Hasipek, Dale Grabowski, Cassandra M Kerr, Vera Adema, Yasunobu Nagata, Valeria Visconte, Tomas Radivoyevitch, Daniel Lindner, Manja Meggendorfer, Mohamed Abazeed, Mikkael A. Sekeres, Torsten Haferlach, **Jaroslaw P. Maciejewski**, Babal K. Jha, TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia (2019) Submitted to the 61<sup>st</sup> American Society of Hematology Annual Meeting
314. Cassandra M Kerr, Vera Adema, Wencke Walter, Stephan Hutter, Christina A. Snider, Yasunobu Nagata, Manja Meggendorfer, Claudia Haferlach, Valeria Visconte, Mikkael A. Sekeres, MD, Thomas Laframboise, Torsten Haferlach, **Jaroslaw P. Maciejewski** Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets (2019) Submitted to the 61<sup>st</sup> American Society of Hematology Annual Meeting
315. Ryunosuke Saiki, Yusuke Shiozawa, Tetsuichi Yoshizato, Yasuhito Nannya, June Takeda, Kenichi Yoshida, Yuichi Shiraishi, Hiroko Tanaka, Kenichi Chiba, Yoshiko Atsuta, MD, Makoto Onizuka, Hidehiro Itonaga, Masashi Sanada, Yoshinobu Kanda, Bartłomiej Przychodzen, Mikkael A. Sekeres, Kathryn Guinta, Yogenthiran Sauntharajah, Lee-Yung Shih, Shuichi Miyawaki, Tsuyoshi Nakamaki, Masataka Taguchi, Shigeo Fuji, Nana Sasaki, Nobuhiko Uoshima, Yasunori Ueda, Yasushi Miyazaki, Kensuke Usuki, Kazunori Imada, Akifumi Takaori-Kondo, Shigeru Chiba, Senji Kasahara, Toru Kiguchi, Hisashi Tsurumi, Luca Malcovati, Mario Cazzola, Takayuki Ishikawa, Satoru Miyano, **Jaroslaw P. Maciejewski**, Hideki Makishima, Seishi Ogawa, Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms (2019) Submitted to the 61<sup>st</sup> American Society of Hematology Annual Meeting
316. Hassan Awada, Ashwin Kishtagari, Teodora Kuzmanovic, Jibrán Durrani, Cassandra M Kerr, Manja Meggendorfer, P Anjali S. Advani, Aziz Nazha, Hetty E. Carraway, Torsten Haferlach, Mikkael A. Sekeres, Valeria Visconte, **Jaroslaw P. Maciejewski**, Impact and Outcomes of *RAS* gene Mutations in Core Binding Factor Acute Myeloid Leukemia (2019) Submitted to the 61<sup>st</sup> American Society of Hematology Annual Meeting
317. Sunisa Kongkiatkamon, Anand Tiwari, Vera Adema, Cassandra M Kerr, Bartłomiej Przychodzen, Hassan Awada, Jibrán Durrani, Yvonne Parker, Drew Adams, Yuriy Fedorov, Hetty E. Carraway, Chao-Yie Yang, Mikkael A. Sekeres, Daniel J. Lindner, James G Phillips, **Jaroslaw P. Maciejewski**, Valeria Visconte, Therapeutic Applications of a Unique Calcium Channel Blocker to Target *SF3B1* MDS (2019) Submitted to the 61<sup>st</sup> American Society of Hematology Annual Meeting
318. Ashwin Kishtagari, Yihong Guan, Cassandra M Kerr, Hassan Awada, Jibrán Durrani, Edward F Greenberg, Xiaorong Gu, Feng Pan, Valeria Visconte, Dewen You, Guangbo Qu, Amy C Graham, Bartłomiej P. Przychodzen, Thomas Laframboise, Hideki Makishima, Daniel Gackowski, Ryszard Ólinski, Yu-Wei Cheng, Mikkael A. Sekeres, Mingjiang Xu, Babal K. Jha, **Jaroslaw P. Maciejewski**, TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins (2019) Submitted to the 61<sup>st</sup> American Society of Hematology Annual Meeting
319. Sanghee Hong, Cassandra M Kerr, Lisa Rybicki, Valeria Visconte, Jibrán Durrani, Hassan Awada, Betty K. Hamilton, Ronald Sobecks, Matt Kalaycio, Aaron T. Gerds, Mikkael A. Sekeres, Hetty E. Carraway, Sudipto Mukherjee, Anjali S. Advani, Aziz Nazha, Navneet S. Majhail, **Jaroslaw P. Maciejewski**, Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) (2019) Submitted to the 61<sup>st</sup>

## American Society of Hematology Annual Meeting

320. Austin Kulasekararaj, Antonio M. Risitano, **Jaroslaw P. Maciejewski**, Rosario Notaro, Peter Browett, Jong-Wook Lee, Mingjun Huang, Michael Geffner, Robert A. Brodsky, A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy (2019) Submitted to the 61st American Society of Hematology Annual Meeting
321. Cameron Beau Hilton, Manja Meggendorfer, Mikkael A. Sekeres, Jacob Shreve, Nathan Radakovich, Yazan Roupail, Wencke Walter, Stephan Hutter, Eric Padron, Michael R. Savona, Aaron T. Gerds, Sudipto Mukherjee, Brianna N Smith, Yasunobu Nagata, Cassandra M. Hirsch, Rami S. Komrokji, MD, Babal K. Jha, Claudia Haferlach, **Jaroslaw P. Maciejewski**, Torsten Haferlach, Aziz Nazha, Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms (2019) Submitted to the 61st American Society of Hematology Annual Meeting
322. Xiaoxian Zhao, Bartłomiej Przychodzen, Juraj Bodo, Lisa Durkin, Daniel Lindner, Neetha Parameswaran, Michael Clemente, Sarah L. Ondrejka, **Jaroslaw P. Maciejewski**, Deepa Jagadeesh, Eric D. Hsi, Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations (2019) Submitted to the 61st American Society of Hematology Annual Meeting
323. Antonio M. Risitano, Jong Wook Lee, Rosario Notaro, Robert A. Brodsky, Austin Kulasekararaj, **Jaroslaw P. Maciejewski**, Mingjun Huang, Peter Browett, Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) (2019) Submitted to the 61st American Society of Hematology Annual Meeting
324. Courtney E Hershberger, Devlin C Moyer, Wencke Walter, Stephan Hutter, Claudia Haferlach, Torsten Haferlach, **Jaroslaw P. Maciejewski**, Richard A Padgett, The Biological and Clinical Implications of the Alternative Splicing Landscape of 1,258 Myeloid Neoplasm Cases (2019) Submitted to the 61st American Society of Hematology Annual Meeting
325. June Takeda, Kenichi Yoshida, Yasuhito Nannya, Lee-Yung Shih, Ayana Kon, MD, Akinori Yoda, Yotaro Ochi, Yusuke Shiozawa, Tetsuichi Yoshizato, Cassandra M Kerr, Yuichi Shiraishi, Kenichi Chiba, Yasunobu Nagata, M Akira Hangaishi, Toshiyuki Kitano, Ken Ishiyama, Hisashi Tsurumi, Yasushi Miyazaki, Nobuhiro Hiramoto, Takayuki Ishikawa, Akifumi Takaori-Kondo, Masahiro Nakagawa, Masashi Sanada, Hideyuki Nakazawa, Keisuke Kataoka, Ryunosuke Saiki, Hiroko Tanaka, Kensuke Usuki, Shuichi Miyawaki, Satoru Miyano, Arnold Ganser, Michael Heuser, **Jaroslaw P. Maciejewski**, Felicitas Thol, Hideki Makishima, Seishi Ogawa, Novel Molecular Pathogenesis and Therapeutic Target in Acute Erythroid Leukemia (2019) Submitted to the 61st American Society of Hematology Annual Meeting
326. Jani Huhtanen, Sofie Lundgren, Mikko A Keränen, Xingmin Feng, Cassandra M Kerr, Emmi Jokinen, Markus Heinonen, Paula Savola, Tiina Kelkka, Freja Ebeling, Georgina L Ryland, Lucy Fox, MD, Piers Blombery, Eva Hellstrom Lindberg, Neal S. Young, **Jaroslaw P. Maciejewski**, Harri Lähdesmäki, Satu Mustjoki, Cell Landscape of Immune Aplastic Anemia Reveals a Convergent Antigen-Specific Signature (2019) Submitted to the 61st American Society of Hematology Annual Meeting
327. Metis Hasipek, Yihong Guan, Dale Grabowski, **Jaroslaw P. Maciejewski**, Hetty E. Carraway, Babal K. Jha, Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia (2019) Submitted to the 61st American Society of Hematology Annual Meeting
328. Xiaorong Gu, Rita Tohme, Benjamin K. Tomlinson, Lisa Durkin, Caroline Schuerger, Asmaa M Zidan, Tomas Radivoyevitch, Hetty E. Carraway, Ronald Sobecks, Betty K. Hamilton, Alan Lichtin, **Jaroslaw P. Maciejewski**, Yogenthiran Sauntharajah, Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine (2019) Submitted to the 61st American Society of Hematology Annual Meeting

329. Hideki Makishima, MD, PhD, Yasuhito Nannya, MD, PhD, June Takeda, MD, Yukihide Momozawa, DVM, Ph.D, Ryunosuke Saiki, MD, Tetsuichi Yoshizato, MD, PhD, Yoshiko Atsuta, MD, PhD, Yuka Iijima-Yamashita, Kenichi Yoshida, MD, PhD, Yuichi Shiraishi, PhD, Yasunobu Nagata, MD, PhD, Yusuke Shiozawa, MD, PhD, Makoto Onizuka, MD, PhD, Kenichi Chiba, Hiroko Tanaka, Nobuyuki Kakiuchi, M.D., Yotaro Ochi, MD, Hiroo Ueno, MD, PhD, Hidehiro Itonaga, MD, PhD, Yoshinobu Kanda, MD, PhD, Masashi Sanada, MD, Ayana Kon, MD, Ph.D, Yasushi Miyazaki, MD, PhD, Keizo Horibe, MD, PhD, Maria Creignou, Magnus Tobiaasson, MD, Hisashi Tsurumi, MD, PhD, Senji Kasahara, MD, PhD, Chantana Polprasert, MD, Eva Hellstrom Lindberg, MD, PhD, Akifumi Kondo Takaori, MD, PhD, Toru Kiguchi, MD, PhD, Mario Cazzola, Fumihiko Matsuda, MD, PhD, Kazuma Ohyashiki, MD, PhD, **Jaroslaw P. Maciejewski, MD, PhD**, Torsten Haferlach, MD, Yoichiro Kamatani, MD, Ph.D, Michiaki Kubo, MD, Ph.D, Satoru Miyano, PhD and Seishi Ogawa, MD, PhD. Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
330. Hassan Awada, MD, Cassandra M Kerr, MS, Heesun J. Rogers, MD, PhD, **Jaroslaw P. Maciejewski, MD, PhD** and Valeria Visconte, PhD, Molecular and Clinical Aspects of Acute Myeloid Leukemia with Inv(3)(q21q26)/t(3;3)(q21;q26) Carrying Spliceosomal Mutations (2020) Submitted to the 62nd American Society of Hematology Annual Meeting
331. Hassan Awada, MD, Cassandra M. Kerr, MS, Vera Adema, PhD, Carmelo Gurnari, MD, Simona Pagliuca, MD, Heesun J. Rogers, MD, PhD, Hetty E. Carraway, MD, MBA, Mikkael A. Sekeres, MD, MS, **Jaroslaw P. Maciejewski, MD, PhD** and Valeria Visconte, PhD. The Clonal Trajectories of *SF3B1* Mutations in Myeloid Neoplasia. (2020) Submitted to the 62nd American Society of Hematology Annual Meeting
332. Aziz Nazha, MD, Sudipto Mukherjee, MD, PhD, MPH, Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Eric Parsons, RN, Jenna Thomas, Hetty E. Carraway, MD, MBA, Dale Grabowski, BS, Yihong Guan, PhD, Aaron T. Gerds, MD, MS, Bhumika J. Patel, MD, Anjali S Advani, MD, **Jaroslaw P. Maciejewski, MD, PhD** and Mikkael A. Sekeres, MD, MS A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia (2020) Submitted to the 62nd American Society of Hematology Annual Meeting
333. Carmelo Gurnari, MD, Simona Pagliuca, MD, Bhumika J. Patel, MD, Hassan Awada, MD, Cassandra M Kerr, MS, Wenyi Shen, MD, Sunisa Kongkiatkamon, MD, Laila Terkawi, Misam Zawit, MBBS, Jibrán Durrani, MD, Valeria Visconte, PhD, Seth J. Corey, MD, Maria Teresa Voso, MD, Hetty E. Carraway, MD, MBA and **Jaroslaw P. Maciejewski, MD, PhD** The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
334. Carmelo Gurnari, MD, Simona Pagliuca, MD, Cassandra M Kerr, MS, Hassan Awada, MD, Sunisa Kongkiatkamon, MD, Laila Terkawi, Neetha Parameswaran, PhD, Misam Zawit, MBBS, Adam Wahida, Valeria Visconte, PhD and **Jaroslaw P. Maciejewski, MD, PhD** Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape (2020) Submitted to the 62nd American Society of Hematology Annual Meeting
335. Sunisa Kongkiatkamon, MD, Yasunobu Nagata, MD, PhD, Vera Adema, PhD, Hassan Awada, MD, Misam Zawit, MD, Laila Terkawi, Simona Pagliuca, MD, Carmelo Gurnari, MD, Cassandra M Kerr, MS, Mikkael A. Sekeres, MD, MS, Hetty E. Carraway, MD, MBA, Yogenthiran Sauntharajah, MD, Bhumika J. Patel, MD, **Jaroslaw P. Maciejewski, MD, PhD** and Valeria Visconte, PhD Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
336. Jacob Shreve, BS, MD, MS, Manja Meggendorfer, PhD, Sudipto Mukherjee, MD, PhD, MPH, Wencke Walter, PhD, Stephan Hutter, PhD, Ahed Makhoul, MD, Nathan Radakovich, BA, Hassan Awada, MD, Yihong Guan, PhD, Teodora Kuzmanovic, BA, **Jaroslaw P. Maciejewski, MD, PhD**, Claudia Haferlach, MD, Mikkael A. Sekeres, MD, MS, Torsten Haferlach, MD and Aziz Nazha, MD Molecular Dissection of Normal Karyotype Acute Myeloid Leukemia (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting

337. Tracy I. George, MD, Mehrdad Abedi, MD, Christopher R. Cogle, Harry P. Erba, Guillermo Garcia-Manero, MD, David L. Grinblatt, MD, Pavel Kiselev, Rami S. Komrokji, MD, Chrystal U. Louis, **Jaroslaw P. Maciejewski, MD, PhD**, Melissa Nifenecker, Daniel A. Pollyea, MD, Gail J. Roboz, MD, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, David P. Steensma, MD, Michael A. Thompson, MD, PhD and Jay L. Patel, MD Changing Molecular Diagnostic Testing Patterns for Patients (Pts) with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) in the Connect<sup>®</sup> MDS/AML Disease Registry(2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
338. Hassan Awada, MD, Arda Durmaz, Carmel Gurnari, MD, Ashwin Kishtagari, MBBS, Manja Meggendorfer, PhD, Cassandra M. Kerr, MS, Teodora Kuzmanovic, Jibrán Durrani, MD, Yasunobu Nagata, MD, PhD, Tomas Radivoyevitch, PhD, Anjali S Advani, MD, Farhad Ravandi, MBBS, Hetty E. Carraway, MD, MBA, Aziz Nazha, MD, Claudia Haferlach, MD, Yogenthiran Sauntharajah, MD, Jacob Scott, MD, Valeria Visconte, PhD, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD, Mikkael A. Sekeres, Torsten Haferlach, MD and **Jaroslaw P. Maciejewski, MD, PhD** The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
339. Hassan Awada, MD, Arda Durmaz, Cassandra M. Kerr, MS, Jaroslaw P. Maciejewski, MD, PhD and Valeria Visconte, PhD Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
340. Carmelo Gurnari, MD, Simona Pagliuca, MD, Bhumika J. Patel, MD, Hassan Awada, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Laila Terkawi, Misam Zawit, MBBS, Valeria Visconte, PhD, Adam Wahida and **Jaroslaw P. Maciejewski, MD, PhD** Implication of PIGA Genotype on Clinical Features of PNH (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
341. Simona Pagliuca, MD, Carmelo Gurnari, MD, Sanghee Hong, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Hassan Awada, MD, Ashwin Kishtagari, MBBS, Misam Zawit, MBBS, Laila Terkawi, Valeria Visconte, PhD, Eric D. Hsi, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD, MBA, Navneet S. Majhail, MD, MS and **Jaroslaw P. Maciejewski, MD, PhD** Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/II HLA Mutations (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
342. Simona Pagliuca, MD, Carmelo Gurnari, MD, Hassan Awada, MD, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Laila Terkawi, Misam Zawit, MBBS, Sunisa Kongkiatkamon, MD, Pedro H Prata, MD, Ashwin Kishtagari, MBBS, Adam Wahida, Thomas Laframboise, PhD Valeria Visconte, PhD, Regis Peffault De Latour, MD, PhD and **Jaroslaw P. Maciejewski, MD, PhD** Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
343. Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD, FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD, PhD, MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, BS, MD, MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, **Jaroslaw P. Maciejewski, MD, PhD**, Mikkael A. Sekeres, MD, MS and Aziz Nazha, MD Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS) (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
344. Vera Adema, PhD, Cassandra M Kerr, MS, Hassan Awada, MD, Sunisa Kongkiatkamon, MD, Bhumika J. Patel, MD, Mikkael A. Sekeres, MD, MS, Valeria Visconte, PhD, John Barnard, **Jaroslaw P. Maciejewski, MD, PhD** and Torsten Haferlach, MD Molecular and Expression Characterization of Monosomy 7 and Del(7q) (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting



345. Hassan Awada, MD, Arda Durmaz, Carmelo Gurnari, MD, Misam Zawit, MBBS, Sunisa Kongkiatkamon, MD, Simona Pagliuca, MD, Cassandra M. Kerr, MS, Hetty E. Carraway, MD, MBA, Aziz Nazha, MD, Mikkael A. Sekeres, MD, MS, **Jaroslaw P. Maciejewski, MD, PhD** and Valeria Visconte. PhD The Genomic Landscape of *Wilms' Tumor 1 (WT1)* Mutant Acute Myeloid Leukemia (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
346. Misam Zawit, MBBS, Jibran Durrani, MD, Wenyi Shen, MD, Vera Adema, PhD, Cassandra M Kerr, MS, Hassan Awada, MD, Sunisa Kongkiatkamon, MD, Carmelo Gurnari, MD, Simona Pagliuca, MD, Laila Terkawi, Bhumika J. Patel, MD, Valeria Visconte, PhD, Hetty E. Carraway, MD, MBA, Thomas LaFramboise, Ph.D., Seth J. Corey, MD, Torsten Haferlach, MD and **Jaroslaw P. Maciejewski, MD, PhD** Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes *Vs.* Myeloid Neoplasia(2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
347. Carmelo Gurnari, MD, Vera Adema, PhD, Hassan Awada, MD, Simona Pagliuca, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Thomas Laframboise, PhD, Valeria Visconte, PhD, Maria Teresa Voso, MD, Mikkael A. Sekeres, MD, MS, Hetty E. Carraway, MD, MBA, Torsten Haferlach, MD and **Jaroslaw P. Maciejewski, MD, PhD** Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
348. Simona Pagliuca, MD, Yihong Guan, PhD, Anand D. Tiwari, PhD, Dale Grabowski, BS, Carmelo Gurnari, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Metis Hasipek, PhD, Laila Terkawi, Misam Zawit, MBBS, Hassan Awada, MD, Valeria Visconte, PhD, Yogenthiran Sauntharajah, MD, James G Phillips, PhD, **Jaroslaw P. Maciejewski, MD, PhD** and Babal K. Jha, PhD Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
349. Johannes B Goll, MSc, Travis L Jensen, BS, R. Coleman Lindsley, MD, PhD, Rafael Bejar, MD, PhD, Jason Walker, Robert Fulton, MS, Gregory A. Abel, MD, MPH, Tareq Al Baghdadi, MD, H. Joachim Deeg, MD, Amy E. DeZern, MD, Benjamin L. Ebert, MD, PhD, James M. Foran, MD, Edward J. Gorak, DO, MBA, MS, Steven D. Gore, MD, Rami Komrokji, MD, Jane Jijun Liu, MD, **Jaroslaw P. Maciejewski, MD, PhD**, Eric Padron, MD, Wael Saber, MD, MS, Daniel Starczynowski, PhD, Myron Wacławiw, PhD, Steffanie H. Wilson, PhD, Donnie Hebert, PhD, Harrison Reed, MSc, Nancy L. DiFronzo, PhD, Mikkael A. Sekeres, MD, MS, Alexandra M. Harrington, MD, MT(ASCP), Steven H. Kroft, MD, Ling Zhang, MD and Matthew J. Walter, MD Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
350. Sunisa Kongkiatkamon, MD, Samuel Li, BA, Tatiana Dombrowski, Laila Terkawi, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD, PhD, Wencke Walter, PhD, Hassan Awada, MD, Bartłomiej Przychodzen, Stephan Hutter, PhD, Carmelo Gurnari, MD, Simona Pagliuca, MD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Valeria Visconte, PhD, Torsten Haferlach, MD, **Jaroslaw P. Maciejewski, MD, PhD** and Thomas LaFramboise, Ph.D. Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
351. Yazan Roupail, Nathan Radakovich, BA, Jacob Shreve, BS, MD, MS, Sudipto Mukherjee, MD, PhD, MPH, Babal K. Jha, PhD, **Jaroslaw P. Maciejewski, MD, PhD**, Mikkael A. Sekeres, MD, MS and Aziz Nazha, MD Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
352. Nathan Radakovich, BA, Luca Malcovati, MD, Manja Meggendorfer, PhD, Mikkael A. Sekeres, MD, MS, Jacob Shreve, BS, MD, MS, Cameron Beau Hilton, MD, Yazan Roupail, Wencke Walter, PhD, Stephan Hutter, PhD,

- Anna Galli, Sarah Pozzi, Aaron T. Gerds, MD, MS, Sudipto Mukherjee, MD, PhD, MPH, Cassandra M Kerr, MS, Babal K. Jha, PhD, Claudia Haferlach, MD, **Jaroslaw P. Maciejewski, MD, PhD**, Torsten Haferlach, MD and Aziz Nazha, MD Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
353. June Takeda, MD, Kenichi Yoshida, MD, PhD, Akinori Yoda, PhD, Lee-Yung Shih, MD, Yasuhito Nannya, MD, PhD, Yotaro Ochi, MD, Ayana Kon, MD, PhD, Kenichi Chiba, Yuichi Shiraishi, PhD, Yusuke Shiozawa, MD, PhD, Tetsuichi Yoshizato, MD, PhD, Cassandra M Kerr, MS, Yasunobu Nagata, MD, PhD, Toshiyuki Kitano, MD, PhD, Akira Hangaishi, MD, PhD, Ken Ishiyama, MD, PhD, Hisashi Tsurumi, MD, PhD, Yasushi Miyazaki, MD, PhD, Nobuhiro Hiramoto, MD, Takayuki Ishikawa, MD, PhD, Masahiro Marshall Nakagawa, MD, PhD, Akifumi Takaori-Kondo, MD, PhD, Shigeru Chiba, MD, PhD, Hideyuki Nakazawa, MD, PhD, Ming-Chung Kuo, M.D., Keisuke Kataoka, MD, PhD, Ryunosuke Saiki, MD, Hiroko Tanaka, Kensuke Usuki, MD, PhD, Shuichi Miyawaki, MD, PhD, Satoru Miyano, PhD, **Jaroslaw P. Maciejewski, MD, PhD**, Arnold Ganser, Michael Heuser, Prof., MD, Felicitas Thol, Hideki Makishima, MD, PhD and Seishi Ogawa, MD, PhD Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
354. Adam Wahida, Stephan Hutter, PhD, Manja Meggendorfer, PhD, Cassandra M. Kerr, MS, Carmelo Gurnari, MD, Elisabeth Weiss, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, **Jaroslaw P. Maciejewski, MD, PhD** and Torsten Haferlach, MD Leveraging Whole Genome Sequencing to Define the Mutational Landscape in Paroxysmal Nocturnal Hemoglobinuria (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
355. Xiaorong Gu, PhD, Rita Tohme, PhD, Mendel Goldfinger, MD, Benjamin K. Tomlinson, MD, Nneha Sakre, PhD, Shannon Hanmer, Babal K. Jha, PhD, **Jaroslaw P. Maciejewski, MD, PhD**, Amit Verma, MBBS and Yogenthiran Sauntharajah, MD Venetoclax Inhibition of Pyrimidine Synthesis Guides Methods for Integration with Decitabine or 5-Azacytidine That Are Non-Myelosuppressive (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
356. Adam Wahida, Stephan Hutter, PhD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, **Jaroslaw P. Maciejewski, MD, PhD** and Torsten Haferlach, MD Aberrant Telomere Length and Composition Are Recurrent Features of Myeloid Disorders (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
357. Metis Hasipek, PhD, Yihong Guan, PhD, Dale Grabowski, BS, Xiaorong Gu, PhD, Yogenthiran Sauntharajah, MD, Robert Silverman, PhD, George R Stark, PhD, **Jaroslaw Maciejewski, MD, PhD** and Babal K. Jha, PhD Role of Oligoadenylate Synthetases in Myeloid Neoplasia (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
358. Yihong Guan, PhD, Metis Hasipek, PhD, Bhumika J. Patel, MD, Dale Grabowski, BS, Anand D. Tiwari, PhD, Sunisa Kongkiatkamon, MD, Cassandra M Kerr, MS, Aziz Nazha, MD, Yogenthiran Sauntharajah, MD, Mikkael A. Sekeres, MD, MS, **Jaroslaw P. Maciejewski, MD, PhD** and Babal K. Jha, PhD TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
359. Jakob Woerner, Yidi Huang, MS, Yimin Huang, Janet Wang, BS, Jesus M Hernández-Sánchez, PhD, **Jaroslaw P. Maciejewski, MD, PhD**, Mehmet Koyuturk, PhD, Stephan Hutter, PhD, Torsten Haferlach, MD and Thomas Laframboise, PhD Characterization of the Blood and Bone Marrow Microbiome of MDS Patients and Associations with Clinical Features (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
360. Nathan Radakovich, BA, Manja Meggendorfer, PhD, Luca Malcovati, MD, Mikkael A. Sekeres, Jacob Shreve, MD,

MS, Cameron Beau Hilton, MD, Yazan Rouphail, Wencke Walter, PhD, Stephan Hutter, PhD, Sudipto Mukherjee, MD, PhD, MPH, Cassandra M. Kerr, MS, Babal K. Jha, PhD, Anna Galli, Sarah Pozzi, Aaron T. Gerds, MD, MS, Cassandra M Kerr, MS, Claudia Haferlach, MD, **Jaroslav P. Maciejewski, MD, PhD**, Torsten Haferlach, MD and Aziz Nazha, MD A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting

361. **Simona Pagliuca, MD**, Carmelo Gurnari, MD, Diego Chowell, PhD, Chirag Krishna, Bhumika J. Patel, MD, Hassan Awada, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Ashwin Kishtagari, MBBS, Thomas Laframboise, PhD, Yogenthiran Sauntharajah, MD, Babal K. Jha, PhD, Valeria Visconte, PhD, Timothy Chan, MD, PhD and **Jaroslav Maciejewski, MD., PhD** Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting
362. Metis Hasipek, PhD, Dale Grabowski, BS, Yihong Guan, PhD, Anand D. Tiwari, PhD, Xiaorong Gu, PhD, Jason Valent, MD, **Jaroslav Maciejewski, MD., PhD**, Frederic Joel Reu, James G Phillips, PhD and Babal K. Jha, PhD A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase (2020) Submitted to the 62<sup>nd</sup> American Society of Hematology Annual Meeting